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Abstract
Impact of Sensing and Actuation Characteristics
on Artificial Pancreas Design
by
Lauren Maria Huyett
Type 1 diabetes mellitus (T1DM) is a chronic disease characterized by the body’s
inability to produce insulin, leading to chronically high blood glucose (BG) concen-
trations. T1DM is treated by frequent self-administration of insulin based on BG
measurements; however, there is a fine line between too little and too much insulin,
and an overdose can lead to a dangerous drop in BG. The artificial pancreas (AP), con-
sisting of a glucose sensor, an insulin pump, and a feedback control algorithm, will
replace self-treatment by automatically calculating and delivering insulin dosages
based on continuous glucose measurements. Many iterations of the AP utilize com-
mercially available subcutaneous (SC) insulin pumps and glucose sensors, but these
devices introduce physiological limitations that make control difficult.
In this work, we present a clinical evaluation of an AP that uses SC devices, as
well as an investigation of the intraperitoneal (IP) space as an alternative site for in-
sulin delivery and glucose sensing to improve AP performance. Our results show that
glucose sensors placed in the IP space have a lower time constant than SC sensors, al-
lowing the controller to respond more quickly to BG disturbances. Similarly, insulin
xii
Abstract
delivered through the IP space has faster pharmacokinetic and pharmacodynamic
characteristics than SC insulin. Based on models of the sensing and actuation dy-
namics, a proportional-integral-derivative control algorithm with anti-reset windup
protection was designed for the IP-IP route and evaluated on 10 simulated T1DM
subjects. Using the IP-IP route led to a more robust controller that provided excellent
control during the simulation studies. Our results support the development of a fully
implantable AP that will operate within the IP space to safely and effectively control
BG levels.
xiii
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Chapter 1
Introduction1
Type 1 diabetes mellitus (T1DM) is a disease that requires intensive self-treatment.
A small miscalculation or wrong decision can lead to both immediate and long-
term health problems. Technological advancements have greatly improved the way
that T1DM is treated. Even so, this disease is an ideal candidate for an automated
treatment solution, and in fact efforts have been in place to develop one for over 30
years [2]. Continuous insulin infusion pumps and glucose sensors are commercially
available, but the loop must remain open until a suitable controller is designed. The
development of automated control for T1DM will increase the quality of life of those
with the disease by reducing the burden of self-treatment, as well as by providing
improved health outcomes. The objective of this dissertation is to investigate the
characteristics of glucose sensing and insulin action through different routes, as well
as the impact that they have on the development of safe, effective closed-loop control
for T1DM.
1Some content from this chapter is published in F. J. Doyle III, L. M. Huyett, J. B. Lee, H. C. Zisser,
and E. Dassau, “Closed-loop artificial pancreas systems: engineering the algorithms,” Diabetes Care,
vol. 37, pp. 1191-7, 2014. [1]
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1.1 Type 1 Diabetes Mellitus
As of 2010, an estimated 1 in every 300 people under the age of 18 in the United
States has T1DM [3]. This disease is characterized by the autoimmune destruction of
pancreatic beta cells. The cause of this destruction is unknown, but it is hypothesized
to involve both genetic and environmental factors [3, 4].
The pancreas is charged with regulating the blood glucose concentration (BG)
within the body. The regulation process is depicted in Figure 1.1. Cells receive
much of their energy by processing glucose, which is absorbed into the blood stream
through the digestion of carbohydrate-containing food. The pancreas then controls
the uptake of glucose from the blood stream into tissue cells and the liver to maintain
BG homeostasis by secreting insulin, glucagon, and other hormones. In response to
elevated levels of glucose in the blood, the pancreas produces insulin to stimulate
the uptake of glucose into muscle and fat cells to be used for energy. Glucose is also
stored in the liver as glycogen. In response to low levels of glucose in the blood, the
pancreas produces glucagon, which stimulates the conversion of the stored glycogen
to glucose. This process can be viewed as a closed-loop control system, where the
pancreas acts together with the liver to control the BG within the body [4].
1.1.1 Pathophysiology
When the beta cells are destroyed, the pancreas can no longer produce insulin,
which disrupts the feedback loop by removing one of the manipulated variables [6].
The inability to produce insulin leads to chronically high glucose concentrations in
the blood (BG>180 mg/dL), known as hyperglycemia. Glucose is toxic to the vas-
culature at high concentrations. Common long-term complications of hyperglycemia
2
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Figure 1.1: Schematic of glucose homeostasis maintained by the pan-
creas and the liver. In response to elevated levels of glucose in the blood,
the pancreas produces insulin to stimulate the uptake of glucose into mus-
cle and fat cells to be used for energy. Glucose is also stored in the liver
as glycogen. In response to low levels of glucose in the blood, the pan-
creas produces glucagon, which stimulates the conversion of glycogen to
glucose. Figure adapted from [4] and [5].
3
Chapter 1. Introduction
include nephropathy, retinopathy, neuropathy, and cardiovascular disease [4].
In addition to the long-term complications related to chronic hyperglycemia, un-
treated T1DM leads to diabetic ketoacidosis (DKA) in the short-term. This compli-
cation begins when the glucose uptake by cells decreases, while the breakdown of
glycogen and other non-carbohydrate molecules occurs, leading to an excess of glu-
cose within the bloodstream. At the same time, lipids are broken down to form
ketones, which can provide energy to cells as a replacement for glucose. The kid-
neys begin to remove the excess glucose and ketones from the blood, causing water
and electrolytes to be secreted as well. The resulting dehydration leads to increased
urination and thirst, which are both common symptoms of undiagnosed T1DM. This
process ultimately leads to reduced arterial blood pressure and brain blood flow,
while the blood becomes more acidic due to elevated ketone levels. If left unim-
peded, the result of DKA is impaired brain function, coma, and death [4, 6].
1.1.2 Treating Type 1 Diabetes Mellitus
Before insulin was isolated in the early 1920s, there was no way to successfully
treat T1DM [4]. Once the commercial production of insulin began, it was used suc-
cessfully by people with T1DM to replace the role of their absent beta cells. While
this treatment with exogenous insulin allowed people with T1DM to survive, much
improvement in the treatment process was still needed to achieve better long-term pa-
tient outcomes. A key event in this process of improvement was the landmark study
by the Diabetes Control and Complications Trial Research Group, which showed that
intensive insulin treatment reduces the severity and delays the onset of long-term
complications of T1DM [7].
While intensive insulin therapy can reduce the long-term complications of hy-
perglycemia, it also increases the risk of hypoglycemia, or a BG that is too low
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(BG<70 mg/dL). Hypoglycemia can occur if an overdose of exogenous insulin is
delivered. Other potential causes are exercise or malnourishment. When the glucose
concentration becomes too low, the sympathetic nervous system is triggered. The
resulting symptoms include increased heart rate, trembling, nervousness, sweating,
and anxiety. In addition, severe hypoglycemia deprives the brain of glucose, lead-
ing to headache, confusion, dizziness, slurred speech, convulsions, coma, and death
[4, 6].
The goal of T1DM treatment is to minimize hyperglycemia, while avoiding hypo-
glycemia, through the delivery of exogenous insulin. The desired range for prepran-
dial glucose is 80-130 mg/dL, with a peak postprandial glucose less than 180 mg/dL.
Additionally, it is recommended that the glycated hemoglobin (HbA1c), a measure
used to indicate BG levels over the past few months, be maintained lower than
7.0% [8]. Successful treatment is accomplished by using a combination of tools and
techniques to monitor the BG and adjust insulin delivery according to those mea-
surements, as well as in anticipation of meals and other daily-life events that affect
glycemia.
1.2 Technology and Diabetes Treatment
1.2.1 Insulin Delivery
To effectively treat T1DM, exogenous insulin must be delivered on a daily basis.
Insulin is needed both at a low background level, known as basal insulin, as well as
in larger doses in response to meals or to correct a high BG. While the most desired
method for the delivery of chronic medication is the oral route, taking an insulin pill
currently is not an option due to low bioavailability through this route [9]. In fact,
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for decades the only option for insulin delivery was through subcutaneous injections
with a syringe [10]. Over time, insulin delivery regimes have grown more refined in
an attempt to exert finer glycemic control.
The two regimens for insulin delivery used most often today were both intro-
duced in the 1970s. The first is multiple daily subcutaneous injections (MDI) of
insulin, which includes doses for basal insulin and doses for meals [11]. MDI was
improved by the development of insulin pens in the 1980s, which allowed for more
convenient and comfortable injections [12]. However, people with T1DM find that
injections can be inconvenient, complex, lacking in precision, and difficult to use in
conjunction with variation in day-to-day activities [13]. Additionally, injections must
use combinations of slow- and fast-acting insulin to meet both the basal and prandial
insulin requirements [13].
The second insulin delivery method used today is continuous subcutaneous in-
sulin infusion (CSII) using a miniature pump. The pump delivers insulin via a can-
nula that is inserted subcutaneously [10]. Insulin pumps use only fast-acting insulin.
They meet basal insulin requirements by delivering small amounts of insulin (called
microboluses) every five minutes. They can also be commanded to deliver larger
boluses to meet insulin requirements for meals and correction doses. CSII has be-
come much more advanced over the years, with the development of pumps that can
be programmed to fine-tune and customize basal insulin delivery and allow easy
calculations for meal and correction boluses [13].
CSII has been associated with improved glycemic control, decreased hypo-
glycemia, and better quality of life [14–16]. Still, there are several disadvantages
of this delivery route. Using CSII means that the patient is attached to an external
device, which may be inconvenient in daily life. Additionally, it is recommended
to change the infusion set every three days to reduce problems with site irritation
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and irregularity in insulin delivery caused by blocked catheters, insulin leakage, or
cannula dislodgement [17]. A failure of the infusion set can lead to hyperglycemia,
and potentially DKA if the problem is not detected in time.
The subcutaneous route of insulin administration is not ideal for many reasons.
This route is nonphysiological and results in peripheral hyperinsulinemia [18]. The
pharmacokinetic and pharmacodynamic characteristics of insulin delivered through
CSII cause delays between delivery and effect, and the insulin can remain active for as
long as 4-6 hours following injection. In addition, inter- and intrapatient variabilities
in insulin sensitivity and absorption through the subcutaneous route can cause in-
consistent pharmacokinetic and pharmacodynamic properties [19]. For these reasons,
the development of alternative insulin delivery routes is an important and active area
of research. One such alternate route that has shown promise in overcoming the dis-
advantages of the subcutaneous route is delivery through the intraperitoneal space.
The use of intraperitoneal insulin delivery is discussed more in Chapters 4 and 5 of
this dissertation.
1.2.2 Glucose Measurement
Accurate BG measurement is essential for safe and successful treatment of T1DM.
The current standard of care for BG measurement is the capillary blood test [20]. A
lancet is used to prick the fingertip to release a small drop of capillary blood, which
is placed onto a test strip in a handheld glucose meter. This method requires active
work by the user and is somewhat painful, meaning that it can be expected to be
performed at most once every few hours, and only while the patient is awake. In
fact, a conventional approach to glucose monitoring will result in only three to four
measurements per day [21]. These measurements create a discrete picture of the BG
over time, but often miss important trends.
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The development of glucose sensors that operate in vivo to provide a continuous
estimation of the BG has allowed patients to observe the continuous trajectory of their
BG over time. The first continuous glucose monitor (CGM) was approved for use in
the United States in 1999 [22]. This device, produced by MiniMed (later bought by
Medtronic in 2001), did not display BG readings in real-time; rather, the data were
downloaded and analyzed retrospectively by the user’s doctor after the 3 day period
of wear [23]. CGM technology has advanced greatly since then, with devices today
providing patients with a real-time readout of their BG over 6 or 7 days of continuous
wear. These sensors are worn on the skin, with a transcutaneous sensing element
inserted into the subcutaneous space [24].
Methods of Glucose Detection
The CGMs currently available in the United States operate through the electro-
chemical detection of glucose using the enzyme glucose oxidase [24]. The following
series of reactions is of interest to the detection of glucose [23]:
Eox +C6H12O6 −→ Ered +C6H12O6 (1.1)
C6H10O6 +H2O←→ C6H12O7 (1.2)
Ered +O2 −→ Eox +H2O2 (1.3)
Ered +Mox −→ Eox +Mred. (1.4)
In these reactions, Ered and Eox are the reduced and oxidized forms of the enzyme,
respectively. The fourth step represents the optional inclusion of a mediator to react
directly with the enzyme, with Mox being the oxidized mediator and Mred being the
reduced mediator. Examples of mediators are ferrocene or Os(III). The glucose con-
centration can be inferred either by measuring the production of hydrogen peroxide
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or the production of the reduced mediator (if in use) [23]. The hydrogen peroxide
concentration or the reduced mediator concentration is measured amperometrically
by inducing its oxidation at a suitable electrode. This process is described by the
following reactions:
H2O2 −→ O2 + 2 H+ + 2 e− (1.5)
Mred −→ Mox + 2 e−. (1.6)
To make the measurement, a constant voltage is applied across the working and
reference electrode to make the reaction thermodynamically favorable.
The two continuous glucose monitors on the market today (Dexcom G4 Platinum
and G5 Mobile, Dexcom, San Diego, California and the Medtronic Enlite, Medtronic
Diabetes, Northridge, California) utilize the detection of hydrogen peroxide, with
no additional mediator used. A schematic diagram of an electrochemical sensor
using this method is shown in Figure 1.2. As the hydrogen peroxide is oxidized,
an electrical current is produced in proportion to the number of molecules that have
reacted. In order for this reaction scheme to be useful, the electrical current produced
must be directly proportional to the concentration of glucose in the range of interest
(approximately 30-360 mg/dL of glucose). The best way to ensure this linearity is
to design the sensor so the mass transport of glucose to the enzyme layer of the
electrode is the rate limiting step [23, 25].
The CGM sensor is designed with a series of selective membranes to limit the pro-
duction rate of hydrogen peroxide by the diffusion of glucose. The outer layer allows
a higher flux of oxygen than glucose. This membrane creates an excess of oxygen
within the enzyme layer, ensuring that the rate of production of hydrogen peroxide
will not be limited by the concentration of oxygen. This diffusion-limiting step is
9
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needed because in the interstitial fluid (ISF) where the sensor is placed, oxygen is
usually found in concentrations that are an order of magnitude smaller than glucose
concentrations. The next layer of the electrode is the enzyme layer, which contains
immobilized glucose oxidase. Excess enzyme is included so the glucose molecules
react as soon as they reach the enzyme layer. The hydrogen peroxide produced by
the reaction diffuses through the interference layer into the electrode layer. The in-
terference layer is a selective membrane that is included to prevent other species that
could be oxidized at the electrode from passing through. The hydrogen peroxide
reacts immediately upon arrival at the surface of the working electrode to produce a
current in proportion to the number of molecules oxidized. Since the process is de-
signed to be limited by the diffusion of glucose, the current produced will be linear
in glucose concentration [23].
To be used for in vivo glucose measurements, the sensing element must be in-
serted transcutaneously so that one end sits in the subcutaneous space, while the
other end connects to the transmitter that is placed on the outside of the body. The
sensor measures the electrical current produced in reaction to the ISF. This current
is calibrated to the BG [23]. Both the Dexcom and the Medtronic sensors require
calibration with a fingerstick measurement every 12 h throughout the sensor wear
period, because the relationship between the glucose concentration and the resulting
electrical current changes over time [23, 24]. While the sensor directly measures the
glucose concentration in the ISF, this measurement is used as an estimation of the
BG. The transmitter sends a value to the receiver at a frequent time interval (usually
every five minutes) [23].
The Abbott FreeStyle Libre is a new type of glucose sensor that is available in
Europe, but not yet in the United States. This sensor is designed to replace fingerstick
measurements in determining insulin doses. The sensor can be worn for 14 days
10
Chapter 1. Introduction
GOx
Glucose
O2
H202
2e-
H202
Outer
Layer
Enzyme
Layer
Int.
Layer
Elec.
Layer
Working
Electrode
A.
B.
Figure 1.2: Schematic representation of a sensing element that could
be used in a CGM. (A) Cross section of the electrode. (B) Layers of the
glucose sensing electrode. Figure adapted from [23] and [25].
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and is factory-calibrated, meaning that no fingerstick measurements are required
throughout the entire device wear period. However, this sensor is not yet a CGM.
Rather than continuously transmitting measurements to a monitor for a real-time
readout, the sensor provides the measurement only when the meter is used to scan
the sensor. Upon scanning, the most recent measurement, plus a history of up to 8 h,
is provided [26]. In the future, this sensor may become available as a true factory-
calibrated CGM.
The FreeStyle Libre operates through Wired Enzyme™ technology, which was
previously used in the FreeStyle Navigator CGM [26, 27]. This technology uses the
detection of a mediator, rather than hydrogen peroxide, to measure the glucose con-
centration. To prevent the mediator from diffusing out of the sensor, it is bound
within a redox active gel, which contains the glucose oxidase and the Os-based
mediator attached by anchors to a polymeric backbone film enzyme. This sensing
mechanism provides a more stable response over the lifetime of the sensor than hy-
drogen peroxide-based sensors. Additionally, the use of the mediator removes the
dependence on the oxygen concentration, so the system of selective membranes to
orchestrate a higher concentration of oxygen is no longer necessary. Since oxygen is
no longer a key component for glucose detection, the glucose measurement will not
be affected by fluctuations in oxygen concentration in the in vivo environment. Lastly,
the potential that needs to be applied to the working electrode to drive the reaction
is much smaller than what is needed for hydrogen peroxide sensors (40 mV versus
500-700 mV). Using this smaller potential removes the possibility of interference from
other electroactive compounds, such as acetaminophen [23, 26]. The feasibility of a
factory calibration was enabled by advances in the sensor manufacturing process that
ensure consistent and reproducible sensor production [27, 28].
An emerging type of CGM operates without using glucose oxidase or any other
12
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electrochemical reaction. Instead, it detects glucose using a fluorescent indicator. The
sensor consists of a hydrogel containing the fluorescent indicator, an LED to excite
the indicator, and photodiodes to measure the fluorescence intensity. Glucose binds
with the indicator in a reversible reaction that prevents fluorescence quenching, thus
increasing the fluorescence in proportion to the glucose concentration. The fluores-
cent sensor in development by Senseonics (Germantown, MA) is designed to be fully
implantable within the subcutaneous space, meaning there is no transcutaneous com-
ponent. The implanted sensor uses an antenna to communicate with the transmitter
placed on the skin above the sensor site [29]. Data from a clinical study show that
the implanted sensor is able to measure glucose for at least 90 days, which is a sig-
nificant improvement over the 6, 7, or 14 day wear period of other sensors [30]. The
Senseonics Eversense CGM System has recently received the CE mark for adjunctive
use and will be commercialized beginning in Sweden [31].
Subcutaneous Glucose Sensing Characteristics
Subcutaneous CGMs are advantageous for many reasons: they require little pa-
tient effort, capture trends that would be missed by capillary glucose measurements,
continue working even while the patient is asleep, and are painless apart from the
initial insertion. The disadvantages are that the sensors need to be calibrated by cap-
illary glucose measurement every 12 h, pressure on the sensor site during sleep can
cause the signal to drop, and measurements may not be accurate or may lag behind
the true BG [32, 33]. Despite these drawbacks, CGMs have been shown to improve
treatment for adults and children with T1DM, especially when combined with pump
therapy [34–36].
Understanding the glucose measurement process and potential errors associated
with it is important to ensuring that these sensors have a positive impact on patient
13
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Figure 1.3: Block diagram demonstrating factors that contribute to CGM
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glucose measurement. Glucose is transported from the blood to the ISF,
where it is then detected by the sensing mechanism. Calibration is used to
convert the measurement from electrical current to glucose concentration.
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14
Chapter 1. Introduction
care. Since the sensor is acting in vivo, there are many sources of error that can affect
the measurement [23, 37]. The block diagram in Figure 1.3 depicts the measurement
process from the intravenous (IV) glucose concentration to the measured CGM value.
Glucose must be transported from the blood to the ISF, which adds a diffusion lag
[38]. Pressure on the sensor site can affect the volume of the ISF, acting as a dis-
turbance to the transport process [33, 39]. The ISF concentration is measured by
the CGM, which produces an electrical current (isig) that is designed to be linear in
glucose concentration. Various factors such as biofouling, corrosion, and invalid ki-
netic assumptions can affect the accuracy of the measurement. Random signal noise
(ξCGM) is present as well.
The electrical current is processed with filters as designed by the manufacturer.
The signal is then operated upon by the calibration function to produce a signal in
concentration units. The calibration function receives capillary BG updates periodi-
cally (approximately every 12 h). The capillary glucose measurements are used to fit
a linear relationship between electrical current and glucose concentration, although
the exact method used is typically proprietary information of the manufacturer [23].
Any error in the capillary measurement will potentially lead to an incorrect cali-
bration, which will create a persistent error in the CGM measurement. Finally, the
calibrated glucose signal may be filtered by a noise spike filter to remove unrealisti-
cally large changes in concentration. The CGM measurement thus produced is often
compared to a measurement of the IV BG by a standard reference instrument, which
can also have a small error.
The error present in the glucose measurement process can be dangerous to the
patient if it is significant enough to cause incorrect treatment. Conversely, small
errors in the measurement are not important and will result in the same overall
treatment. The performance characteristics of various CGMs as observed in clinical
15
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Table 1.1: Performance characteristics of various CGMs over time.
Source of reference measurement is listed as YSI (venous blood with YSI
glucose analyzer), GS (venous blood with GlucoScout), VB (venous blood),
or SMBG (capillary blood measurement).
Mfgr. Model Ref. Year N Comp. MARD
(%)
CEG A
(%)
CEG
A+B
(%)
Dexcom G4 Platinum [40] 2015 72 YSI 13 81 98
[41] 2015 51 YSI 9 92.4 99.5
[42] 2015 24 YSI 13.6 79.9 94.9
[43] 2014 24 GS 10.8 84.5 99.6
[44] 2014 38 SMBG 13.9
[45] 2013 72 YSI 13 79
Seven Plus [45] 2013 53 YSI 16 73
[46] 2013 6 GS 16.5 76.2 98.9
Seven [47] 2009 72 YSI 16.7 70.4 97.9
[48] 2009 14 YSI 16.8 72 94.8
STS [49] 2008 14 YSI 21.2 55.4 100
Medtronic Enlite [42] 2015 24 YSI 16.6 72.3 92.3
[50] 2014 90 YSI 14.71 81.3 98.6
[43] 2014 24 GS 17.9 69.1 98.9
[44] 2014 38 SMBG 17.8
Guardian [46] 2013 6 GS 20.3 63.7 96.9
[49] 2008 14 YSI 15.2 76.3 97.5
Abbott FreeStyle
Libre
[27] 2015 72 YSI 12
Freestyle
Navigator II
[51] 2015 57 SMBG 14.2
Navigator [43] 2014 24 GS 12.3 84.2 98.4
[46] 2013 6 GS 11.8 80.6 98.9
[48] 2009 14 YSI 16.1 77.5 93.2
[49] 2008 14 YSI 15.3 76.3 99.7
Senseonics Senseonics [30] 2015 24 VB 11.4 87 99.5
16
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studies are displayed in Table 1.1. The table includes the number of subjects (N)
involved in each study. The accuracy is presented as the mean absolute relative
difference (MARD) between the sensor measurement and the reference measurement.
Another measure of accuracy is given by the Clarke Error Grid (CEG), which is used
to determine the clinical implications of the CGM error [52]. The CGM measurements
are plotted against the corresponding reference measurements on a graph that is
divided into five zones: A, where the glucose sensor measurement was within 20%
of the reference; B, where the error was greater than 20% of the reference, but the
treatment determined from the glucose sensor and reference would have been the
same; C, where unnecessary treatment would have been given that could have led to
dangerous hyperglycemia or hypoglycemia; D, where dangerous hyperglycemia or
hypoglycemia would have gone undetected; and E, where the treatment given would
have been the opposite of the required treatment [52]. According to one source, the
percentage of points in the A and B zones should be higher than 98% to be acceptable
[23]. The table reports both the percentage of points in the CEG A zone and the
acceptable A+B zones.
The improved control quality resulting from increased CGM accuracy can be an-
alyzed as a return on investment. Once the glucose sensor reaches a certain level of
accuracy, increasing it any further will no longer lead to improved control. Much
research has been done to investigate and characterize CGM error, with the goal of
using this knowledge to improve the sensor or design filtering and processing tech-
niques to reduce the error [38, 40, 53–59]. While CGMs are not currently approved
for nonadjunctive use in the United States, it is anticipated that they will eventually
be approved for use in treatment decisions once accuracy standards are established
[20]. A major concern with the use of subcutaneous glucose sensors is the measure-
ment lag introduced by diffusion between the blood and the ISF. Placing the sensor
17
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in a different location may reduce this lag, thereby making the sensor more accurate
and reliable [38]. The characterization and impact of sensor lag are discussed more
in Chapters 3 and 4 of this dissertation.
1.3 Closed-Loop Control for Type 1 Diabetes Mellitus
1.3.1 Motivation
Even with the current standards of treatment and technology available, the risk
of premature death for people with T1DM is two times that of the average person
without it [4]. One study found that the number of participants who reach the recom-
mended HbA1c level of <7.0% was less than 15% [60]. Data from 16,061 participants
in the T1D Exchange clinical registry showed that the mean HbA1c was 8.2%, with
an average of 9.2% in 19-year-olds. Of 2,561 participants who responded to the ques-
tionnaire, 6% listed that they experienced a seizure or loss of consciousness due to
hypoglycemia within the past 3 months [61]. A separate analysis of the 13,316 par-
ticipants in the T1D Exchange aged younger than 20 years showed that only 21% of
participants met the HbA1c criteria for their age group [62].
While physicians can advise patients on how to best use their prescribed insulin,
the onus of most treatment decisions falls on the patient. The degree to which treat-
ment is successful depends greatly on the amount of effort the patient (or patient’s
guardian) is willing and/or able to exert. The patient must take over the role of the
pancreatic beta cells by frequently monitoring the BG and calculating the appropriate
insulin dose to avoid both hyperglycemia and hypoglycemia. This process is made
difficult by the myriad factors that affect insulin sensitivity and BG [63]. Since hypo-
glycemia has severe and immediate health effects, many patients become fearful of
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their BG going low and are therefore more willing to spend time in hyperglycemia,
especially since the consequences are less severe on short time scales [64]. The requi-
site constant self-monitoring can cause psychological disorders as well. For example,
people with T1DM are more likely to develop depression [65]. An algorithm that au-
tomatically controls the BG of people with T1DM by connecting a CGM and insulin
pump in a feedback loop would lessen the burden of treatment while improving the
quality of control that can be achieved.
1.3.2 Design and Implementation
The components required for closed-loop control of BG are a CGM, an insulin
pump, and a control algorithm, with appropriate communication between the three.
This combination of devices is often referred to as an artificial pancreas (AP). Beyond
the inclusion of these three essential components, there are many different choices
that can be made to design a specific AP implementation. The block diagram in
Figure 1.4 depicts the design choices that have been made in AP development. The
major components are discussed in the sections below.
Control Target
The control target is a necessary specification for an AP design. The desired BG
can be set as either a range, as in [66] or a setpoint, as in [67], depending on the
controller design [1]. The target can also be fixed or time-varying. For example,
some controller designs raise the target to a more conservative value overnight to
prevent hypoglycemia [68]. In [67], the controller target is raised from 120 mg/dL to
160 mg/dL upon announcement of exercise. On the other hand, some designs use
the same target throughout the entire operation, as in [69].
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Figure 1.4: Block diagram demonstrating the design choices available
for the artificial pancreas. A specific artificial pancreas configuration is
created by selecting options for each of the major elements shown in the
figure. Solid lines demonstrate connections that are always present and
dashed lines represent connections that may be present in only some con-
figurations. The tuning, model, and desired glucose concentration are all
part of the controller, as signified by the black arrows. The green dash-dot
line distinguishes physiological states or properties from measured or dig-
ital signals. Black lines are used to indicate predetermined features of a
block, and blue lines indicate signals or actions conducted during closed-
loop operation. Reprinted with permission from [1].
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Control Algorithm
Automatic control is a field that has been well-developed within the chemical
process industry [70]. The same algorithms that are applied to regulate the flow from
a tank or the concentration of product leaving a reactor can be successfully applied
to regulate the BG in the human body. The most frequently used control algorithms
for AP applications are model predictive control (MPC) and proportional-integral-
derivative control (PID), although other strategies such as proportional-derivative
control, fuzzy logic, and empirical algorithms have also been applied [1].
MPC is an advanced control method that utilizes a process model to predict the
future trajectory of the system based on past measurements and inputs [70]. While
an MPC controller can be designed to track a single setpoint value, it can also be
designed to keep the controlled variable within a desired zone. The latter approach
is ideal for application in T1DM, since there is no clear choice for a specific setpoint
value [71]. This approach, known as zone model predictive control (ZMPC), has been
applied successfully in several clinical studies [66, 72, 73].
The plots in Figure 1.5 demonstrate two ZMPC scenarios. At each time step, the
controller predicts the measured output P steps into the future, while calculating the
necessary input for each of the next M steps to achieve the control objective. The
objective is to minimize a cost function that weights the output error and the input
energy based on their relative importance for the system. The first calculated input
step is then implemented, after which the next measurement is received and the
process repeats [70].
When using ZMPC, action is taken only if the measured variable is predicted to
leave the desired zone. For example, in the first panel of Figure 1.5, the controlled
variable is predicted to remain within the desired zone, so the output from the con-
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Figure 1.5: Schematic representation of zone model predictive control.
At a given time-point, the controller chooses the next M inputs in order
to minimize the cost function, which includes excursions from the desired
zone for the next P predicted output values. The first input is then imple-
mented, and the process is repeated at the next time-point.
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troller will be the nominal value of the manipulated variable. In the second panel, the
measured value is predicted to leave the desired zone, so the necessary inputs over
the next M steps required to return to the zone are calculated. An additional feature
of MPC is the ability to directly incorporate constraints into the optimization process.
For example, the ZMPC controller is designed to incorporate both physiological and
safety constraints [68, 71, 74, 75]. More information about the ZMPC controller is
presented in Chapter 2.
PID controllers first became commercially available in the 1930s. This type of con-
troller includes three modes that are added together to produce the final controller
action. The proportional mode produces controller action in proportion to the error
(defined as the difference between the measurement and the setpoint). The integral
mode eliminates persistent error between the measurement and the setpoint by act-
ing in proportion to the integral of the error over time. Lastly, the derivative mode
contributes to the controller action in proportion to the rate of change of the error
[70]. PID control has been applied in several AP designs in clinical studies [67, 76–81].
This type of controller is explored more in Chapters 4 and 5 of this dissertation.
Once the controller type has been selected, it must be tuned to meet the safety
and performance requirements of the system. Additionally, predictive controllers
require the selection of a process model [70]. The tuning of the control algorithm
determines how aggressively it will react to BG deviations from the desired value.
While the specifics of the tuning procedure depend on the type of controller being
used, typically the parameters are selected using a combination of process modeling
and simulation studies [82–84]. The controller output and resulting glucose measure-
ments may be used to update the controller or model parameters through adaptation,
as demonstrated in run-to-run approaches and adaptive learning schemes [85–89].
The control algorithm generates an output for insulin delivery and may also cal-
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culate glucagon, pramlintide, and/or additional glucoregulatory hormone delivery.
The controller output is calculated at discrete times determined by the controller ac-
tion interval. This interval has typically been selected as between 5 and 15 minutes
[1].
Actuation
Following the computation of the desired controller action, this signal must be
communicated to the actuator. In nearly all clinical evaluations of the AP thus far,
the actuator has been a subcutaneous insulin pump. A limited number of trials have
used an intraperitoneal insulin pump to take advantage of the faster insulin phar-
macokinetic and pharmacodynamic properties of this route [90, 91]. A majority of
systems have used insulin alone as the manipulated variable, but some implementa-
tions have added glucagon or pramlintide as a second input [88, 92–96]. The addition
of glucagon allows the controller to have a mechanism of raising the BG in the case
of current or impending hypoglycemia [97].
Sensing
All AP implementations require at least one CGM. Typically, commercially avail-
able subcutaneous enzymatic CGMs are used. While including more than one glu-
cose sensor would make the system more robust, this approach would not be ac-
cepted by patients due to the limited space on the body for sensor placement [1].
Other types of sensors may be included to provide additional inputs to the con-
troller. For example, an activity sensor that measures heart rate and accelerometry
data may be included to detect exercise or determine whether the user is sleeping
[98]. All sensor signals need to be processed and filtered before being communicated
to the control algorithm in order to prevent undesired controller action based on sen-
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sor noise or erroneous measurements. After receiving the updated measurements,
the control cycle repeats at the next sample time [1].
User Interaction
Ideally, the AP would be fully automated, with no input required from the user.
However, due to the realities of physiological limitations in the speed of insulin ac-
tion, user input or action may be required to achieve satisfactory control. The most
frequently encountered type of user action is the meal announcement. The user is re-
quired to enter an estimate of the meal carbohydrate content prior to consuming the
meal. This announcement is a type of feedforward action that triggers an immediate
insulin bolus based on the insulin to carbohydrate ratio. However, including user
action introduces human error into the control loop. Over- or underestimation of
the meal size could lead to suboptimal performance and safety risks [1]. Additional
options for user interaction include the announcement of exercise, as in [99].
Safety Systems
While the AP is designed to result in better health outcomes for people with
T1DM, there are safety risks involved that need to be considered in the design. The
most prominent risk is hypoglycemia due to over-delivery of insulin. Most AP de-
signs include an algorithm to limit the commanded insulin dosage based on the
glucose and insulin history. The two most commonly used algorithms are Insulin On
Board (IOB) [100] and Insulin Feedback (IFB) [101]. Both of these methods use the
insulin delivery history to adjust the current insulin dose to account for how much
active insulin is already in the blood. An AP may also include an independent safety
system to detect and alert the user to impending hypoglycemia. An example of this
type of safety system is the Health Monitoring System, which alerts the user to pre-
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dicted hypoglycemia and recommends the consumption of 16 g CHO to prevent or
mitigate the episode [72, 102].
1.3.3 Recent Progress in Clinical Evaluation
To date, there have been 99 published clinical evaluations of AP devices. A full
bibliography of these studies is included in Appendix A. As shown in Figure 1.6, the
number of studies published per year has been increasing steadily since 2004, with
the peak reached in 2014. The clinical protocols used to evaluate AP designs have
varied greatly, making it difficult to compare results across different studies. Varying
factors include the number, type, and size of meals, whether meals are announced,
the presence of physical activity, the level of supervision, the setting, the length of
time spent in closed-loop, and the age and number of subjects [1].
The fifteen2 studies that were published in 2015 are summarized in Table 1.2. Of
these fifteen studies, nine took place in the outpatient environment, whether at a
diabetes camp [67, 96], in a house/hotel/outpatient suite [66, 103, 104], or at home
[81, 92, 105, 106]. The other studies simulated daily-life conditions as closely as
possible to ensure a realistic evaluation of the system. In recent years, the difference
between inpatient and outpatient evaluation has become difficult to delineate, as
studies outside the clinic can still involve significant supervision by study staff. The
transition space between inpatient studies to fully unsupervised outpatient studies is
truly a spectrum, with each study falling somewhere in between the two extremes.
A new trend observed in 2015 is the inclusion of meal announcement in all but one
of the twelve studies that included closed-loop meals [66, 67, 69, 73, 81, 94, 103, 105–
108]. Most studies used the subjects’ usual parameters to calculate either a full or par-
2The study in [69] was published online in 2015 and so is included in this discussion, although the
print publication year is 2016.
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Table 1.2: Summary of artificial pancreas clinical trials published in 2015.
Ref. Glucagon Setting Bolus Type Exercise
During CL
Controller Device
Platform
[105] No Home Full Variable MPC Android
Phone
[81] No Home Full Variable PID+IFB Android
Phone
[106] No Home Full Variable MPC Android
Phone
[92] Yes vs. No Home No CL
Meals
None MPC Computer
[96] Yes vs. No Camp No CL
Meals
None MPC Tablet
Computer
[67] No Camp Full Basketball,
Soccer,
Football,
Running,
etc.
PID+IFB Pump
[103] No Hotel Full None MPC Android
Phone
[104] No House,
Hotel
No CL
Meals
None Other Android
Phone
[66] No House,
Hotel,
Outpatient
Suite
Full
(Adjusted or
Usual I:C)
Treadmill,
Stationary
Bicycle, etc.
MPC Tablet
Computer
[107] No Clinic Full or
Partial
(100% or
75%)
Stationary
Bicycle
MPC N/A
[108] No Clinic Full None MPC Computer
[73] No Clinic Partial:
Inhaled
Insulin
Stationary
Bicycle
MPC Computer
[94] Yes vs. No Clinic Full or
Partial
(70-100%)
Treadmill MPC Computer
[69] No Clinic Full and
Partial and
None
None Other Low-power
Miniatur-
ized
Chip
[109] No Clinic None Stationary
Bicycle
FL Computer
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tial premeal bolus; however, some included novel approaches. In Zisser, et al. [73], a
partial priming bolus of fast-acting inhaled insulin equivalent to 4U of subcutaneous
insulin was delivered prior to each meal, with no carbohydrate estimate necessary.
In Dassau, et al. [66], an algorithmic adjustment was made using open-loop data to
improve the basal pattern and insulin-to-carbohydrate ratio, with the controller eval-
uated using the initial versus the adapted parameters. Lastly, Mauseth, et al. [109]
presented a study designed to push their fuzzy logic AP system to its limits. Their
challenges included unannounced exercise followed by an unannounced meal and a
large, high-fat unannounced meal (120 g carbohydrate). Testing the controller with
these extreme but realistic challenges revealed valuable information that was used to
improve the controller design.
Three of the fifteen studies used glucagon as a second hormone delivered by the
AP. Two evaluated outpatient overnight control [92, 96], while the other provided 24 h
control in clinic [94]. The 24 h study did not find significant differences between the
glycemic control provided by a single or dual hormone AP; however, the study was
short and conducted in the inpatient setting. An AP system incorporating glucagon
remains a promising area of research during the transition into longer, unsupervised
outpatient studies.
Ten of the studies published in 2015 used model predictive control (MPC) [66, 73,
92, 94, 96, 103, 105–108]. Other controllers used were fuzzy logic [109], proportional-
integral-derivative plus insulin feedback (PID+IFB) [67, 81], and empirical or model-
based controllers [69, 104]. Five of the studies hosted their algorithm on an Android
phone [81, 103–106], one directly on the pump [67], one on a miniaturized low-power
microchip [69], two on tablet computers [66, 96], and five on computers [73, 92, 94,
108, 109].
Exercise is a part of daily life for most people, so the AP will certainly need to
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handle this challenge. For this reason, it has become almost standard to include
exercise activities during closed-loop. The studies in 2015 included many types of
exercise, including using a treadmill [66, 94], using a stationary bicycle [66, 73, 107,
109], playing sports (basketball, soccer, football, running) [67], or following subjects’
typical exercise routine [81, 106].
Overall, the year 2015 in clinical AP research represents the transition period from
inpatient to outpatient studies. New territory is being crossed as researchers learn of
the unique and perhaps unanticipated challenges that must be met to incorporate the
AP into a person’s daily routine. Included in this process is the transition from laptop
computers to more portable devices. Studies moving into the fully outpatient envi-
ronment inevitably become less controlled than supervised inpatient studies, while
at the same time providing a better picture of the work that still needs to be done to
make the AP a viable product for patients. Studying the protocol details and results
of these publications will allow the research community to learn valuable lessons as
they plan their next round of studies and move toward the goal of an AP to improve
care for people with T1DM.
The studies that have been published as of May 20163 are presented in Table 1.3.
The trends observed in 2015 have continued. All of the studies took place in an out-
patient environment except for those in [95, 111, 112], which took place in the clinic to
meet their purposes of rigorously comparing different meal bolus strategies or study-
ing the effects of liraglutide or pramlintide injections. Exercise was included in all
but three studies, and most were conducted on a smart phone or custom integrated
device.
3The studies presented in [110] and [69] are not included in this table because they were published
online ahead of print in 2014 and 2015, respectively, although the print publication dates are 2016.
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Table 1.3: Summary of artificial pancreas clinical trials published in 2016.
Ref. Glucagon Setting Bolus Type Exercise
During CL
Controller Device
Platform
[113] No Home Full Usual
Routine
Empirical
Control-to-
Range
Android
Phone
[114] No Home Full Usual
Routine
MPC Nexus 5
Phone
[115] No Home Full Usual
Routine
MPC Nexus 4
Phone
[116] Yes Home None Usual
Routine
PID Custom
Integrated
Device
[80] No Protected
Home
Full Variable PID+IFB Android
Phone
[117] No Camp Unknown Moderate to
High
Intensity
MPC Android
Phone
[118] No Camp No CL
Meals
None PID+IFB Android
Phone
[119] Yes Camp Partial Usual
Routine
MPC iPhone 4S
[99] No Hotel Full Usual
Routine
PID+IFB Pump
[120] Yes vs. No Outpatient Full or
Simplified
Usual
Routine
MPC Tablet
Computer
[111] No Clinic None None PID+IFB Unknown
[112] No Clinic None None PID+IFB Laptop
Computer
[95] Yes Clinic Full or
Partial or
None
Walking MPC Computer
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1.3.4 Challenges and Future Directions
The AP system must be able to handle frequent disturbances to the BG that are
part of daily life. Important challenges include meals and physical activity, both of
which result in rapid changes in the BG. Nearly all of the AP designs developed so far
have utilized subcutaneous glucose measurements paired with subcutaneous insulin
delivery. An significant disadvantage of this route is that it depends on molecular
transport between the blood and ISF. The delays associated with this route culmi-
nate in approximately 90 minutes between when insulin is delivered and when its
effects on the subcutaneous glucose concentration are seen [121]. Such a large delay
makes compensation for meal disturbances difficult, so many researchers have added
a prandial insulin bolus or meal announcement to their control scheme [1, 122]. While
this approach may result in better control, it is not ideal because the system is not
fully automated and human action is added to the control loop. For this reason, an
important future direction for AP development is the investigation of alternate in-
sulin delivery and glucose sensing sites. As discussed in the following section, this
dissertation is focused on characterizing these alternate insulin delivery and glucose
sensing sites and evaluating their use in the AP.
1.4 Thesis Overview
In this dissertation, the development of the AP is explored, with a specific focus
on the role of the glucose sensing and insulin delivery route in determining overall
controller performance. Chapter 2 presents the application of the state-of-the-art
ZMPC+HMS AP in adolescents. During the trial there were significant challenges
to the controller, including twice-daily mild to moderate exercise and free-choice
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announced meals.
Since subcutaneous CGMs measure glucose concentration within the ISF, they
introduce an undesirable diffusion lag to the measurement process. We hypothesized
that placing the sensor in the intraperitoneal space would decrease the diffusion lag.
In Chapter 3, experimental data is used to quantify the diffusion lag experienced by
subcutaneous and intraperitoneal sensors placed in non-diabetic swine. Additionally,
the effect of long-term sensor implantation is explored.
In Chapter 4, the lag estimation from Chapter 3 is used to explore the impact of
glucose sensor dynamics on the AP. The error caused by various amounts of sensor
lag is quantified using retrospective analysis of clinical data. Robust performance
and stability analysis, as well as simulation studies, are used to quantify the effect of
sensor lag on the AP controller performance.
Current implementations of the AP are limited by the properties of subcutaneous
glucose sensors and insulin pumps. Chapter 5 outlines the process used to design a
robust PID controller for use in a fully implantable AP that is designed to work with
intraperitoneal devices. Data from the sensor lag studies, as well as from previous
studies of intraperitoneal insulin pharmacokinetic and pharmacodynamic properties,
inform the design of the controller.
Chapter 6 provides a summary of the conclusions made in this dissertation. The
future directions of the work described here are also outlined.
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Outpatient Evaluation of Artificial
Pancreas with Exercise in Adolescents1
2.1 Introduction
As discussed in Chapter 1, advances in medical device technology have enabled
vast improvements in the way that type 1 diabetes mellitus (T1DM) is treated. For
example, the use of continuous glucose monitors (CGMs) provides patients with a
wealth of information about their blood glucose concentration (BG), its history, and
its real-time trends, allowing them to make more informed adjustments to their in-
sulin therapy. Improvements in CGM technology have increased the accuracy of these
devices, with the prediction that they will soon be approved for non-adjunctive use in
the United States [20]. In addition to CGMs, rapid-acting insulins and programmable
pumps for continuous subcutaneous insulin infusion (CSII) have also shown promise
in allowing patients to exert finer control over their BG; however, successful imple-
1 Portions of this chapter were submitted for publication in the journal Pediatric Diabetes on 13
May 2016 [123]. This study is registered on clinicaltrials.gov with clinical trial registration number
NCT02506764.
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mentation of CSII and CGMs requires time, effort, and ongoing education on the part
of patients and their families [124]. The development of a closed-loop artificial pan-
creas (AP) device to regulate the BG by adjusting insulin delivery in real-time based
on feedback from a CGM will automate the treatment process, removing much of the
daily patient effort and active decision-making that are a part of manual treatment
[1]. While AP devices have been shown to be safe and effective in the inpatient envi-
ronment [66, 72, 78, 125–129], a great challenge remains in determining their safety
and feasibility in a free-living outpatient environment [81, 96, 105, 106, 130–136].
Model predictive control (MPC) is an advanced control strategy that has been
widely implemented in the chemical industry for controlling complex processes with
input and output constraints [70, 137, 138]. This control strategy is promising for use
in the AP, especially due to its ability to directly incorporate physiological constraints
(i.e., cannot remove insulin from the body), its capacity to handle delays in insulin
action, and its customizability in designing the objective function to optimize insulin
delivery according to clinical needs [71, 72]. The state-of-the-art Zone Model Predic-
tive Control (ZMPC) AP algorithm developed at UCSB and Harvard University uses
a model to predict the future BG trajectory and calculate the optimal insulin dose
needed to maintain the BG trajectory within a desired zone, rather than at a specific
set point [71, 74, 75]. When the BG is predicted to be within the desired zone, the
controller delivers the usual basal insulin dose to minimize excessive controller ac-
tion in response to small changes in glucose, such as may occur with noise in CGM
measurements. When the predicted BG trajectory includes excursions from the zone,
the controller modulates the insulin dose up or down to deliver the optimal dose to
produce safe and effective glucose control as calculated by the objective function. The
Health Monitoring System (HMS) provides an additional safety layer, independent
of the controller, to predict and alert the user to impending hypoglycemia [72, 102].
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The ZMPC algorithm has performed well in several controlled inpatient and re-
search suite evaluations in adults with T1DM [66, 72, 73]. For this controller to be
tested in the outpatient setting, a portable platform is required. To this end, the
ZMPC+HMS algorithms were integrated into the Diabetes Assistant (DiAs) platform
from the University of Virginia (UVA), hosted on an Android smartphone [139]. The
DiAs system has undergone extensive clinical testing to demonstrate its safety and
feasibility for use in the outpatient setting [139]. The remaining components of the
AP system are a Dexcom G4P Share CGM (San Diego, CA) and a Roche Accu-Chek
Spirit Combo pump (Mannheim, Germany), as shown in Figure 2.1. The devices
communicate wirelessly via BluetoothTM, eliminating the need for hard-wired con-
nections. The data is automatically transferred by the DiAs platform to a secured
server to allow the subject’s status to be monitored remotely.
3G/
WiFi
Zone Model 
Predicve Control
Health 
Monitoring System
Roche Accu-Check 
Insulin Pump
Wireless
Connecvity
Dexcom G4P CGM
with Share
Remote
Monitoring
Server
Clinical and 
Technical Sta!
Figure 2.1: Components of the ZMPC+HMS/DiAs system. The
ZMPC+HMS algorithms are hosted on the DiAs platform, which runs
on medical Android on a Nexus 5 phone. The DiAs platform commu-
nicates with the Roche Accu-Chek insulin pump and the Dexcom G4P
CGM via Bluetooth. The DiAs platform also communicates with the DiAs
Web Monitoring site by 3G or internet connection.
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While the feasibility of the AP with ZMPC+HMS has been demonstrated in the
adult population in controlled inpatient or research suite settings, it has neither been
evaluated in children or adolescents, nor in highly ambulatory settings with frequent
exercise [66, 72]. Satisfactory glucose control in adolescents and children with T1DM
is notoriously difficult to achieve, with T1D Exchange data showing that approxi-
mately 80% of adolescents have hemoglobin A1c (HbA1c) values above the American
Diabetes Association target of 7.5% (58 mmol/mol)[61, 62]. This trend is particularly
concerning for older adolescents, who saw an average HbA1c of 9.0% (75 mmol/mol)
in the 13-17 year-old age group [61]. Adolescents experience both physiological chal-
lenges due to changes in insulin sensitivity related to puberty [140–143] and psy-
chosocial barriers presenting as missed meal boluses, less frequent self-monitoring
of blood glucose (SMBG) testing, and difficulty following a fixed plan or regimen
[144]. Significantly elevated insulin resistance in pubertal teenagers presents a chal-
lenge to model-based controllers, as the parameters for this population may differ
from those modeled for adults with T1DM. Additional challenges to AP systems in
this age group include school-based sports and more frequently missed meal boluses.
The purpose of this study was to determine the feasibility of the AP with
ZMPC+HMS in adolescents with T1DM engaging in supervised, free-living condi-
tions with twice-daily mild to moderate intensity exercise. This study represents the
first evaluation of the ZMPC+HMS algorithms in the adolescent population. Addi-
tionally, this study is the first evaluation of the ZMPC+HMS algorithms in the transi-
tional hotel environment with frequent repeated exercise, thus bridging between the
inpatient and unsupervised outpatient settings.
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2.2 Research Design and Methods
2.2.1 ZMPC+HMS/DiAs System
The integration of the ZMPC+HMS algorithms with the DiAs platform and de-
vices comprises a portable automated glucose management system (see Figure 2.1).
The ZMPC algorithm automatically regulates the insulin dose based on the glucose
level as determined by current and historical CGM measurements, predicted glucose
trends, historical insulin delivery, and patient-specific information. The model used
by the controller to predict future glucose concentrations is personalized using the
subject’s total daily insulin dose (TDI). The algorithm is designed to drive the BG to
a target zone. During the day (06:00-22:00) the target zone is 80-140 mg/dL and dur-
ing the night (24:00-04:00) the target zone is 90-140 mg/dL, with smooth, two hour
transitions in between the two. As long as the BG is predicted to remain in the target
zone, the controller delivers the subject’s usual basal rate. A previous iteration of the
ZMPC algorithm is described in detail in [68]. Additional features that modify the
objective function to enhance performance in correcting hyperglycemia, while also
reducing the risk of hypoglycemia, are presented in [74, 75].
The HMS provides an additional safety layer outside of the ZMPC algorithm
by analyzing CGM data and trends to detect impending hypoglycemia [102]. This
system produces an audio-visual alarm when the CGM is predicted to cross the
65 mg/dL threshold within 15 min. The user is prompted to perform a SMBG mea-
surement and to treat with oral carbohydrates (CHO), thus preventing or mitigating
the impending hypoglycemic episode.
The ZMPC+HMS/DiAs system is programmed at the start of the study with the
subject’s TDI, as well as the insulin to CHO ratio (CR), correction factor (CF), and
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basal rate profiles. Meal announcements are made through the DiAs interface to
trigger a bolus. The bolus size is computed using the preprogrammed CR and CF
profiles based on the meal size estimate and a SMBG measurement. If the SMBG
at the time of the meal is <120 mg/dL or if no SMBG is entered, the bolus size is
80% of the value computed using the CR. If the SMBG at the time of the meal is
>120 mg/dL, the bolus size is 100% of the value computed using the CR. Lastly, if
the SMBG is >150 mg/dL, the full meal bolus is accompanied by a correction bolus
to 150 mg/dL calculated using the CF. The correction bolus is added only if there has
not been another meal bolus with a correction bolus within the past two hours.
The insulin dose calculated by the controller is subject to safety constraints. At
each five-minute interval, the insulin dose is limited to be less than 1 U (excluding
meal/correction boluses). During the period of 22:00 to 04:00, the insulin infusion
is constrained to be less than 1.8 times the basal rate. Lastly, the Insulin on Board
(IOB) algorithm prevents over-delivery of insulin by taking into account the insulin
infusion history over the past eight hours [75, 100].
2.2.2 Study Design
The primary objective of this study was to determine safe and feasible operation
of the ZMPC+HMS/DiAs system in adolescents with T1DM engaging in free-living
conditions with twice-daily unannounced mild to moderate intensity exercise. Ten
subjects were recruited for the study (5 subjects each at Stanford University (SU) and
the Barbara Davis Center (BDC)). Subjects resided in a hotel setting for three days,
where they slept overnight and engaged in mild to moderate intensity exercise at
least twice daily, with clinical staff in attendance at all times. Subjects chose the
size, content, and timing of their meals to emulate free-living conditions, with no
restriction on meal size. The study protocol was approved by the Stanford University
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Institutional Review Board and the Colorado Multiple Institutional Review Board.
The inclusion criteria for the study were: clinical diagnosis of T1DM, daily insulin
therapy for at least 12 months, aged 10 to 19 years, insulin pump use for at least 3
months with current use of a downloadable pump, TDI requirement >0.4 U/kg/day
over the preceding two weeks, and ability to speak and understand English. Addi-
tional criteria for female participants were: use of acceptable method of contraception
if sexually active and a negative urine pregnancy test for subjects who have entered
menarche. Informed consent was obtained from subjects and/or parents and the as-
sent form signed by the subject if <18 years. Study exclusion criteria were diabetic
ketoacidosis (DKA) in the past month, history of seizure or loss of consciousness in
the last 6 months, or any medical disorder that would affect the completion of the
protocol.
2.2.3 Study Preparation
The Dexcom G4P Share CGM was inserted during a screening visit at least 72 h
prior to the hotel admission. Subjects continued with their usual sensor-augmented
pump therapy (SAP) during the period between CGM insertion and the beginning of
the CLC phase. The data from this period were analyzed to determine the subjects’
usual glycemic control. Upon arrival for the CLC phase, subjects removed their own
pumps and inserted a new infusion set for use with the study pump. After program-
ming the pump and DiAs system with the subjects’ information and establishing
communication between the study devices, CLC was commenced.
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2.2.4 Daily Study Procedures
A full timeline of events at each site is shown in Figure 2.2. The daily procedures
for the trial proceeded as follows: subjects ate breakfast at the hotel, then left for su-
pervised sessions of physical activity in the morning and afternoon. Exercise was not
announced to the system. The physical activity sessions included a variety of mild
to moderate intensity exercise of variable duration lasting at least 30 min. The exer-
cise sessions included activities such as soccer, basketball, tennis, ultimate FrisbeeTM,
walking, and bicycling. Lunch was provided during the afternoon between physi-
cal activity sessions. Dinner was consumed in the evening, followed by additional
activities such as playing pool, completing schoolwork, and watching movies. CLC
continued for three full days (72 h). Throughout the study, subjects made their own
food choices and decided their own meal size announcement. At least three meals
were consumed per day, with no restrictions on food selection. Subjects were also
free to choose the type and intensity of physical activity.
Start CL
10:00
Overnight Overnight Overnight
Exercise Exercise Exercise
End CL
10:00
Meals Meals Meals
24:00 08:00 24:00 08:00 24:00 08:00
Meal
Start CL
17:00
Overnight Overnight Overnight
ExerciseExercise Exercise
End CL
17:00
Meal Meals Meals
24:00 08:00 24:00 08:00 24:00 08:00
Meals
Figure 2.2: Timeline of the 72 h protocol at each clinical site. The timeline
indicates timing of meals, exercise, and overnight periods. The top panel
shows the timeline for SU, and the bottom panel shows the timeline for
BDC.
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Participants were provided with a meter for fingerstick SMBG measurements and
test strips. SMBG measurements were required at a minimum of 5 times daily (before
meals, prior to and after exercise and at bedtime) throughout the study. An additional
SMBG check was done by study staff at 03:00. CGMs were calibrated as per the
manufacturer’s instructions (at least twice daily), and any time there was a calibration
request from the CGM itself, provided that the SMBG was between 40-400 mg/dL
and the CGM indicated a low rate of change by displaying a horizontal arrow. The
CGM was also calibrated if the error compared to SMBG was >20%.
2.2.5 Safety and Remote Monitoring
At least one clinical staff member was present at all times to supervise use of the
system during the day and night. Monitoring was performed by visually observing
the subjects or by checking the remote monitoring website to view the current status
of all subjects. Subjects were asked to respond to HMS alerts by taking a SMBG
measurement. The HMS alert prompted the user to enter the SMBG and to indicate
whether treatment was given. In the case that SMBG>70 mg/dL, the subject was
prompted to treat with oral CHO, but the treatment was not required. In the case
that SMBG<70 mg/dL or the subject was symptomatic, the subject was given oral
CHO and the SMBG check and treatment process was repeated every 15 min until
SMBG>70 mg/dL and/or the subject was no longer symptomatic.
2.2.6 Statistical Methods
The primary outcome of this study was the feasibility of the system in this co-
hort and setting. Feasibility was defined as proper functioning of the system for at
least 75% of the total study time. Secondary outcomes included percentage of time
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spent in various glycemic ranges and mean CGM (as described in the recommen-
dations published in [145]). The secondary outcomes were evaluated using CGM
values from the entire CLC period. The data are presented as either mean±standard
deviation (SD) or median (interquartile range (IQR)), depending on the determined
distribution. Comparison between the CLC and SAP data was done using either a
paired sample Student’s t test for normally distributed data, or the Wilcoxon signed
rank test for non-normal data. Normality was determined using the Shapiro-Wilk
goodness-of-fit test. The statistical analysis was performed using Matlab 2015b.
2.3 Results
Ten adolescents (11-17 years, 5M/5F) completed 3 days of CLC in a hotel setting,
resulting in 30 person-days of CLC. Subject information is shown in Table 2.1. Data
from 95±14 h of SAP immediately prior to CLC are included to provide a comparison
to the subjects’ glycemic control with their usual therapy.
Table 2.1: Subject demographics for the study (N=10).
Characteristic
Age, years, mean ± SD (range) 15.3 ± 1.8 (11.9-17.7)
Gender, n (%)
Female 5 (50)
Male 5 (50)
Race and ethnicity, n
White 9
Native Hawaiian or Pacific Islander 1
Weight, kg, mean ± SD (range) 58.4 ± 13.9 (37.4-85.2)
Body mass index, kg/m2, mean ± SD (range) 21.5 ± 3.6 (15.6-26.9)
Hemoglobin A1c,
%, mean ± SD (range) 8.1 ± 1.3 (6.8-11.2)
mmol/mol, mean ± SD (range) 65 ± 14 (51-99)
Duration of diabetes, years, mean ± SD (range) 5.1 ± 2.3 (2.3-9.6)
Total daily dose (U/day, mean ± SD (range) 48.8 ± 18.2 (26.8-86.1)
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2.3.1 System Performance
The system demonstrated feasibility in this cohort, with CLC active for 95.0±1.1%
of the intended study time, or 97.3±1.7% of the time when excluding the two hours
of disconnection resulting from CGM change required in 6 of the 10 subjects. The
primary cause of time spent out of CLC was disruption in the Bluetooth connection
between the devices. The system was safe in this cohort, with no episodes of DKA
or severe hypoglycemia resulting in seizure or coma. All system safety alerts for hy-
poglycemia and hyperglycemia performed as expected. In one subject (referred to as
subject 4), the controller did not perform as intended due to a technical issue with the
integration of the DiAs and ZMPC systems. Due to a timing anomaly the controller
did not exploit CGM feedback properly for approximately 60% of the study duration.
During this time the controller was not able to respond as designed to increasing or
decreasing CGM trends. Instead, basal insulin delivery was commanded. The issue
was not detected until the data analysis stage of the study, and did not affect safety
during the trial. The subject’s data was included in the analysis on an intention-to-
treat basis for the feasibility and glucose control endpoints; however, the subject is
delineated from the others during discussions of controller performance.
2.3.2 Glucose control
The glycemic control characteristics during CLC and SAP are summarized in Ta-
ble 2.2 and Figure 2.3. Overall, subjects spent 71±10% of time in the desired range
of 70-180 mg/dL. The CLC period showed a significant improvement over the sub-
jects’ usual therapy, where only 57±16% of time was spent in the 70-180 mg/dL
range (p=0.012). Additionally, time in the tight control range of 80-140 mg/dL was
significantly higher during the CLC session, with 47% (39%, 53%) of time in range
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during CLC, as compared to 30% (21%, 42%) during SAP (p=0.002). In general, CLC
provided a tighter distribution of CGM values, with a narrower vertical band on the
cumulative histogram (Figure 2.4).
Table 2.2: Comparison of glycemic control during daytime and overnight
for CLC versus SAP therapy.
CLC SAP p-value
Day and Night
Mean CGM (mg/dL) 150 ± 19 173 ± 31 0.042*
SD CGM (mg/dL) 58 ± 13 95 ± 14 0.23
COV CGM (%) 39 ± 5 38 ± 8 0.87
% of Time
70-180 mg/dL 71 ± 10 57 ± 16 0.012*
80-140 mg/dL 47 (39, 53) 30 (21, 42) 0.002*
>180 mg/dL 26 ± 11 39 ± 18 0.033*
>250 mg/dL 8 ± 6.9 16 ± 14 0.088
>300 mg/dL 3.5 ± 3.9 7 ± 7.6 0.22
<70 mg/dL 2.5 ± 1.8 4.2 ± 3.1 0.13
<60 mg/dL 0.68 ± 0.63 1.9 ± 1.8 0.076
<50 mg/dL 0.13 ± 0.26 0.44 ± 0.5 0.125
Overnight (00:00-07:00)
Mean CGM (mg/dL) 154 ± 30 157 ± 45 0.832
SD CGM (mg/dL) 45 ± 16 46 ± 19 0.91
COV CGM (%) 29 ± 8 30 ± 9 0.88
% of Time
70-180 mg/dL 71 ± 22.5 67 ± 23 0.713
80-140 mg/dL 46 ± 26 34 ± 17 0.18
>180 mg/dL 29 ± 23 27 ± 28 0.902
>250 mg/dL 6 ± 7.1 11 ± 18 0.456
>300 mg/dL 2.2 ± 3.8 4.2 ± 7.1 0.448
<70 mg/dL 0 (0, 0.6) 1.1 (0, 14) 0.078
<60 mg/dL 0 (0, 0.2) 0.1 (0, 7.6) 0.156
<50 mg/dL 0 (0, 0) 0 (0, 1.5) 0.25
The proportion of time that each subject spent with CGM>180 mg/dL and
CGM<70 mg/dL during CLC and SAP is indicated by the points plotted in Fig-
ure 2.5. The contour lines on the plot represent the percentage of time with CGM in
the range of 70-180 mg/dL. Ideal control is represented by the lower left corner of
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Figure 2.3: Box and whisker plot showing the percentage of time with
CGM in various ranges for SAP and CLC. The horizontal blue lines in-
dicate the medians, the box represents the IQR, and the thin vertical lines
represent the range. Outliers are shown as plus symbols.
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Figure 2.4: Cumulative histogram of CGM values for all 10 subjects
during SAP and CLC. The thick line represents the average, and the thin
lines represent the minimum and maximum values. The red, green, and
blue shaded areas show <50 mg/dL, 70-140 mg/dL, and 140-180 mg/dL,
respectively.
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the plot, with improvements in control demonstrated by movement toward this ideal
corner. The subjects showed a migration toward the lower-left corner during CLC,
with an overall narrower distribution on the plot demonstrating consistent control
between subjects. The SAP results are scattered across the upper and right portions
of the plot, demonstrating wide variability in quality of control during usual therapy.
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Figure 2.5: Plot of percent time >180 mg/dL versus percent time <70
mg/dL for each subject. The symbols indicate CLC (red triangles) or SAP
therapy (blue circles). The parallel dotted lines show contours of percent-
age time in range (TIR, 70-180 mg/dL). The large unfilled triangle and
circle indicate the mean for CLC and SAP, respectively.
The mean sensor glucose during closed-loop was 151±19 mg/dL. This result was
significantly lower than the SAP value of 173±31 mg/dL (p=0.042). Excluding subject
4, subjects who had a high mean glucose (>168 mg/dL) during SAP saw a decrease to
48
Chapter 2. Outpatient Evaluation of Artificial Pancreas with Exercise in Adolescents
a lower value during CLC, along with an increase in the percent time in range (Figure
2.6A). For other subjects, the mean glucose remained steady, while the percentage of
time in hypoglycemia remained similar or decreased (Figure 2.6B).
The median CGM traces for 24 h glycemic control for CLC and SAP are shown in
Figure 2.7. The distribution of announced meals and snacks during CLC is shown in
the lower panel of the figure (meal information was not recorded during SAP). The
dinner meals at the Stanford site were consumed late in the evening (19:49, 20:53,
and 20:11), which contributed to the hyperglycemia in the beginning of the overnight
period experienced by some subjects. Individual glucose and insulin traces for each
subject are shown in Appendix B.
2.3.3 Hypoglycemia
Time spent with CGM <70 mg/dL was 2.5±1.8% during CLC. While this is lower
than the SAP value of 4.2±3.1% of time, the difference was not significant. Overnight
(00:00-07:00), time <70 mg/dL during CLC was reduced to 0% (0%, 0.6%). The
amount of time spent in hypoglycemia as defined by various thresholds during CLC
and SAP is shown in Figure 2.8. Information about the number and duration of
hypoglycemic episodes during CLC (defined as a CGM excursion below the speci-
fied threshold for >10 min as recommended in [145]) is shown in Table 2.3. Overall,
there were 1.3 (0.58, 2.0) episodes per subject per day <70 mg/dL and 0.33 (0.0, 0.5)
episodes per subject per day <60 mg/dL. The HMS provided 1.8 (1.3, 3.5) alarms per
subject per day warning of impending hypoglycemia. These alerts allowed subjects
to take a carbohydrate treatment before the hypoglycemic event had started, thereby
preventing or shortening the impending hypoglycemic event.
Three subjects each experienced a single event where the CGM measured below
50 mg/dL. These events lasted 4, 24, and 25 min, respectively. They were preceded
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Figure 2.6: Mean CGM for each subject during SAP and during CLC.
The line connecting icons represents the same subject. (A) The size of the
circle icon indicates the percentage of time spent in range (70-180 mg/dL).
(B) The size of the circle icon indicates the percentage of time spent below
70 mg/dL. The dashed red line represents a mean BG of 168 mg/dL,
which corresponds to an HbA1c of 7.5% (58 mmol/mol) [146]
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Figure 2.7: CGM over 24 h during the closed-loop study during SAP and
CLC periods. The solid and dashed lines show the median CGM value for
10 subjects during CLC and SAP, respectively, while the shaded regions
show the IQR. The lower panel shows the time and size of announced
meals during CLC.
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Figure 2.8: Box and whisker plot showing the percentage of time in
hypoglycemia for various thresholds for SAP and CLC. The horizontal
blue lines indicate the medians, the box represents the IQR, and the thin
vertical lines represent the range. Outliers are shown as plus symbols.
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Table 2.3: Number of hypoglycemic events lasting more than 10 min by
CGM per subject per day. Episodes are broken down during overall 24 h
control, during and 30 min after exercise, and during the overnight period,
shown as median (IQR).
Threshold <50 mg/dL <60 mg/dL <70 mg/dL
Total episodes 2 11 36
Per subject per day
Overall 0 (0, 0.08) 0.33 (0, 0.5) 1.33 (0.58, 2)
Exercise (+30 min) 0 (0, 0) 0.17 (0, 0.42) 0.5 (0.33, 1)
Overnight (00:00-06:00) 0 (0, 0) 0 (0, 0) 0 (0, 0.08)
Number of exercise
sessions with episode per
subject (of 6 or 7)
0 (0, 0) 0.5 (0, 1.3) 1.5 (1, 3)
by 124, 72, and 48 min of pump suspension, which started when the CGMs were
133 mg/dL, 168 mg/dL, and 110 mg/dL. The second event occurred during exer-
cise, although the CGM was already at 87 mg/dL when exercise began. Alerts from
the HMS and corresponding CHO treatments, as well as the controller-directed sus-
pension of insulin delivery, allowed subjects to recover quickly from these episodes,
with no adverse events. Each of these events occurred in the time period 2-4 h after
a meal, indicating that the meal bolus could have contributed to the event.
2.3.4 Insulin
The average TDI during CLC was 47±18 U/day (0.81±0.23 U/kg/day). This
amount was not significantly different from the usual TDI values of 49±18 U/day
(0.82±0.17 U/kg/day) (p=0.52). Still, the percentage of time spent in hyperglycemia
(>180 mg/dL) decreased from 39±18% of time during SAP to 26±11% of time during
CLC (p=0.03). The ZMPC+HMS system was able to significantly reduce the amount
of time spent in hyperglycemia without significantly increasing the TDI or increasing
time spent in hypoglycemia.
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2.3.5 Carbohydrate Consumption
Meal choice throughout the study was determined by the subjects, with no re-
strictions. The average amount of CHO estimated for meals per day was 208±32 g
for female subjects (n=5, mean weight 56 kg) and 259±60 g for male subjects (n=5,
mean weight 61 kg). Meal size estimation and announcement were performed by
subjects. A standard schedule of three daily meals was followed, with opportunities
for snacks as desired.
2.3.6 Exercise
Subjects engaged in 2-3 daily sessions of mild to moderate intensity exercise last-
ing at least 30 min each. This frequency and duration of exercise was intended to
challenge the system, since there was no announcement to the controller of exercise
or pre-exercise preparation, such as lowering or suspending basal insulin delivery.
Additionally, the exercise took place following large breakfast or lunch meals, when
the IOB could be high (estimated IOB at start of exercise was 2.0 U (0.54 U, 4.1 U)).
Since there was no exercise announcement or activity measurement in this study,
the only way for the controller to react to an exercise event was through feedback
from the CGM (i.e., if the CGM is decreasing quickly or approaching hypoglycemia).
In Figure 2.9, the final CGM is plotted versus the minimum rate of change during
each exercise session, with the size of the icon indicating the duration of any associ-
ated controller-directed pump suspension. There are three ways a pump suspension
can be associated with an exercise period: (1) the pump suspension began during the
exercise period, (2) the pump suspension began before the exercise period and lasted
at least 30 min after the start of the exercise period, or (3) the pump suspension began
within 30 min of the end of the exercise period. An indication of desired controller
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performance is a pump suspension when the CGM is low at the end of exercise, es-
pecially if the CGM is also dropping quickly. Additionally, the pump should not be
suspended (or should suspend for only a short period), if the CGM is high and/or if
the CGM was steady or increasing.
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Figure 2.9: CGM at exercise end versus minimum rate of change during
exercise for each exercise period for each subject. The size of the icon
indicates the length of pump suspension associated with that exercise pe-
riod, in minutes. Exercise periods with no pump suspension are filled
red. Exercise periods with no pump suspension for the subject where the
controller was not functioning as intended are filled blue.
As shown in Figure 2.9, the controller performed as desired during exercise in this
study. Excluding subject 4, there were pump suspensions associated with all exercise
periods ending with CGM below 108 mg/dL, regardless of the rate of change. If the
CGM during exercise was dropping any faster than -0.9 mg/dL/min, then there were
pump suspensions for all exercise periods ending with CGM below 131 mg/dL. If
the CGM during exercise was dropping at a rate that was any faster than -1.6 mg/dL,
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there were pump suspensions for all exercise periods, regardless of the final CGM.
Lastly, the pump did not suspend for each exercise period where CGM was dropping
no less than -0.9 mg/dL/min and ending CGM was greater than 150 mg/dL. Includ-
ing subject 4, there were three instances where a pump suspension would have been
desired but did not occur. These results are summarized in Table 2.4. As a result of
the ZMPC+HMS action during exercise, only 1.5 (1, 3) exercise sessions per subject
(of a total 6 or 7 exercise sessions) resulted in a hypoglycemic event with CGM <70
mg/dL.
Table 2.4: Number of exercise periods with pump suspensions out of
total exercise periods for various ranges of minimum rate of change
(ROCmin) and CGM at exercise end (CGMend). The asterisk indicates
cases where there would have been 100% pump suspension excluding sub-
ject 4.
ROCmin (mg/dL/min)
CGMend (mg/dL) < -2.5 -2.5 to -1.6 -1.6 to -0.9 -0.9 to 0 > 0
>150 2/2 1/1 2/4 0/3 0/3
131-150 N/A 1/1 1/3 1/2 N/A
108-131 2/3* 6/6 2/2 1/5 N/A
90-108 2/2 6/7* 3/3 1/1 N/A
<90 7/7 5/6* 2/2 2/2 N/A
2.4 Discussion
In this chapter, we present the first evaluation of ZMPC+HMS in the adolescent
population. This study showed that the use of this system is feasible in this pop-
ulation. Even in the face of challenges such as large free-choice meals, twice-daily
mild to moderate unannounced exercise, and ambulatory conditions in the outpa-
tient environment, the controller was able to achieve 71±10% time in range, which is
an improvement over the subjects’ typical control (57±16% time in range). This im-
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provement was made without increasing the amount of time spent in hypoglycemia
or increasing the TDI.
The glycemic control in this study is comparable to that observed in other day-
and-night studies of CLC for adolescents. For example, Tauschmann, et al. [115]
showed a median (IQR) of 72% (59%, 77%) of time spent with glucose level between
70-180 mg/dL, as compared to our study, which had 72% (64%, 79%) time in range.
Similarly, Ly et al. [67] reported a mean of 70% time spent in range. While the proto-
cols and controller designs of these studies differed, the similarity of the results for
insulin-only systems indicates that performance may be limited by the constraints
of the slow action of subcutaneous insulin and the hormones present during adoles-
cence that make control difficult. Additionally, these systems are not fully automated.
There is work involved for the patients that can introduce error into the system, such
as in meal size estimation and determination of basal, CR, and CR profiles. Innova-
tions in AP design to reduce the need for patient interaction, including faster insulin
action, may be needed to improve above the 70-75% time-in-range mark.
The pattern of hypoglycemic episodes during the postprandial period, especially
visible following breakfast (Figure 2.7) suggests that some of the meal boluses could
have been too large. Although the system is designed to give 80% of the total meal
bolus when BG is below 120 mg/dL, there were 57 out of 161 meals that were an-
nounced with BG >120 mg/dL and therefore received the full bolus. One potential
cause of postprandial hypoglycemia is a CR that is too high. An algorithmic adjust-
ment of the insulin to carbohydrate ratio based on open-loop data as in Dassau, et al.
[66] could potentially reduce postprandial hypoglycemia during CLC. Errors in the
estimation of the meal size could be caused either by subjects estimating CHO for
the entire meal but only consuming part of it, or overestimating the amount of CHO
in the meal. Subject behavior could also be influenced by the clinician-supervised
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setting, where there may be more pressure to demonstrate good control and avoid
under-dosing. Several studies have investigated the use of a partial bolus based on a
percentage of the total calculated bolus for the meal regardless of the SMBG, allowing
the controller to deliver the rest of the required insulin on an as-needed basis using
feedback from the CGM [78, 88, 147]. While Elleri, et al. [107] did not find evidence
that a partial meal bolus reduced the risk of hypoglycemia, they found that it did
not decrease the time spent in range. Further investigation is needed to optimize the
integration of an announced meal bolus within the AP system.
There was some hyperglycemia during the overnight period in this study, espe-
cially in the first half of the night. This hyperglycemia was caused by late-night meals
and snacking, as shown in the lower panel of Figure 2.7. The protocol should always
be kept in mind when interpreting overnight control results calculated using a com-
mon predetermined time range (e.g. 00:00 to 07:00), especially for studies that allow
varying or unusual meal and sleep schedules. Protocols that allow late-night meals
or snacks will inevitably result in more overnight hyperglycemia. Overnight control
in this study was conservative by design, with safety constraints in place to prevent
over-delivery of insulin from 22:00 to 06:00. Using fixed start and end times for the
additional safety measures at night does not allow for flexible or atypical sched-
ules. An added announcement for sleep to start the safety constraints may reduce
overnight hyperglycemia if users are awake and/or eating at atypical times. How-
ever, this extra announcement also creates additional work for the user and may lead
to safety risks if the user forgets to make the announcement. The compromise be-
tween design safety and efficacy will be an important consideration as the AP moves
forward.
Although this study took place in the outpatient environment, subjects were su-
pervised at all times. Study staff were on hand to assist subjects with troubleshooting
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the system, checking infusion sets and CGM sites, and responding to system alerts,
although subjects were responsible for estimating meal size, entering their meal bo-
lus, taking SMBG measurements, and interacting with the DiAs interface. The pres-
ence of the clinical team ensured that HMS and other system alarms were responded
to promptly. The level of supervision in this study could have led to better results
than if the subjects had been unsupervised. When using the device unsupervised in
daily life, subjects may respond less quickly to alerts for hypo- or hyperglycemia or
take longer to repair loss of communication between devices. Alternatively, subjects
may be more vigilant during unsupervised use since they will not have the reassur-
ance that nearby clinical staff provide. Still, the level of supervision in this study,
necessary to comply with regulatory requirements, had the advantage of ensuring
the best possible assessment of the ZMPC algorithm itself, with minimal time spent
out of CLC and no confounding factors related to patient non-compliance.
There were some technical difficulties encountered during this study. These is-
sues represent the primary challenge that is faced when transitioning from a highly
controlled inpatient environment to a more unpredictable outpatient environment. A
timing anomaly between the CGM and the DiAs system caused a malfunction in the
controller for one subject, resulting in suboptimal (but still safe-by-design) perfor-
mance. The potential for this issue has since been addressed in updated versions of
the controller. Additionally, disruptions in the Bluetooth communication between the
pump, CGM, and DiAs system resulted in some time spent out of CLC. These com-
munication issues need to be improved as the system is prepared for more extensive
outpatient use.
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2.5 Conclusions and Future Work
In conclusion, the ZMPC+HMS algorithms were shown to be feasible for use in
the adolescent population. Additionally, the system was able to provide improved
glycemic control as compared to SAP, even in the ambulatory outpatient environment
emulating real-life conditions. The controller was not informed of the twice-daily
exercise sessions, but it was able to react to the decreasing CGM measurements to
lower or suspend insulin delivery during or after exercise as needed. This study
represents a promising step forward for the ZMPC+HMS AP system in the transition
from inpatient to outpatient evaluation, as well as in expanding the user population
to include adolescents as well as adults.
A follow-up study is being conducted to evaluate the system in the fully out-
patient, unsupervised environment. This study will be conducted in a randomized
crossover design, with a total of 10 subjects at each clinical site. Five subjects will be
randomized to use CLC and five will use SAP during a two week period at home.
The subjects will then cross over to the other therapy for the next two-week session.
This design will provide a control group that can be used for efficacy comparisons be-
tween SAP and CLC. This study will be conducted in adults, rather than adolescents,
because the system is not yet ready to be used in a fully outpatient unsupervised set-
ting by adolescents. The study has been approved by the FDA based on supporting
data from this chapter, and will be conducted in May-June 2016.
While the ZMPC+HMS algorithms are able to provide control of the BG, the use of
subcutaneous insulin delivery and glucose sensing places fundamental limitations on
the quality of control that can be achieved. The system is not fully automated, since
users must enter an estimate for the meal carbohydrate content prior to eating. Even
with this meal announcement and subsequent insulin bolus prior to the meal, there
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are still postprandial BG values reaching above 300 mg/dL. Additionally, suspending
the pump is not always enough to prevent hypoglycemia due to the long residence
time of subcutaneously delivered insulin in the body. For these reasons, a promising
area of research related to the artificial pancreas is the investigation of alternative
insulin delivery and glucose sensing routes. In the next three chapters, the use of
the intraperitoneal space for glucose sensing and insulin delivery for the artificial
pancreas is explored.
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Chapter 3
Modeling Glucose Sensor Dynamics1
3.1 Introduction
An important factor in diabetes treatment is the ability to measure blood glucose
concentration (BG) accurately in real-time. As discussed in Chapter 1, the devel-
opment of continuous glucose monitors (CGMs) has greatly improved the ability of
people with diabetes to be aware of their glycemic status beyond the few isolated
capillary measurements that used to be the norm [21]. However, the decision on
where to place the sensor in the body is not easily made. The first application of
CGM was done in the intravenous space. These sensors provided fast and accurate
BG measurements, but were not feasible for use outside of a hospital and came with
unacceptable safety risks [2, 149]. The selection of a CGM site requires a balance
between proximity to the vasculature and the level of invasiveness required.
The placement of a CGM in the subcutaneous (SC) space has been adopted
1 Portions of this chapter are published in D. R. Burnett, L. M. Huyett, H. C. Zisser, F. J. Doyle III,
and B. D. Mensh, “Glucose sensing in the peritoneal space offers faster kinetics than sensing in the
subcutaneous space,” Diabetes, vol. 63, pp. 2498-505, 2014 [38], and L. M. Huyett, R. Mittal, H. C.
Zisser, E. S. Luxon, A. Yee, E. Dassau, F. J. Doyle III, and D. R. Burnett, “Preliminary evaluation of
a long-term intraperitoneal glucose sensor with flushing mechanism,” Journal of Diabetes Science and
Technology, 2016 [148].
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for commercial application. This placement meets the requirements of being close
enough to the vasculature to capture real-time changes in BG, while minimizing in-
vasiveness by requiring only a small wire to be inserted under the skin [23]. Glucose
enters the body through the ingestion of food. After the glucose is absorbed through
digestion, it travels through the major and minor blood vessels to reach the brain,
muscle cells, and other tissues. To reach individual cells, the glucose first diffuses
from capillaries into the interstitial fluid (ISF), as depicted in Figure 3.1. The ISF of
the SC space has been established as a minimally invasive site for a sensor to provide
a continuous estimation of the BG. Commercially available glucose sensors detect the
glucose once it has reached the ISF using a transcutaneous electrode or other sensing
mechanism [23].
While the sensor measures the glucose concentration in the ISF, the raw sensor
signal is calibrated using a measurement of the glucose concentration in the capillary
blood. The gradient between the glucose concentration in the blood and the ISF at
steady state has been reported as anywhere from 50% to 100%, but is difficult to
establish definitively due to the lack of techniques for directly measuring the concen-
tration of glucose in the ISF [53, 150]. However, many studies have established the
accuracy of SC glucose sensors that are calibrated to BG values across a wide range of
physiological BG values, making it a reasonable assumption that the concentrations
are directly proportional or equal at steady state [20].
CGM in the SC space has several limitations. The sensor insertion below the skin
induces an inflammatory response, leading to biofouling and tissue encapsulation
[23, 151, 152]. This response limits the lifetime of the sensor to one to two weeks, after
which a new sensor must be inserted. SC sensors are sensitive to external factors
such as pressure on the sensor site, often induced during sleep by laying on the
sensor site. Studies have shown that this pressure effect causes large and persistent
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Figure 3.1: Schematic representation of the glucose transport process
from the blood vessel to the ISF. This diagram is based on the model
presented in [150].
inaccuracies in the measurement [33, 39]. Pressure effects on sensor measurements
are problematic, given that accurate measurements are particularly important during
sleep when patients are vulnerable to hypoglycemia [33, 153–162].
A limitation of SC CGM that is especially relevant to artificial pancreas (AP) ap-
plications is the dynamic lag that is introduced by sensing in the ISF. Before reaching
the sensor site, glucose must diffuse from the bloodstream into the ISF. Experimental
evidence has shown that SC CGM measurements appear to lag behind the BG [163–
171], an effect that is exacerbated by encapsulation [172, 173]. Recent studies have
found that radiolabeled glucose could be detected in the SC space with a pure delay
of 5-6 minutes after IV injection [57, 58].
While the SC space has become the most popular route for diabetes applications
such as glucose sensing and insulin delivery, the intraperitoneal (IP) space has long
been known as an alternative. The IP space was first introduced as an alternative
insulin delivery route in the 1970s [174]. Insulin delivered through the IP route has
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faster pharmacokinetic and pharmacodynamic characteristics than insulin delivered
through the SC route: when insulin is delivered through the SC route, the absorption
peak occurs 50-60 minutes later [175], as opposed to 20-25 minutes when using the
IP route [176]. The insulin is also cleared more quickly: insulin delivered through
the SC route has a residence time of 6-8 hours [175], while IP insulin has a much
shorter residence time of 1-2 hours [176]. Characteristics of the IP space that make
it an ideal candidate for CGM location include its proximity to copious blood flow
through vessels lining the peritoneal cavity [177–179], its demonstrated foreign-body
tolerance in humans [180–182], and its isolation from external factors (temperature
and pressure).
In this chapter, we present a direct comparison of enzymatic glucose sensors
placed in the IP and SC space of anesthetized pigs. We hypothesized that a sen-
sor placed in the IP space would respond more quickly to changes in BG than a
sensor placed in the SC space of the same animal.
3.2 Research Design and Methods
3.2.1 Overview of Animal Experiments
Experiments were conducted under an IACUC-approved protocol. Multiple sen-
sors (described below) were placed in the SC, IP, IV, and intra-arterial (IA) spaces of
eight anesthetized nondiabetic juvenile female Yorkshire pigs weighing between 60
and 90 kg. After allowing several hours for sensor wetting and baseline measures, in-
travenous hyperglycemia challenges similar to a glucose tolerance test (IVGTT) were
administered, consisting of 250 mg/kg of D50 pushed over 2 minutes intravenously
by an infusion pump. Venous samples were drawn at frequent intervals post-injection
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and analyzed by glucometer and YSI (YSI Inc., Yellow Springs, OH) assay. In several
animals, an additional IVGTT was administered, separated from the first challenge
by at least 90 minutes.
3.2.2 Sensors and Placement
The sensors used in the SC space were commercially available Dexcom Seven
(DEXCOM, San Diego, CA) sensors placed in the pre-abdominal SC tissue using
standard technique for sensor placement per manufacturer instructions. The sensors
used in the intravenous and intra-arterial spaces were modified Dexcom Seven sen-
sors, lengthened by attaching 30-gauge wires to the silver and platinum electrodes
using conductive silver epoxy, and encapsulating these joints with epoxy to prevent
shorts due to fluid intrusion. The IA and IV sensors were placed through introduc-
ers after cut-downs to the femoral or jugular vessels. The sensors used in the IP
space were modified Dexcom Seven sensors, lengthened in the same manner as the
IA/IV sensors and splinted to a short length of Teflon-coated coaxial wire with sili-
cone o-rings in order to prevent the sensors from bending excessively or perforating
IP tissues. IP sensors were placed in the peritoneal cavity via the Hassan technique.
The signal from all sensors was captured with custom potentiostat electronics and
read into LabVIEW via an analog-to-digital converter. Prior to all analyses, sensor
data was smoothed using a 60-s moving average filter. Some of the data logging for
experimental manipulations was done using a clock with 1-minute resolution, which
could introduce a ±30-second error relative to the sensor board (which recorded at
1-second resolution).
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3.2.3 Data Analysis: Response Time
Response characteristics for each sensor were initially quantified using two mea-
sures on each sensor waveform during the IVGTT. First, to quantify latency between
rapid increases in BG and extravascular sensor measures, we calculated the time
to half-maximum (from beginning of IVGTT). Second, to quantify how rapidly the
extravascular measures recover toward baseline glucose levels after the bolus, we cal-
culated the percentage by which each sensor reading returned (from its maximum)
to baseline at 35 minutes post-glucose-injection.
3.2.4 Data Analysis: Compartmental Modeling
Glucose sensors placed in either the IP or SC space do not directly contact the
blood; rather, they contact the ISF of the sensing space. The diffusion process be-
tween the blood and the ISF means that the concentration measured by the sensor
may lag behind the BG, especially when the BG is increasing or decreasing at a high
rate of change. However, it is hypothesized that the lag will be smaller for IP sen-
sors due to the proximity to major vasculature. In order to quantify the lag from
experimental data, a two-compartment model can be used to represent the glucose
diffusion process. This type of two-compartment model has been used in previous
studies to approximate the transport of glucose between the vascular compartment
and the SC compartment [183–187]. The schematic in Figure 3.1 demonstrates the
two-compartment system. The first compartment is the blood within the vessel, and
the second is the ISF. Glucose diffuses between the blood vessel and the ISF, and vice
versa. Glucose is also taken up from the ISF into cells.
A mass balance can be done on the ISF compartment to determine the rate of
change of the glucose concentration in that compartment. The resulting first-order
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model for ISF glucose concentration as a function of the glucose concentration in the
major blood vessels as follows, where all time-dependent variables are measuring the
deviation from steady-state:
dCm(t)
dt
= −(k3 + k2)Cm(t) + k1 VbVis f CIV(t− θS) (3.1)
where Cm(t) is the glucose concentration measured by the sensor (mg/dL), CIV(t)
is the glucose concentration in the blood (mg/dL), k1, k2, and k3 (min−1) are the
rate constants for the diffusion processes as defined in Figure 3.1, Vb and Vis f are
the volumes of the blood and ISF, respectively, and θS is the time delay (min). By
grouping constants together, this model can be expressed as:
dCm(t)
dt
=
1
τS
(KˆSCIV(t− θS)− Cm(t)). (3.2)
Here τS = 1k3+k2 (min) and KˆS =
k1Vb
(k3+k2)Vis f
.
The glucose sensors used in this study record the measurement signal as an elec-
trical current (nA). The glucose concentration depends linearly on the current as
given in the following equations:
Cm(t) = aIm(t) (3.3)
CIV(t) = bIIV(t) (3.4)
where a and b are constants (mg/dL)/(nA). The model in Equation (3.2) can be
expressed generically as:
dym(t)
dt
=
1
τS
(KSyIV(t− θS)− ym(t)) (3.5)
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where yIV(t) is the model input (mg/dL or nA) and ym(t) is the model output
(mg/dL or nA). If it is desired to use the uncalibrated sensor signal as the output
of the model, then KS = 1a KˆS (nA/(mg/dL)). Similarly, if it is desired to use the
uncalibrated sensor signal as the model input, then KS = ba KˆS. Note that a and b
change between each individual enzymatic sensor, meaning that it will be difficult to
validate the model parameters identified from one sensor signal on another sensor
signal when using uncalibrated sensor signals. Lastly, before modeling, each sensor
signal can be normalized by its maximum value. The additional ratio of yIV,maxym,max will be
absorbed into the identified parameter KS. Note that even with all these adjustments,
the lag τS can still be identified.
Equation (3.5) can be expressed as a transfer function in the Laplace domain as
follows:
GS(s) =
Ym(s)
YIV(s)
=
KSe−θSs
τSs + 1
. (3.6)
The identifiable parameters in this transfer function model are the sensor time con-
stant τS (min), the sensor delay θS (min), and the model gain KS. Since the most
challenging aspects of AP design involve time periods where the glucose is changing
rapidly (after meals or during exercise), the filtering effect of the sensor dynamics is
expected to have a detrimental effect on the control quality.
To determine the dynamic response characteristics of each space, the IP and SC
sensor signals were modeled for each IVGTT challenge as a function of the vascular
glucose concentration. The Systems Identification Toolbox in MATLAB (The Math-
Works Inc., Natick, MA) was used to numerically fit the data to a first-order transfer
function with time delay using least-squares regression. The time delay quantifies
the amount of time it takes for the SC or IP sensor signal to begin to respond to a
change in the vascular glucose. The time constant represents the amount of time it
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would take for the IP or SC signal to reach 63% of the vascular glucose concentration
if a step change in vascular glucose were applied.
The models were initially fit using glucometer measurements of venous blood
to represent the glucose concentration in the vascular compartment (yIV(t)), while
either the IP or SC sensor signal was used for ym(t). The normalized root-mean-
square error fitness value was used to quantify the goodness of fit of the model. This
quantity is given by the following equation:
F = 100(1− ||y− yˆ||||y− y¯|| ) (3.7)
where y is the experimental data (in this case, the sensor signal), yˆ is the output of
the fitted model, y¯ is the mean of y, and F is the goodness of fit (%).
If more than one sensor was placed in a particular space during a challenge, the
resulting model parameters were averaged. The robustness of the result was sub-
sequently bolstered by comparing model parameters using the following additional
data sources as yIV(t) in the model: signal from an indwelling IV sensor and signal
from an indwelling IA sensor. In all cases, the parameters generated by compartmen-
tal modeling (most importantly the time constant) are a model-specific measure.
3.2.5 Data Analysis: Statistics
Thirteen IVGTT challenges in 8 animals were performed. In general, the null
hypothesis for the study was that SC and IP sensor performance is equal. For each set
of data in which we asked whether the null hypothesis was rejected, we carried out
two statistical tests: one in which we assumed that the challenges were independent
even when performed in the same animal (thus, n=13), and one in which we assumed
that challenges performed in the same animal were completely dependent (thus,
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n=8). In both cases we used the binomial test, which is an exact, non-parametric
test of the significance of deviations from a theoretically expected distribution of
observations into two categories. The expected distribution according to the null
hypothesis is that there is a 50% chance that for a given challenge (or animal) that IP
will be faster than SC, and vice-versa.
3.3 Results
Figure 3.2 shows raw sensor current data from a hyperglycemia challenge. Of
note are the rapid rise and fall of the intravascular (IA and IV) sensors, and the less
rapid waveforms from the extravascular (IP and SC) sensors. Figure 3.2B illustrates
the response-time analysis described above, in which latency (a measure of how
rapidly the tissue glucose increases after a vascular bolus) and recovery (a measure
of how rapidly the tissue glucose decreases as the vascular glucose decreases over 35
minutes post-bolus) were read from each sensor curve.
Figure 3.3A compares the latency between sensors in the SC and IP spaces for the
13 IVGTT challenges (across eight animals) that were successfully carried out. On this
plot, each challenge is depicted as a single point in which the IP latency (y-axis) is
plotted against the SC latency (x-axis) for the same challenge. For each space, latency
was calculated as the mean time to half-maximum for all sensors in that space for that
challenge. SC latency was in the 4-8 minute range, consistent with the faster end of
the range from prior published results (see Introduction). A diagonal line of identity
is included in the plot, which illustrates that for all 13 challenges in all 8 animals, IP
latency was shorter than SC latency (p<0.001 for challenges, p<0.01 for animals). To
assess whether wetting time might influence the results, two of the 13 challenges were
conducted using SC sensors that had been wetted overnight instead of for several
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Figure 3.2: Example of experimental data used in this study. (A) Sample
raw data from an intravenous glucose challenge in one pig. Unfiltered
data were collected every second (1 Hz). (B) Calculation of latency (time-
to-half-maximum) and recovery (percent return-to-baseline at 35 minutes)
for a sample IP trace. Data are filtered using a 1-minute sliding window
average. Baseline is determined by the average reading for the 3 minutes
prior to onset of glucose challenge. As with baseline, the value at 35
minutes is also determined by a 3-minute average (33.5 to 36.5 minutes).
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hours on the morning of the experiments. The results from these sensors were in the
middle of the range of the overall results, suggesting that overnight wetting does not
have a large effect on SC response times. However, because we only performed this
on two sensors, we do not have the statistical power to quantify small influences.
Figure 3.3B compares the post-glucose-bolus recovery between the two sensor
spaces, in a plot similar to Figure 3.3A. The average recovery for the SC space was
33%, compared to 59% for the IP space. For all challenges, the IP space showed more
complete return to pre-challenge baseline glucose levels than the SC space (all points
above diagonal identity line, p<0.001 for challenges, p<0.01 for animals). Finally, we
quantified the glucose kinetics of the SC and IP spaces using compartmental mod-
eling, in which the glucometer measurements served as an input function and the
transport of glucose into the body spaces was modeled with a first-order transfer
function. The glucometer measurements were used in place of the YSI measure-
ments because the YSI data was too sparse to use as a model input. This approach
yielded excellent fits to the data, as illustrated in Figure 3.4; across all challenges the
mean goodness of fit was 75.6% (standard deviation (SD) 8.5%) for the IP sensor data
and 83.2% (SD 8.9%) for the SC sensor data. The uncertainty of the parameters as
determined from the covariance matrix was so small as to be negligible (standard
deviations on the order of 1% of fitted values).
As illustrated in Figure 3.5, IP glucose kinetics during IVGTT were an average of
2.3 times faster than SC (range: 1.2 to 4.1, standard deviation: 1). The mean time
constant was 5.6 (SD 2.9) minutes for the IP space and 12.4 (SD 3.6) minutes for
the SC space. The difference between the SC and IP time constants was statistically
significant, with the IP time constant smaller than that of SC for all 13 challenges
(by paired t-test, p < 0.001; by binomial test p < 0.001 for challenges, p < 0.01 for
animals). The mean time delays were 0.68 (SD 0.58) minutes and 1.4 (SD 0.90) minutes
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Figure 3.3: Comparison of response speed between IP and SC sensors.
(A) Latency (time to half-maximum) is plotted for IP vs. SC for all 13 chal-
lenges across eight pigs. The diagonal line represents IP=SC; thus points
below the line indicate IP faster than SC. (B) Recovery (Percent return to
baseline at 35 minutes, see Figure 3.2B for definition) is plotted for IP vs.
SC for all 13 challenges across eight pigs. The diagonal line of identity
represents IP=SC; thus points above the line indicate IP sensor readings
returning to baseline by a greater amount than SC sensors returned to
baseline for the same IVGTT challenge.
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Figure 3.4: Sample of compartmental modeling fit to data. This plot
shows an example of the model fitting process for a single challenge, using
glucometer measurements as the input (black circles). Shown on the plot
are the experimental measurements made by the IP and SC sensors (white
triangles and white squares, respectively), as well as the model predicted
output for each sensor (solid line and dashed line). The goodness of fit
values for the IP and SC models shown were 89% and 90%, with time
constants of 1.7 min. and 13.1 min., respectively.
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for IP and SC sensors, respectively, although there was an estimated tolerance of 30
seconds to account for potential differences in clock synchronization. The delay for
the IP sensor was significantly smaller than the SC delay (by paired t-test, p = 0.019).
The addition of second-order dynamics did not improve the model fit.
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Figure 3.5: Comparison of kinetic-modeling-based response speed be-
tween IP and SC sensors for all 13 challenges. The diagonal line repre-
sents IP=SC; thus points below the line indicate IP time constants smaller
(faster) than SC.
To demonstrate the robustness of the finding that IP kinetics are more than twice
as fast as SC kinetics, we repeated the modeling analysis using additional sources of
data to represent the vascular glucose concentration in the model (yIV(t)) in Equa-
tion 3.5). For the challenges that had usable indwelling IA and/or IV sensors, the
readings from those sensors were used as the input for modeling. Thus, the kinetics
were modeled using the following three representations of the BG, unless a viable
signal was not available: indwelling IV sensor, indwelling IA sensor, and glucome-
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ter measurements of venous blood. Figure 3.6 demonstrates that the greater than
twofold speed increase for IP over SC is independent of input-function source.
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Figure 3.6: Comparison of kinetic time constants between subcutaneous
and IP sensors from models fit using three different input sources for
vascular glucose concentration. The average ratio is shown, with error
bars indicating the standard error. The number above the bar specifies the
number of challenges that had a usable signal from that particular type of
input. For each type of input, the average IP time constant was less than
half of the SC time constant from the same challenge.
3.4 Discussion
In summary, we show that glucose kinetics between the bloodstream and the
IP space are substantially faster than between the bloodstream and the SC space,
77
Chapter 3. Modeling Glucose Sensor Dynamics
demonstrating the suitability of the IP space for more rapidly measuring changes in
BG. This improvement is likely due to the robustness of peritoneal transport, which
is, for example, why this space is effectively used for dialysis in patients with renal
failure.
The performance difference between sensing in the IP and SC spaces is of par-
ticular importance when considered in the context of closed-loop AP implementa-
tions. After a carbohydrate-containing meal, an ideal AP system would bring plasma
glucose levels back to baseline nearly as quickly as an endogenous pancreas; how-
ever, with sensor lag in SC CGM devices and slow SC insulin pharmacokinetic and
pharmacodynamic properties, there will inevitably be time spent in hyperglycemia
following the meal. Reduction of delays in the feedback loop for the AP has been
shown to provide quantitative improvements in controller performance [188]. In
Chapter 4 of this dissertation, the mathematical model for glucose sensing kinetics
developed in this study is used to inform an in silico evaluation of the benefits of IP
sensors for closed-loop control with an AP in combination with IP insulin delivery.
As described in the introduction, the decision of where to place in vivo glucose
sensors involves a trade-off between rapid access to plasma glucose, durability with
respect to avoidance of tissue effects, and invasiveness-related complications. The
IP space may optimize this trade-off, as previous work has shown that the IP space
has an excellent safety profile, with no peritonitis across 63 patients over 381 patient
years of implantation [180]. While the safety risk profile will not be identical, since
the sensor does not deliver a hormone with growth-like properties, we do expect a
sensor to have a nearly identical safety risk profile. Furthermore, unlike catheters
placed in the central vasculature, which have been found to occlude in up to 36% of
patients within 1-2 years [189], peritoneal dialysis catheters have been found to have
a mechanical failure rate of only 0.5% over 21 months when the catheter is placed in
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the true pelvis beyond the reach of the omentum [190]. In addition, while this space
would have very little, if any, inherent lag, central venous catheters place patients
at risk for long-term vascular complications related to catheter-related thrombosis
which occurs in up to 50% of children and 66% of adults with a long-term central
venous catheterization [189].
However, tissue effects are still a potential problem, particularly with catheters
placed in the upper quadrants of the peritoneal cavity. Haveman also showed that in
the absence of a mechanism to prevent encapsulation, 49 re-operations were required
in 63 patients over 381 patient years for catheter clogging [180]. Thus, although the
development of encapsulation in the IP space is much slower than in the SC space,
it is still an issue that needs to be contended with, in order to realize the goal of a
long-term, fully-implanted, durable AP. Additionally, although the IP space is more
mechanically protected than the SC space (by virtue of being further from intrusion
by objects in the environment), the IP space does experience mechanical motion and
pressure fluctuations during normal activities such as breathing and peristalsis which
may impact signal stability.
3.5 Long-term Sensor Evaluation
The direct comparison between SC and IP enzymatic glucose sensors presented
in this chapter demonstrated that the IP sensors had a smaller dynamic lag than
the SC sensors. However, in order to be used in a fully implantable AP, the IP
sensor would need to maintain this same level of responsiveness over long periods of
implantation on the order of one year. Tissue encapsulation is known to deteriorate
the performance of long-term implantable SC continuous glucose monitors (CGMs),
preventing these devices from meeting the functionality requirements for widespread
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use and creating a bottleneck in AP development [23, 191]. While recent studies of
implanted SC sensors have shown promising results, there is still much room for
improvement, including the reduction of encapsulation-induced sensor lag [30, 152].
We present a proof-of-concept study of a novel flushing-assembly developed by our
collaborators at TheraNova, LLC to routinely clean the sensor surface of an IP-placed
sensor, thereby prolonging its lifetime, while also taking advantage of the smaller
sensing lag in this space. Placing the sensor in the IP space allows flushing with
saline that would not be possible in the restricted SC space.
Fluorescent glucose sensors were implanted in the SC or IP space of sheep. Sen-
sors were provided by the manufacturer in a lengthened, tethered format. The IP
sensors were modified with silicone tubing, flush port, Dacron cuff, and adaptors to
allow flushing with saline solution. Experiments were conducted under an IACUC-
approved protocol by BioSurg, Inc. (Davis, CA). After preliminary testing to optimize
the flushing procedure, long-term responsiveness was evaluated with an IP sensor
placed in one sheep and an SC sensor placed in a second sheep. The IP sensor was
flushed weekly with saline. Glucose response challenges were performed periodi-
cally over three months by infusing 0.5 g/kg dextrose through an ear vein over 60
seconds (13 challenges over 114 d for IP, 9 challenges over 91 d for SC). The results
are summarized in Figure 3.7.
The IP sensor demonstrated anomalously slow response during the first chal-
lenge (day 8) due to tissue trauma following implantation, which is known to cause
inflammatory response [152]. Excluding day 8, the IP sensor maintained consistent
responsiveness throughout the 114 d period, with time to half-maximum (t1/2) be-
tween 2.7-4.7 min and time to maximum (tmax) between 11.6-17.2 min. Conversely,
the non-flushed sensor in the SC space gradually lost responsiveness, with t1/2 be-
tween 2.6-13.5 min and tmax between 9.7-72 min. By 91 d following implantation, the
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Figure 3.7: Demonstration of the sensor signal response to intravenous
glucose challenge. (A) Representative signal response curves to IVGTT
from sensor in the IP space which was flushed. The solid, dashed, and
dash-dot lines represent days 20, 63, and 98, respectively. (B) Represen-
tative signal response curves to IVGTT from the sensor in the SC space
without flushing. The solid, dashed, and dash-dot lines represent days
41, 55, and 91, respectively. (C) The number of days since insertion for
each challenge is indicated on the y-axis, while the time-course of the
challenge is shown on the x-axis. The time at which the signal reached
half-maximum is indicated by a blue star for SC and a red plus sign for
IP. The time at which the signal reached maximum is indicated by a blue
square for SC and a red circle for IP. The length of the dotted line con-
necting each pair of points shows the amount of time that passed between
reaching half-maximum and reaching maximum.
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SC sensor signal did not peak within the 60 min testing period (see Figure 3.7B).
The development of long-term implantable CGMs is a key step toward making
this technology more practical; however, CGM performance is hindered by diffu-
sion lag and loss of sensitivity caused by encapsulation driven by the foreign body
response [152, 191]. The IP space has already been shown to be valuable to AP ap-
plications, with experimental evidence showing both faster insulin action and faster
glucose sensing in this space [19, 38]. The performance of the flushed IP sensor pre-
sented here far exceeded that of the conventional SC sensor, showing promise for
further investigation of the flushing method. Further studies with a larger sample
size will be needed to confirm this effect.
3.6 Conclusions and Future Work
The IP space shows promise for glucose sensing as part of a fully implantable AP.
A direct comparison in an animal study showed that sensors placed in the IP space
have about half of the dynamic lag of sensors placed in the SC space of the same
animal. In order to make the IP sensor practical for long-term implantation, it needs
to have protection from tissue encapsulation. A proof-of-concept study introduced
the use of a flushing mechanism to allow CGM in the IP space with consistent re-
sponsiveness during 3 months in vivo. This flushing mechanism will be investigated
in further studies with larger sample sizes and control sensors to verify its efficacy
in preventing encapsulation. Future iterations of this system will utilize automated
flushing of the sensing element with small volumes of fluid drawn from the patient’s
bodily fluids. Data generated from the studies presented in this chapter will guide
the development of an IP CGM to enable an implantable AP and improve practicality
of CGM use for day-to-day diabetes therapy. In the following chapter, the effect of
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sensor lag on the closed-loop AP is considered.
3.7 Acknowledgments
I gratefully acknowledge the contributions of my collaborators from TheraNova,
LLC to this chapter and corresponding publications [38, 148]. Dr. Daniel Burnett
and Dr. Brett Mensh designed and conducted the experiments to provide the ex-
perimental data for the modeling analysis. They also contributed to discussions that
informed the data analysis strategy and to the writing of the publication.
83
Chapter 4
Impact of Glucose Sensing Dynamics
on the Artificial Pancreas1
4.1 Introduction
As introduced in previous chapters, the artificial pancreas (AP) comprises a con-
trol algorithm, an insulin pump, and a glucose concentration sensor. The system
is depicted by the block diagram in Figure 4.1. The control algorithm delivers in-
sulin to maintain the blood glucose concentration (BG) within the clinically desired
range. The performance of the AP is constrained by the physical limitations in-
troduced by the choice of location for the insulin pump and glucose sensor. Most
clinically tested AP devices have used subcutaneous (SC) insulin delivery and glu-
cose sensing devices, which are minimally invasive and commercially available for
use [1, 193]. However, as discussed in the previous chapter, the SC route intro-
duces transport processes in both the absorption of insulin from the SC space to
1Portions of this chapter are reproduced from L. M. Huyett, E. Dassau, H. C. Zisser, and F. J. Doyle
III, “Impact of glucose sensing dynamics on the closed-loop artificial pancreas,” 2015 American Control
Conference (ACC), Chicago, IL, 2015, ©2015 IEEE, and portions were submitted for publication in IEEE
Control Systems on 31 May 2016 [192].
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the blood and the diffusion of glucose from the blood to the SC space, adding time
lags to the control loop [1, 18, 186]. For this reason, most AP systems are not fully
automated; instead, the system requires the user to manually enter the amount of
carbohydrates in a meal before eating it to trigger a bolus of insulin. Such hybrid
systems have been recently evaluated in clinical studies using model predictive con-
trol (MPC), proportional-integral-derivative control (PID), and fuzzy logic control
schemes. These AP designs have been able to achieve an average of 68%-81% of time
in the range 70-180 mg/dL, depending on the protocol, length of closed-loop, degree
of supervision, and controller design [66, 67, 80, 106, 115, 119].
Glucose/Insulin
Interaction
Controller+
-
Insulin
PK
Control
Objective
Blood Glucose 
Concentration
Glucose
Sensor
Digestion
Process
Meal
Individual 
with T1DM
u
y
ym
Insulin
Pump
u
Figure 4.1: Block diagram representation of the artificial pancreas. The
controller receives the measured glucose concentration, ym, and compares
it to the control objective. The controller then determines the desired in-
sulin dose, u, and sends it to the insulin pump. Depending on the insulin
delivery route, the insulin is absorbed into the bloodstream with a specific
pharmacokinetic (PK) profile. The insulin then acts to change the glucose
concentration, which is affected by other disturbances such as meals. The
blood glucose concentration is measured by the sensor. Depending on the
sensor type and placement, the transfer function may have a different char-
acteristic time constant. The shaded blocks show the parts of the process
that can be changed through pump and sensor site selection.
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In order to improve the percentage of time spent in the desired range, it may
be necessary to alter the system design. For example, there are means to reduce
the lags observed with the SC route, such as implanting the pump and/or sensor
in the intraperitoneal (IP) space. This location is closer to major vasculature, which
increases the speed of glucose diffusion and insulin absorption as compared to that
observed in the SC space. Insulin delivery through the IP route has been shown to
reduce the frequency of hypoglycemic episodes and improve the glycemic control of
people with type 1 diabetes mellitus (T1DM) [194–196]. Additionally, as presented in
the previous chapter, placing the sensor in the IP space has been shown to reduce the
lag associated with the glucose measurement. However, the benefit of this placement
must outweigh the cost of increased invasiveness [19, 38]. Devices in the IP space
require surgery to conduct the placement, while SC devices are primarily external
and involve only a small transcutaneous insertion that can be done by the patient.
The improvement in AP performance gained by decreasing the insulin pharma-
cokinetic time constant was quantified in a previous study [188]. Additionally, im-
proved controller performance has been observed in clinical studies using IP or in-
haled insulin, which are both associated with faster pharmacokinetic and pharmaco-
dynamic properties than the SC space [73, 90, 197]. In this chapter, a complementary
study to [188] is performed to quantify the impact that glucose sensing lag has on an
AP that uses either SC or IP insulin delivery.
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4.2 Continuous Glucose Sensing
4.2.1 Modeling the Sensor Response
As discussed in the previous chapter, the diffusion process between the blood and
the ISF means that the concentration measured by the glucose sensor may lag behind
the BG, especially when the BG is increasing or decreasing at a high rate of change.
A two-compartment model can be used to represent the glucose diffusion process
and quantify this lag. The sensing dynamics can be expressed as a transfer function
in the Laplace domain as initially introduced in Chapter 3:
GS(s) =
Ym(s)
YIV(s)
=
KSe−θSs
τSs + 1
(3.6)
where Ym(s) and YIV(s) are the Laplace transforms of the sensor measurement
(mg/dL) and the BG (mg/dL), respectively. The identifiable parameters in this trans-
fer function model are the sensor time constant τS (min), the time delay θS (min), and
the model gain KS. Note that from this point onward, θS will be set to zero, since
it was found to be negligibly small through experimental evidence [38]. Also, the
sensor measurement is expected to equal the BG measurement at steady-state when
the sensor is calibrated properly, so the gain KS is set to 1. The resulting simplified
model of sensor dynamics is:
GS(s) =
1
τSs + 1
. (4.1)
Since the most challenging aspects of AP design involve time periods where the BG
is changing rapidly (after meals or during exercise), the filtering effect of the sensor
dynamics is expected to have a detrimental impact on the control quality. This effect
is demonstrated in the Bode plot in Figure 4.2. The smaller the sensor lag is, the
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higher frequencies of input can be tolerated without losing response tracking.
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Figure 4.2: Bode plot showing the deterioration of sensor response for
values of τS from 5 to 30 min. The smaller the sensor lag is, the higher
frequencies of input can be tolerated without losing response tracking.
Placing the sensing mechanism in a more highly vascularized area, such as the
IP space, has been shown to facilitate more rapid sensing of glucose changes. The
experimental data presented in Chapter 3 was used to quantify the dynamic response
of glucose sensors placed in either the SC or the IP space of non-diabetic swine. This
animal model is often used for studies that require a model of the human endocrine
system. The data showed that the sensors implanted in the IP space of swine had
faster dynamics than the SC sensors placed in the same animal. The distribution of
fitted time constants of the model in Equation (3.6) for sensors in each space was
5.6±2.9 min for the IP sensors and 12.4±3.6 min for the SC sensors [38]. In general,
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the IP sensors had a lower mean time constant and a tighter distribution, while the
SC sensors had a higher mean time constant and wider distribution. Data from a
human clinical study found that SC sensors have time constants ranging from 2 to 20
min [55]. Lastly, the results of a tracer kinetics study showed that the time constant
in the SC space for people with T1DM was 11.0±3.3 min [53].
In the computational work presented in this chapter, τS is varied to investigate a
wide range of sensor dynamics (0 to 30 min) using the model in Equation (4.1). The
intent is not to replicate a specific sensor placement, but to interrogate the relation-
ship between sensor lag and AP performance. In general, SC sensors that are already
in use are expected to be on the higher end of the lag distribution, while IP sensors
that are in development are expected to have a smaller lag [38]. An ideal BG sensor
is represented by the case when τS=0 min.
4.2.2 Dynamic Measurement Error
Dynamic lags in the measurement process lead to error between the true and
measured BG values. One measure of this error can be computed by determining the
measurement response to a ramp input [70]. The ramp should be selected to have
the maximum rate of change that is expected for the process. For a ramp of slope a,
the upper bound on the error is given by
emax = |ym(t)− yIV(t)|max (4.2)
where yIV(t) = at (a ramp input in blood glucose concentration). The time-domain
response to a ramp for a transfer function with first-order dynamics and unity gain,
such as that in Equation (4.1), is determined by substituting the Laplace transform of
the ramp (YIV(s) = as2 ) into Equation (4.1) and taking the inverse Laplace transform
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to get:
ym(t) = aτS(e−t/τS − 1) + at. (4.3)
By substituting Equation (4.3) into Equation (4.2), the error reduces to
emax = |aτS(e−t/τS − 1)|max. (4.4)
The maximum error occurs when t >> τS, giving
emax = |aτS|. (4.5)
The maximum rate of change expected in glucose concentration data can be esti-
mated as between an absolute value of 4 and 5 mg/dL/min, as seen in clinical data
[102, 198]. The upper bounds on the measurement error given a ramp of 4 and 5
mg/dL/min for sensor time constants ranging from 5 to 30 min are shown in Table
4.1. Reducing the glucose sensor lag will reduce the upper bound on the dynamic
measurement error in a linear relationship.
The upper bound on the error provided by Equation (4.5) is a conservative esti-
mate for BG monitoring applications, where the rate of change is unlikely to continue
at the maximum value for times t >> τS. Therefore, it is useful to consider the tran-
sient error response to a ramp of maximum slope lasting 15 min. Figure 4.3 shows
the transient response for simulated glucose sensors with τS equal to 5, 10, 20, and 30
min for a BG ramp of slope -4.5 mg/dL/min. The starting glucose concentration is
set to 130 mg/dL. After 15 min, the BG has crossed the threshold into hypoglycemia;
however, none of the simulated sensors would have detected this safety risk at the
time it happened. Detection of rapid changes in BG is critical to the AP, especially if
the change presents a safety risk such as hypoglycemia. Figure 4.3 demonstrates the
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Table 4.1: Summary of dynamic error characteristics resulting from sim-
ulated glucose sensors with different values of τS. Sensor measurements
are simulated based on experimental BG data (clinical data from [72], clin-
icaltrials.gov ID NCT01472406).
τS (min)
5 10 20 30
emax (mg/dL)
a = 4 mg/dL/min 20 40 80 120
a = 5 mg/dL/min 25 50 100 150
MARD (%) 1.9 3.6 6.4 8.6
Clarke Zone (%)
A 98.9 98.4 95.5 90.1
B 1.1 1.6 4.5 9.7
C 0 0 0 0
D 0 0 0 0.16
E 0 0 0 0
A+B (%) 100 100 100 99.8
danger of a lagging sensor measurement, which produces an error that is correlated
in time and becomes larger for higher rates of change.
The measurement error due to dynamic sensor lag that would occur for typical
BG trajectories can be investigated using retrospective analysis of data from a previ-
ous clinical study. During a 24 h clinical evaluation of an AP device in 12 subjects,
BG measurements were taken every 30 min, or every 15 min during exercise and
hypo- or hyperglycemic episodes [72]. This study is registered on clinicaltrials.gov
with clinical trial registration number NCT01472406. The BG measurements were
taken from venous blood using a YSI 2300 STAT PlusTM glucose and lactate analyzer
(Yellow Springs Instruments, Yellow Springs, OH), which is considered to be the gold
standard in glucose measurement. Using this data and the sensor model in Equation
(4.1), measurements from sensors with different time constants were simulated. An
example of the experimental YSI measurements and simulated sensor measurements
for one subject are shown in Figure 4.4.
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Figure 4.3: Error introduced by a sensor lag in the transient time re-
sponse for a ramp BG change with slope -4.5 mg/dL/min. The red dashed
line shows the hypoglycemia threshold of 70 mg/dL/min. The varying
values of τS are represented by symbol type and color. The symbols indi-
cate the sampling time of a glucose sensor, which is 5 min. (Top) The ramp
BG and simulated sensor measurements over time. (Middle) The error be-
tween the ramp BG and the simulated sensor measurements. (Bottom)
The error between the rate of change estimated from the sensor versus the
rate of change of the ramp BG.
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Figure 4.4: Blood glucose measurement data from a clinical trial of
an AP. Simulated sensor measurements with different dynamic lags are
shown with different types of icons. The vertical black line can be used to
visualize the offset between the BG measurement and the sensor measure-
ment at a given instant in time during a decrease toward hypoglycemia
(clinical data from [72], clinicaltrials.gov ID NCT01472406).
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A histogram of the error between BG measurement and simulated sensor mea-
surement is shown in Figure 4.5. The mean absolute relative difference (MARD) is
typically used to characterize glucose sensor error during a given time period. This
measure is calculated as
MARD =
1
n
n
∑
i
|ym,i − yIV,i|
yIV,i
× 100. (4.6)
The MARD for each simulated sensor run on the clinical data is shown in Table 4.1.
As seen in the table, the MARD ranges from 1.9% to 8.6% for a τS of 5 to 30 min. The
MARD is considered an important value when reporting glucose sensor accuracy,
and may determine whether the glucose sensor can be used as a replacement for
capillary blood measurements to determine insulin dosing. For example, it is stated
in [20] that glucose sensors must reach a MARD below 10% before they can be cleared
for use in determining insulin dosage.
While the MARD gives a general idea of the glucose sensor performance, it does
not demonstrate how that error might affect control action. For this reason, the sensor
readings were examined using a Clarke Error Grid to determine the clinical impli-
cations of the error [52]. The simulated glucose sensor measurements were plotted
against the corresponding reference measurements on a graph that was divided into
five zones, as shown in Figure 4.6. The zones are: A, where the glucose sensor mea-
surement was within 20% of the reference; B, where the error was greater than 20%
of the reference, but the treatment determined from the glucose sensor and reference
would have been the same; C, where unnecessary treatment would have been given
that could have led to dangerous hyperglycemia or hypoglycemia; D, where dan-
gerous hyperglycemia or hypoglycemia would have gone undetected; and E, where
the treatment given would have been the opposite of the required treatment [52].
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Figure 4.5: Histogram of the error induced by dynamic sensor lag for
simulated sensors and experimental BG data. The error distribution be-
comes wider with higher sensor lag (clinical data from [72], clinicaltri-
als.gov ID NCT01472406).
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According to one source, the percentage of points in the A and B zones should be
higher than 98% to be acceptable [23].
As shown in Figure 4.6 and Table 4.1, 100% of points fell within the A or B
zones for values of τS from 5 to 30 min. Therefore, as shown by the MARD and
the Clarke Error Grid, the point-wise error caused by the dynamic sensor lag does
not exceed limits for clinical usability. However, the dynamic nature of the error is
expected to cause problems for the artificial pancreas, which relies on the glucose
trajectory over time to make accurate and timely insulin dose recommendations. A
lag in the measurement will lead to a lag in the controller action, especially when
responding to large disturbances such as meals. In the following sections, control
theory and simulation studies are used to quantify the effect of sensor lag on an
artificial pancreas controller.
4.3 Controller Design and Tuning
Following an analogous approach to the one outlined in [188], a model-based PID
controller design was chosen in this study to highlight the effects of sensor dynamics
on control quality. The following third-order discrete-time model of insulin action on
BG has been previously identified, with different parameters to represent either IP or
SC insulin delivery [199, 200]:
MD =
K(TDI)−1z−3
(1− a1z−1)(1− a2z−1)2 (4.7)
where TDI (U) is the total daily insulin dose of the patient and the sampling time is
5 min. The inclusion of the total daily dose allows the gain to be personalized based
on each individual patient’s response to insulin. The model parameters are given in
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Figure 4.6: Clarke Error Grid for simulated sensors with different lags.
The grid shows that for values of τS from 5 to 20 min, all of the points
fall into the A+B (acceptable error) zones. For τS equal to 30 min, 99.8%
of points fall into the acceptable error zones, with 0.16% in the D zone
(clinical data from [72], clinicaltrials.gov ID NCT01472406).
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Table 4.2, based on previous work [199–201].
Table 4.2: Parameters for the discrete, continuous, and reduced models
of IP and SC insulin action. Reprinted from [202].
Discrete Continuous
K a1 a2 K′ τ1 τ2
(h·mg/dL) (h·mg/dL) (min) (min)
IP -15 0.98 0.75 -12000 247 17
SC -0.30 0.98 0.965 -12294 247 140
Reduced
τˆ1 (min) τˆ2 (min) θˆ (min)
IP 247 26 11
SC 247 210 73
The model was converted to continuous time using the zero-pole matching
method [203] to obtain the following third-order continuous model:
MC =
K′(TDI)−1
(τ1s + 1)(τ2s + 1)2
. (4.8)
The parameters for the resulting continuous model are also shown in Table 4.2. The
third-order model was then reduced to a second-order model using Skogestad’s half
rule [204] to obtain
G =
K′(TDI)−1e−θˆs
(τˆ1s + 1)(τˆ2s + 1)
, (4.9)
where the reduced-order model parameters are determined by the following rela-
tions:
τˆ1 = τ1, τˆ2 = τ2 +
τ2
2
, and θˆ =
τ2
2
+
∆t
2
, (4.10)
with the resulting reduced model parameters included in Table 4.2. Here, ∆t is the
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sampling time that will be used in the implementation of the controller. The con-
troller parameters were determined from Equation (4.9) using internal model control
tuning rules. Internal model control is a model-based controller design method de-
veloped to give an analytical expression for a controller based on a dynamic model
of the process [70]. The design process leaves a single tuning knob, the characteristic
time constant τC, which sets the robustness of the controller. Internal model control
design for a second-order transfer function model yields an equivalent PID controller,
so direct relations between the model parameters and the PID tuning parameters can
be expressed [70]:
KC =
τˆ1 + τˆ2
K′(TDI)−1(τC + θˆ)
(4.11)
τI = τˆ1 + τˆ2 (4.12)
τD =
τˆ1τˆ2
τˆ1 + τˆ2
. (4.13)
The choices for τC in this study were determined from the dominant time constants
(τdom) of the IP and SC models, which were found by inspection of the step response
to be 285 and 564 min for the IP and SC systems, respectively. Values for τC were
selected as τdom[0.1, 0.3, 0.5, 0.7] as indicated by the tuning guidelines in [70]. The PID
controller was then implemented using the discrete position form with a sampling
time of 5 min:
u(k) = u¯ + KC[e(k) +
∆t
τI
k
∑
j=1
e(j) +
τD
∆t
[e(k)− e(k− 1)]] (4.14)
where u(k) is the insulin delivery computed by the controller (U/h), u¯ is the steady
state insulin delivery rate (U/h), KC is the controller gain ([U/h]/[mg/dL]), τI is the
integral time constant (min), τD is the derivative time constant (min), and e(k) is the
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difference between the glucose measurement and the setpoint of 110 mg/dL. While
there is no obvious choice for setpoint based on physiology, 110 mg/dL was chosen
because it is in the middle of the tight glycemic control range of 80-140 mg/dL. This
setpoint has been used in previous AP designs, including in [188].
4.4 Frequency Response and Robustness Analysis
In order for the AP to be safe for clinical use, it must be robust to model uncer-
tainty. The human body’s reaction to insulin can vary depending on the time of day,
hormonal changes, exercise, and other factors that are part of daily life. Changes
in insulin sensitivity of up to 50% have been experimentally observed [205]. These
changes can be considered as perturbations to the gain and delay of the nominal
model. A controller is said to be robust if it is insensitive to differences between the
actual system being controlled and the model of the system that was used determine
the controller tuning parameters. Robustness is determined by checking that the sys-
tem is stable and meets performance requirements even for the worst-case scenario
of model uncertainty [206]. A robust design is crucial for AP applications, since the
controller will be part of a medical device that needs to meet its design specifications
even in the face of model uncertainty introduced between different patients or over
time in the same patient.
4.4.1 Gain and Phase Margin
Gain and phase margins were used to perform a preliminary screening of the
system robustness. These two measures are based on the frequency response analysis
of the open-loop transfer function. The gain margin reflects how much the open-loop
gain can increase before reaching instability, while the phase margin shows how
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much the open-loop delay can increase before instability occurs.
4.4.2 Robust Stability and Performance
Robust stability and performance analysis is a more formal measure of system
robustness to model uncertainty. The family of possible plants ΠI that exist given a
nominal process model with specified uncertainty was represented using multiplica-
tive uncertainty as follows:
ΠI : GP(s) = G(s)(1+ wI(s)∆I(s)); |∆I(jω)| ≤ 1, ∀ω (4.15)
where GP is a potential process model, and G is the nominal process model. The
uncertainty weight fulfills the relation |wI(jω)| ≤ lI(ω), ∀ω where
lI(ω) = max
GP∈ΠI
|GP(jω)− G(jω)
G(jω)
|. (4.16)
The condition for robust stability (RS) is then given by:
RS ⇐⇒ ||wIT||∞ < 1 ∀ω (4.17)
where T is the complementary sensitivity function and wI is the multiplicative un-
certainty weight as defined previously. The weight for parametric uncertainty in the
gain and delay for the model in Equation (4.9) is given by
wI =
(1+ rk2 )θmaxs + rk
θmax
2 s + 1
(4.18)
where rk =
Kmax−Kmin
Kmax+Kmin
and θmax is the maximum uncertainty in the delay considered
[206]. In this study, gains on the range Knom[1 − δ, 1 + δ] were considered, where
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δ was allowed to vary from 0.1 to 0.9. The nominal gain Knom was chosen as the
non-personalized gain of -200 (mg/dL)/(U/h) [199–201]. The maximum delay un-
certainty tested was 30 min.
The robust performance criterion is used to determine whether specified perfor-
mance measures will be met in the presence of model uncertainty. The condition for
robust performance (RP) is given by:
RP ⇐⇒ max
ω
(|wPS|+ |wIT|) < 1 (4.19)
where S is the sensitivity function. The performance weight wP is given by
wP(s) =
s
M +ω
∗
B
s +ω∗B A
(4.20)
where M is the maximum peak of the sensitivity function, A is the steady state
tracking error, and ω∗B is the bandwidth frequency [206]. In this study, A = 10
−2,
ω∗B = 5× 10−5 rad/s, and M = 2. The value of A was chosen to be approximately
zero because it is important for the controller to track the setpoint closely at steady
state, even in the presence of model uncertainty. The value for M was chosen in
accordance with the recommendation in [70]. The bandwidth frequency was selected
based on the bandwidth of a closed-loop system using SC insulin delivery, which is
the current state-of-the-art configuration used in clinical evaluations [1, 188].
4.4.3 Results and Discussion
The calculated gain and phase margins for varying values of τS and τC are shown
in Tables 4.3 and 4.4. A Bode plot demonstrating the calculation of the gain and
phase margin for IP insulin with τC=0.1τdom is shown in Figure 4.7. These values
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show that increasing τS and/or decreasing τC reduces the margin for error before
instability is reached. Overall, the IP system has higher margins than the SC system,
which is due to the faster actuation available through the IP route.
Table 4.3: Gain margin for varying sensor time constants and tuning
parameters. Reprinted from [202].
Intraperitoneal Delivery
τS\τC 0.1τdom 0.3τdom 0.5τdom 0.7τdom
0 min 5.7 14 22 30
10 min 4.1 10 16 22
20 min 3.9 9.5 15 21
30 min 3.8 9.3 15 20
Subcutaneous Delivery
τS\τC 0.1τdom 0.3τdom 0.5τdom 0.7τdom
0 min 2.8 5.2 7.6 10
10 min 2.5 4.7 6.8 9.0
20 min 2.3 4.4 6.4 8.4
30 min 2.2 4.2 6.1 8.0
A general recommendation for the gain and phase margin given in [70] states that
a well-tuned controller will have a gain margin between 1.7 and 4.0 and a phase mar-
gin between 30°and 45° [70]. The gain and phase margins obtained for the controller
design presented in this chapter are similar to those presented in [188], in which the
impact of insulin pharmacokinetic and pharmacodynamic properties on the AP was
evaluated. As in that study, the gain and phase margins in Tables 4.3 and 4.4 are
within or higher than the range of published guidelines in [70] due to the conserva-
tive controller design required for safety in medical applications. Smaller values of
gain and phase margin can lead to an oscillatory response, which must absolutely be
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Figure 4.7: Bode plot demonstrating the calculation of the gain and
phase margin for IP insulin. The plot is shown for τC=0.1τdom, and for
various values of τS. The gain margin is calculated by 1ARc , where ARc
is the magnitude at the critical frequency where the phase crosses -180°.
The phase margin is calculated as 180+φg, where φg is the phase at the
gain-crossover frequency where the magnitude equals 1 [70].
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Table 4.4: Phase margin for varying sensor time constants and tuning
parameters. Reprinted from [202].
Intraperitoneal Delivery
τS\τC 0.1τdom 0.3τdom 0.5τdom 0.7τdom
0 min 74° 83° 86° 87°
10 min 61° 78° 82° 84°
20 min 51° 72° 79° 82°
30 min 44° 67° 75° 79°
Subcutaneous Delivery
τS\τC 0.1τdom 0.3τdom 0.5τdom 0.7τdom
0 min 58° 73° 78° 81°
10 min 53° 70° 77° 80°
20 min 49° 68° 75° 79°
30 min 46° 66° 73° 77°
avoided in the AP system.
The robust stability analysis was conducted to determine how much model uncer-
tainty in the gain and delay would be tolerated for a specified sensor time constant
and controller tuning. The results are shown in Figure 4.8 (top panels). The results
show that the system will remain stable for large model uncertainty for both IP and
SC insulin, even with a sensor time constant of 30 min, for the most aggressive tuning
tested (τC = 0.1τdom). For the larger three values of τC, robust stability is maintained
for all gain and delay uncertainties tested.
Increasing the sensor time constant may cause a loss of robust performance even
for small model uncertainty (Figure 4.8, middle and bottom panels). Thus, there is
less tolerance for model uncertainty when the sensor time constant is increased, and
it is possible that the robust performance specifications will not be met. In fact, the
SC system does not meet robust performance specifications for gain uncertainties
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Figure 4.8: Gain and delay uncertainty allowed while still retaining ro-
bust stability and robust performance for various sensor time constants
using IP and SC insulin. The top plot shows robust stability, while the
middle and bottom plots show robust performance. The top and middle
panels show the analysis for a fixed τC of 0.1τdom. Robust stability was
met for large amounts of model uncertainty for both systems, but the IP
system performance was more robust to model uncertainty than the SC
system. The analysis was repeated for a more conservative τC of 0.3τdom,
for which the robust performance results are shown (bottom panel). The
robust stability results for τC = 0.3τdom are not shown because the system
was robustly stable for all conditions tested. Reprinted from [202].
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greater than 0.1 when using the most aggressive tuning tested, even for the ideal
sensor case. The same analysis for τC = 0.3τdom shows that the SC system is able
to retain robust performance for small amounts of model uncertainty. Overall, the
IP system displays a higher robust performance than the SC system. This trend is
expected as a result of the faster actuation afforded by IP insulin delivery.
Retaining stability in the AP system is of utmost importance, so it is encouraging
to see that both the SC and the IP systems will be robustly stable even for large
sensor time constants. Robust performance will be retained for low sensor time
constants, but may be lost if there is too much lag in the glucose measurement.
For this reason, more experimental data should be collected to determine the sensor
lags present in systems being used in clinic, and new sensing methods that would
provide a faster glucose measurement should be investigated. Two studies that have
already been conducted to measure the lag between the intravascular and interstitial
compartments of humans are presented in [58] and [57].
4.5 Simulation Studies
4.5.1 Methods
In silico tests were performed to evaluate the impact that sensor dynamics have
on the time-domain performance of the AP. The simulations were conducted using
the UVA/Padova metabolic simulator with ten unique simulated adult subjects with
T1DM [207]. This simulator allows artificial pancreas controllers to be evaluated
under many different scenarios to determine the best design before moving to clinical
studies. The use of the simulator also allows controlled studies to be performed
that would not be possible in real life, such as testing various specified sensor time
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constants.
A block diagram depicting the simulation setup is shown in Figure 4.9. The
intravenous port in the simulator was used to simulate IP insulin delivery. This ap-
proximation has been utilized previously, as the intravenous delivery in the simulator
closely mimics IP delivery [200]. The sensor dynamics were implemented by pass-
ing the BG through the first-order model given by Equation 4.1 before sending the
measurement to the controller. The sensor time constants tested, chosen to represent
the range of experimental values observed in [38], were 0, 10, 20, and 30 min. The
additive measurement noise was disabled in order to isolate the effects of the sensor
dynamics on the controller performance. The protocol tested was a fasting period
followed by an unannounced meal disturbance (output disturbance) consisting of
75 g of carbohydrates (CHO).
Simulated 
T1DM 
Patient
PID
Controller
Adjustable
Diffusion
Model, G
+
-
Insulin
Pump
(IP or SC)
+
+
Optional Additive
Measurement
Noise
Set Point
Blood Glucose 
Concentration
Measured
Glucose 
Concentration
S
Figure 4.9: Block diagram showing the closed-loop simulation setup.
The PID controller receives the error between the setpoint and the mea-
sured glucose concentration and sends an insulin dose to the simulated
patient by using either the IP or SC delivery route. The resulting BG is
passed through the glucose diffusion model with an adjustable time con-
stant. Measurement noise can optionally be added before obtaining the
measured glucose concentration. Reprinted from [202].
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4.5.2 Results and Discussion
The data from one representative subject are shown in Figure 4.10. When the
glucose measurement is delayed, it effectively filters the controller action. The peak
insulin delivery is shifted later in time, and the overall response of the AP is more
sluggish. The simulation results for all 10 subjects are summarized in Table 4.5.
Presented in the table are the mean and standard deviation for the time spent in
hyperglycemia (BG>180 mg/dL, thyper), the area of the region below the glucose
curve and above the 180 mg/dL hyperglycemia cutoff (AUC), the peak BG, and the
minimum BG. For both IP and SC insulin delivery, increasing the sensor time constant
significantly raised the maximum BG that was experienced, while it significantly
lowered the minimum BG. This is the expected trend that would be caused by a
lagging measurement.
More telling than the magnitude of the peak is the increased period of hyper-
glycemia caused by an increased sensor lag. The boxplot in Figure 4.11 shows the
amount of time in hyperglycemia and AUC in hyperglycemia following the meal
for the 10 simulated subjects using IP insulin. Both the time in hyperglycemia and
the AUC in hyperglycemia increased greatly as the sensor time constant increased.
For a sensor time constant as small as 10 min, the mean AUC was doubled when
IP insulin delivery was used. The time spent in hyperglycemia increased by 21±8
min for IP insulin and by 13±3 min for SC insulin for a τS of 20 min as compared
to the ideal sensor case. According to experimental data from [38] and [208], 20 min
serves as a conservative estimate for the time constant of an SC sensor, so it would be
possible to encounter this amount of lag in a clinical AP study. The cumulative time
spent in hyperglycemia over a person’s lifetime determines the severity of long-term
health complications [7]. The increased hyperglycemia brought about by a lagging
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Table 4.5: In silico performance measures for varying τS. The parameter
τC = 0.1τdom. Reprinted from [202].
Intraperitoneal Delivery
τS thyper AUC Max BG Min BG
(min) (min) (min·mg/dL) (mg/dL) (mg/dL)
0 38 ± 25 381 ± 343 192 ± 9 86 ± 5
10 50 ± 20* 761 ± 495* 202 ± 12* 83 ± 6*
20 59 ± 19* 1141 ± 670* 208 ± 14* 78 ± 7*
30 67 ± 19* 1508 ± 834* 213 ± 16* 72 ± 10*
Subcutaneous Delivery
τS thyper AUC Max BG Min BG
(min) (min) (min·mg/dL) (mg/dL) (mg/dL)
0 107 ± 25 3643 ± 1829 231 ± 23 88 ± 5
10 113 ± 23* 4354 ± 2082* 237 ± 26* 80 ± 14
20 120 ± 22* 4957 ± 2329* 242 ± 28* 71± 17*
30 126 ± 22* 5510 ± 2577* 245 ± 30* 62 ± 17*
*Statistically different from τS = 0 min by paired t-test.
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Figure 4.10: Representative result from one subject in the UVA/Padova
metabolic simulator (adult subject 1) with four different values for the
sensor time constant using (top) IP insulin and (bottom) SC insulin.
In both cases, τC=0.1τdom. The plot shows the glucose concentration and
insulin delivery for one hour before and eight hours after an unannounced
75 g CHO meal disturbance. The green and yellow zones represent the
tight clinical range (80-140 mg/dL) and safe clinical range (70-180 mg/dL)
for the BG. The setpoint is shown by the horizontal dashed line at 110
mg/dL. Reprinted from [202].
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measurement will add up each time there is a meal disturbance, and could result in
a worse overall health outcome for the patient.
The effect of the characteristic time constant τC is demonstrated in Figure 4.12,
which shows the results for the same representative subject as in Figure 4.10 for IP
insulin using the four different values of τC. A larger value of τC leads to a slower
and less aggressive response from the controller. A controller with a large value of
τC is not able to respond in a timely manner to the rapid change in glucose caused
by a meal. Using a smaller value of τC is desirable as long as the system will remain
robust to model uncertainty and sensor lag.
Figure 4.13 shows a plot of the maximum versus minimum BG for all 10 subjects,
with error bars showing the standard deviation. The plot includes three representa-
tive choices for τC based on the dominant time constant for each system. On this plot,
improved controller performance is indicated by proximity to the lower left corner.
In all cases, decreasing the sensor time constant improved the controller performance
by moving the point on the plot down and to the left. The standard deviation spread
also became narrower as the sensor time constant decreased, meaning that the system
is more reliable for all subjects. An increased sensor lag is detrimental to SC control
because it necessitates a more conservative tuning to be used to avoid dangerous
hypoglycemia (BG<70 mg/dL), at the expense of allowing more hyperglycemia.
A sensor with a small time constant would improve the ability of the AP to re-
ject a meal disturbance. If a faster sensor is not available, other measures such as
feed-forward action may be necessary to obtain the desired level of performance. For
example, the user of the AP could announce that a meal is about to be consumed,
which would cue the AP to deliver a preemptive dose of insulin. While this con-
figuration is being used more often in clinical studies [1], it is not ideal because it
involves a human in the loop, which could lead to safety risks. A faster sensor could
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Figure 4.11: Boxplot showing the amount of time spent in hyperglycemia
and the area under the curve in hyperglycemia for closed-loop control
in 10 in silico subjects using IP insulin with τC = 0.1τdom. The results are
compared for several different values of τs. The horizontal red line rep-
resents the median value, the blue box represents the interquartile range,
and the vertical black bars represent the range.
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Figure 4.12: Representative result from one subject in the UVA/Padova
metabolic simulator (adult subject 1) with four different values for the
characteristic time constant using IP insulin. The sensor time constant for
this case was 0 min. The plot shows the glucose concentration and insulin
delivery for one hour before and eight hours after an unannounced 75 g
CHO meal disturbance. The green and yellow zones represent the tight
clinical range (80-140 mg/dL) and safe clinical range (70-180 mg/dL) for
the BG. The setpoint is shown by the horizontal dashed line at 110 mg/dL.
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Figure 4.13: Mean maximum versus mean minimum BG for different
sensor time constants (0 (blue), 10 (green), 20 (orange), and 30 (red) min)
and tuning parameters for (A) IP insulin delivery and (B) SC insulin
delivery after a 75 g CHO meal disturbance. Error bars show plus or
minus one standard deviation. Decreasing the sensor time constant causes
the data points to move down and to the left, indicating an improvement
of controller response to the meal disturbance. Reprinted from [202].
potentially avoid the need for this feed-forward action, leaving less burden on the
AP user. Still, there may be a limit to the sensing speed that can be achieved. The
cost of developing and manufacturing a faster sensor must be weighed against the
benefit gained from the reduced lag.
4.6 Conclusions and Future Work
When evaluating a new sensor technology, the point-wise error is frequently re-
ported as a measure of the acceptability of that sensor’s accuracy. A point-wise error
that passes thresholds for safety could still include error from a dynamic lag that
could cause problems for an artificial pancreas controller. Decreasing the glucose
sensor lag leads to a decreased period of hyperglycemia following a meal distur-
bance, which could in turn lead to a better health outcome for the patient. The
relative improvement is higher for the IP system than the SC system. This difference
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is attributable to the fact that delays present in SC insulin actuation cause the sen-
sor lag to have less of an impact. In addition, systems with an increased sensor lag
have a lower tolerance for model uncertainty resulting from inter- and intra-patient
variabilities.
The use of an insulin delivery route with faster pharmacokinetic and pharmaco-
dynamic characteristics (IP rather than SC) improves control performance greatly, but
that improvement is only partially realized if a sensor with a dynamic lag is used.
Further experimental investigation of glucose sensor placement will reveal the extent
to which the diffusion lag can be eliminated. The benefit gained from this lag reduc-
tion must be weighed against the cost and invasiveness of such a sensor to determine
the best solution for the patient. In the next chapter, the design and evaluation of a
PID control algorithm for a fully implantable AP using both IP insulin and IP glucose
sensing is presented.
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Robust PID Control for an Implantable
Artificial Pancreas1
5.1 Introduction
As discussed in Chapters 1 and 2 of this dissertation, many variations of the ar-
tificial pancreas (AP) have been tested in clinical studies. Current iterations of the
AP have moved past the inpatient clinical testing phase and into the outpatient en-
vironment. The AP designs used in these studies show promising results, but their
performance is limited by the use of commercially available external insulin pumps
and glucose sensors that operate in the subcutaneous space, introducing severe de-
lays into the control loop. In this chapter, we present a design process for a controller
that will work with implantable insulin pumps and glucose sensors, greatly reducing
the delays and resulting in overall better glycemic control.
1Reproduced with permission from L. M. Huyett, E. Dassau, H. C. Zisser, and F. J. Doyle III,
“Design and evaluation of a robust PID controller for a fully implantable artificial pancreas,” Industrial
& Engineering Chemistry Research, vol. 54, pp. 10311-21, 2015. Copyright 2015 American Chemical
Society (available at http://pubs.acs.org/articlesonrequest/AOR-HTwYV5f3SkcycCeZNfSD) [209].
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5.1.1 Control Objective, Challenges, and Constraints
A primary objective of the AP is to provide safe and effective glycemic control
for people with T1DM by delivering doses of insulin. This objective is typically
quantified as maximizing the percentage of time spent within a desired range of
glucose concentrations. The most frequently used ranges are 70-180 mg/dL or 80-140
mg/dL [1]. In addition, the controller must prevent hypoglycemic episodes. Since
safety must remain the top priority in any medical device system, some AP designs
introduce glucagon as a second manipulated variable [94]. This hormone stimulates
the natural conversion of glycogen stored in the liver to glucose, and may be used as a
rescue treatment when a person’s BG approaches hypoglycemia. However, there are
practical difficulties with using glucagon in a closed-loop system, and the effects of
long-term glucagon use are unknown [133]. In addition, a clinical study designed to
compare an AP with and without glucagon did not find any significant improvement
made by including glucagon in the system [94]. For these reasons, we focus on the
design of an insulin-only system. An important constraint in this system is that
insulin cannot be removed once it has been delivered, so the AP must be tuned
accordingly to avoid a potentially dangerous situation.
There are several disturbance challenges that the AP must face to successfully
control BG. The most difficult disturbances to control occur following the ingestion
of a meal, when the BG concentration increases rapidly. Other challenges include
periods of exercise, which can result in unpredictable BG changes, and overnight
periods, during which the AP user is asleep and therefore dependent on the AP to
maintain the BG within a safe range [1]. Periods of illness and stress, along with
hormonal changes, affect the way the body responds to insulin [210]. The AP must
be able to adapt to changing insulin sensitivity to maintain glycemic control.
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5.1.2 An Implantable System
To effectively reject glycemic disturbances, the AP controller must have access
to sensing and actuation with characteristics that allow the controller to detect and
react to glucose concentration changes. The majority of AP designs tested thus far
rely on commercially available insulin pumps and glucose sensors that operate in the
subcutaneous space [1]. These devices have several advantages: they are minimally
invasive, already approved by the United States Food and Drug Administration, and
easy to use. Unfortunately, diffusion lags between the interstitial fluid and the blood
introduce severe delays in both glucose sensing and insulin action, reducing the abil-
ity of the controller to respond to and correct changing glucose concentrations in a
timely manner [57, 58, 79]. To overcome these delays and improve the glucose control
achieved, most iterations of the AP have incorporated meal announcement, a type of
feedforward action initiated by the user to trigger a bolus of insulin before the meal is
consumed. While the addition of the meal announcement improves the resulting BG
profile following a meal, it also poses a safety risk by requiring the user to accurately
and reliably perform an action [211]. The best solution would be to reduce delays in
the system so that fully-automated control is possible. The reduction of delays may
be accomplished with the use of alternate insulin delivery, more rapid-acting insulin
formulations, and glucose sensing methods.
The intraperitoneal (IP) space was first introduced as an alternative insulin deliv-
ery route in the 1970s [174]. Insulin delivered through the intraperitoneal route has
faster pharmacokinetic and pharmacodynamic characteristics than insulin delivered
through the subcutaneous route: when insulin is delivered through the SC route, the
absorption peak occurs 50-60 minutes later [175], as opposed to 20-25 minutes when
using the IP route [176]. The insulin is also cleared more quickly: insulin delivered
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through the SC route has a residence time of 6-8 hours [175], while IP insulin has
a much shorter residence time of 1-2 hours [176]. A further advantage of IP insulin
delivery is that it mimics healthy pancreatic activity by allowing a high uptake of
insulin by the liver and producing a positive portal-systemic insulin gradient [212].
The use of implanted insulin pumps can also lead to improved quality of life: a
randomized crossover study showed that continuous intraperitoneal insulin infusion
resulted in improved health-related quality of life and treatment satisfaction over
continuous subcutaneous insulin infusion [213]. The main obstacle barring adoption
of IP insulin delivery is that it requires either a pump to be surgically implanted, as
in Logtenberg, et al. [214] or a percutaneous port to be created, as in Liebl, et al.
[194]. The disadvantages of this system are that it is invasive, and may be associated
with higher cost and higher risk of infection [18]. There is no IP insulin delivery
system currently approved for use in the United States, so this hurdle would need to
be passed before the implantable AP could be tested in human clinical trials.
The improvements gained by faster actuation through IP insulin delivery will be
limited without the implementation of fast glucose sensing. In initial clinical stud-
ies, an AP using intraperitoneal insulin delivery did not perform as well as expected
because the sensor introduced a lag to the glucose measurement [215]. As discussed
in Chapters 2 and 3 of this dissertation, several studies have shown that there is a
diffusion lag between the blood and the interstitial fluid, resulting in measurements
that lag behind the blood glucose concentration [57, 58, 184]. The preliminary animal
studies discussed in Chapter 3 have demonstrated that sensors placed in the IP space
provide a more rapid measurement of blood glucose than sensors placed in the SC
space due to the proximity to a highly vascularized area, with the diffusion process
modeled as a first-order transfer function with time constant τS (min) [38, 216]. The
time constants identified from experimental data in a swine model for sensors placed
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in the intraperitoneal and subcutaneous space are shown in Figure 5.1. The IP sensor
time constants were lower and had a tighter distribution than the SC time constants.
This evidence suggests that a glucose sensor implanted within the IP space will pro-
vide a more useful estimation of the blood glucose concentration by reducing the
diffusion lag. As was shown in Chapter 4, reducing the sensor lag leads to a more
robust controller, with better performance in simulation studies.
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Figure 5.1: Sensor dynamics in experimental data. Boxplot showing the
statistical properties of the fitted time constants for sensors placed in the
IP space or the SC space of swine, demonstrating that the IP sensors had
a lower mean time constant and a tighter distribution than the SC sensors.
The primary differences between IP and SC devices are summarized in Table 5.1.
A fully implanted AP will make use of both intraperitoneal insulin delivery and glu-
cose sensing. The pump, sensor, and controller will all be implanted, and the system
will be operated using a handheld remote. This approach will eliminate the need to
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remove and apply new sensors and insulin infusion sets, as must be done with sub-
cutaneous devices. Externally worn devices can be cumbersome, so this approach
may also increase patient compliance. We hypothesize that the glycemic control pro-
vided by a fully implantable system will be superior to that which is possible with a
subcutaneous system. Since the sensing time constant is up to two times faster, the
controller can react promptly to impending hypo- and hyperglycemia [38]. Addition-
ally, pump suspension will have an almost immediate effect on the BG, while with the
SC system the insulin depot in the SC space may delay the effect by up to 60 minutes
[217]. An IP insulin bolus results in a peak in plasma insulin within 40 minutes, and
returns to baseline after 113±63 to 154±55 minutes [176]. The faster insulin action
and clearance will lead to more predictable dynamics, making closed-loop control
more successful.
5.2 Methods
5.2.1 Controller Design and Tuning
As discussed in Chapter 1, several control strategies have been evaluated for AP
applications, including proportional-integral-derivative control (PID), model predic-
tive control (MPC), and fuzzy logic [1]. Records of information related to clinical
trials using each type of controller are available in the searchable database located at
www.thedoylegroup.org/apdatabase. MPC has been proposed as a suitable strategy
for AP designs using subcutaneous insulin delivery and sensing because of the large
delays in these systems. Additionally, this advanced control strategy can directly
incorporate system constraints and other features within the optimization problem
that is solved to calculate the insulin delivery [71, 72]. PID control has also been
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Table 5.1: Summary of differences between subcutaneous and intraperi-
toneal insulin pumps and glucose sensors.
Characteristic Subcutaneous Space Intraperitoneal Space
Insulin absorption
peak
50-60 min [175] 20-25 min [176]
Insulin residence
time
6-8 h [175] 1-2 h [176]
Sensor
measurement time
constant
12.4 min [38] 5.6 min [38]
Device placement External, placed on skin
with adhesive patches and
tubing [13, 23]
Implanted, no components
attached to skin [38, 214]
Device lifetime Replace sensor every 7
days and pump infusion
set every 2-3 days [13, 23]
Implanted pumps last
years, with transcutaneous
insulin refills every few
months [218]
Device invasiveness Minimally invasive [13, 23] Requires surgery [38, 218]
Device availability Commercially available
[13, 23]
In development [38, 215]
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promoted and implemented widely for AP applications. Promising clinical results
have been demonstrated by AP systems using MPC controllers and by ones using
PID controllers [1, 219].
When using intraperitoneal insulin delivery and glucose sensing, the system lags
are highly reduced and we are left with a standard single-input, single-output control
problem. In this case, we anticipate that the advanced control capability of MPC may
no longer needed, and that a PID controller will provide satisfactory performance.
Because the insulin will act quickly and glucose changes will be sensed rapidly, the
system can operate well without the predictive power offered by MPC. Additionally,
PID control is less computationally complex, which may be an advantage when the
system must be embedded on a chip where space and battery power will be at a
premium.
The use of model based tuning is recommended for the AP because online tun-
ing through trial and error is not acceptable for a medical application; however, we
need to find a balance between a general and personalized model. Completing time-
consuming model identification procedures for individual subjects is not feasible,
especially if the AP is to be adopted on a large scale. Still, individual subjects have
widely varying insulin sensitivities [205]. In a previous study, a third-order discrete-
time model structure was identified that adequately captures the behavior of insulin
action on the blood glucose concentration [199, 200]. The poles of the model were
found to be consistent between subjects, while a personalization factor was added in
the model gain. The model that was identified for intraperitoneal insulin action on
blood glucose concentration is:
MD =
G(z−1)
UD(z−1)
=
−15(TDI)−1z−3
(1− 0.98z−1)(1− 0.75z−1)2 (5.1)
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where TDI is the total daily insulin dose of the patient (U), G is the blood glucose
concentration (mg/dL), UD is the insulin delivered through the IP route (U/h), and
the sampling time is five minutes. The inclusion of the TDI allows the model gain to
be tailored to an individual subject’s insulin sensitivity.
Internal model control (IMC) is a comprehensive tuning method that allows PID
parameters to be calculated directly from the process model. This method leaves
a single tuning parameter, τC, which is used to set the closed-loop time constant
[70]. Internal model control tuning has been used successfully in AP designs for
SC insulin delivery [84, 188]. To make the model easier to work with for controller
tuning and robustness analysis, the model MD is converted to continuous time. This
conversion can be done using several methods, but the zero-pole matching method
was determined to best preserve the model characteristics [203]. It should be noted,
however, that the final tuning parameters obtained using other methods of conversion
are the same within choice of τC. Therefore, the final tuning parameters are robust to
the conversion method.
The model resulting from the conversion from discrete to continuous time is:
MC =
−12000(TDI)−1
(247s + 1)(17s + 1)2
(5.2)
where the time constant units are minutes. Internal model control tuning rules re-
quire a second-order model to obtain a PID controller. Skogestad’s half rule can
be used to reduce higher-order models to the first- or second-order model required
to use IMC PID tuning rules [204]. Using this method, the reduced-order model
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parameters are determined by the following relations:
τˆ1 = 247 (5.3)
τˆ2 = 17+ 17/2 (5.4)
θˆ = 17/2+ 5/2. (5.5)
The final model obtained is:
GP =
−12000(TDI)−1e−11s
(247s + 1)(26s + 1)
. (5.6)
Using this model, the tuning parameters are determined using IMC tuning relations
[70]:
Kc =
τˆ1 + τˆ2
Kˆ′(TDI)−1(τC + θˆ)
(5.7)
τI = τˆ1 + τˆ2 (5.8)
τD =
τˆ1τˆ2
τˆ1 + τˆ2
. (5.9)
The digital PID controller is implemented using the velocity form [70], with:
u(k) = u(k− 1) + ∆P(k) + ∆I(k) + ∆D(k) (5.10)
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where
∆P(k) = KC[e(k)− e(k− 1)] (5.11)
∆I(k) = KC
∆t
τI
e(k) = KIe(k) (5.12)
∆D(k) = KC
τD
∆t
[e(k)− 2e(k− 1) + e(k− 2)] (5.13)
e(k) = Gsp(k)− Gm(k). (5.14)
In this set of equations, u (U/h) is the insulin delivery calculated by the controller,
P, I, and D (U/h) represent the proportional, integral, and derivative action terms
respectively (U/h), ∆t is the time step (5 min), and the integer k denotes the sample
number. An important feature of the velocity PID form is that it must include the use
of integral action. If it is desired to exclude integral action, the position form should
be used instead [70].
A derivative filter can be implemented with this controller. The derivative filter
prevents excessive controller action in the presence of measurement noise. In this
case, the derivative term becomes:
∆D(k) =
βτD
∆t + βτD
∆D(k− 1) + KC τD∆t + βτD [e(k)− 2e(k− 1) + e(k− 2)]. (5.15)
The parameter β determines the level of filtering of the derivative term, with a larger
value indicating a higher filtering effect. After preliminary testing we selected β as
0.1, which is a commonly used value [70]. The derivative filter was used when sensor
noise was added during simulation studies.
The tuning parameters obtained using the procedure outlined above are shown in
Table 5.2, along with parameters determined for a PID controller using SC insulin in
Laxminarayan, et al. [82]. The remaining parameter τC will be selected using robust
127
Chapter 5. Robust PID Control for an Implantable Artificial Pancreas
stability and performance considerations.
Table 5.2: Parameters for PID control using IMC tuning for intraperitoneal
insulin compared to parameters previously identified for PID control us-
ing subcutaneous insulin.
Parameter IMC for Intraperitoneal
Insulin
Previously Suggested for
Subcutaneous Insulin [82]
KC ( U/hmg/dL )* 0.023(TDI)(τC + 11)
−1 0.0026 TDIbodyweight
τI (min) 273 450 (day), 150 (night)
τD (min) 23.5 98
*The units on the variables in this row are: bodyweight (kg), TDI (U), and τC
(min).
5.2.2 In Silico Artificial Pancreas Evaluation
As described in previous chapters, the metabolic simulator developed by at the
Universities of Virginia and Padova can be used to evaluate AP controllers in silico
before considering them for use in in vivo application [207, 220]. This platform al-
lows the algorithm to be evaluated on 10 in silico T1DM subjects. In this study, the
metabolic simulator was used to determine the optimal tuning parameters and eval-
uate the controller performance. The setup that was used in this work is shown in
Figure 5.2.
To evaluate the intraperitoneal insulin and intraperitoneal sensing (IP-IP) design
we used the intravenous (IV) insulin port and a simulated IP sensor. The IV port
was used to approximate the delivery of IP insulin, as was done in Lee, et al. [200].
The IP sensor was implemented by a first-order diffusion model from the IV glucose
input with a time constant of five minutes. This value was chosen based on the data
presented in Burnett, et al. [38].
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Figure 5.2: Schematic representation of the UVA/Padova metabolic
simulator. Block diagram representation of the configuration of the
UVA/Padova metabolic simulator used in this work to test a fully im-
plantable AP.
The four clinical scenarios shown below were used to evaluate the controllers.
• Scenario 1: A large meal of 100 g of carbohydrates (CHO) was administered to
evaluate the meal response and the setpoint undershoot.
• Scenario 2: A 30% decrease in insulin sensitivity was tested. The change was
simulated by multiplying the insulin delivered by 0.7.
• Scenario 3: A 30% increase in insulin sensitivity was tested by multiplying the
insulin delivered by 1.3.
• Scenario 4: A 27 hour clinical protocol was simulated to evaluate the controller
performance for a typical real-life scenario. Closed-loop control was initiated
at 14:00, followed by a 70 g CHO meal at 19:00. This meal was followed by
an overnight period from 24:00 to 08:00. A breakfast of 40 g CHO occurred at
08:00, and then a lunch of 70 g CHO followed at 13:00. Closed-loop control was
ended at 17:00.
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Scenarios 1-3 were previously tested in Laxminarayan, et al. [82] for an AP using
subcutaneous insulin. The scenarios were repeated here to allow for direct compar-
ison to show the improvement gained by using IP insulin and the design procedure
implemented in this chapter. The best controller design was selected using Scenarios
1-3. The final controller was tested in Scenario 4, including simulated sensor noise
to demonstrate a true-to-life protocol with potential measurement errors. Scenario
4 was used in Lee, et al. [200] to test a zone-MPC controller using IP insulin de-
livery and SC glucose sensing. We repeated this protocol to show that we achieved
comparable results with our IP-IP PID approach.
5.2.3 Introduction of Anti-Reset Windup
The PID controller may cause the BG to undershoot the setpoint after a large
meal, as shown in Figure 5.3. In this figure, PID control was used on subject 1 in
the UVA/Padova metabolic simulator to control a 100 g CHO meal disturbance. The
bottom panel shows the buildup of the integral term that occurs during the large
meal disturbance, leading to the setpoint undershoot.
This undershoot is highly undesirable because it indicates insulin over-delivery
and increases the risk of hypoglycemia. Several approaches have been used to cir-
cumvent this effect. One option, applied in several clinical studies [88, 210, 221–224]
and the in silico study presented by Laxminarayan, et al. [82] is to remove the inte-
gral component and use a proportional-derivative controller. However, the use of PD
control is not ideal because setpoint tracking is sacrificed. Without setpoint tracking,
the controller will not be able to react to changes in insulin sensitivity. Other clinical
studies have detuned the integral component to prevent insulin over-delivery. For
example, in Steil, et al. [77] and Laxminarayan, et al. [82] the integral time constant
was set to 150 min at night and increased to 450 min during the day when meals
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Figure 5.3: Demonstration of setpoint undershoot encountered when
using integral action after a 100 g CHO meal occurring at 1 h. The top
panel shows the glucose deviation from the setpoint after the meal for
subject 1 under PID control. The bottom panel shows the insulin trace
for PID control (dashed gray line) with the integral component plotted
separately (dashed black line). Also on the bottom panel are the advisory
mode calculations for PID with anti-reset windup protection (solid lines)
with the gray line showing the total insulin and the black line showing the
integral component.
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are expected to occur. Nearly all clinical studies using PID control for the AP have
placed an upper limit on the integral term as an additional safety feature. For exam-
ple, in Steil, et al. the integral term was constrained to be less than three times the
06:00 basal rate when BG>60 mg/dL, and was restricted to KC (GSP − 60) U/h when
BG<60 mg/dL [77]. In Laxminarayan, et al. the integral limits were set to 1.4 times
the basal rate when BG>80 mg/dL, 0.7 times the basal rate when BG<60 mg/dL, and
a linear interpolation between those two limits for 60<BG<80 mg/dL [82].
During initial testing, we found that placing an upper limit on the integral term
to reduce the undershoot negatively affected the setpoint tracking ability of the con-
troller. We found that the best option is to instead implement an anti-reset windup
strategy. The relevant approach here is to use conditional integration, which involves
increasing or decreasing the amount of integration depending on specified condi-
tions. A key feature of the AP is that the controller will frequently encounter large
output disturbances. Even with IP insulin delivery it is anticipated that BG will be
elevated for approximately 3 hours following a meal. The ideal AP would exhibit
the characteristics of a PD controller during large but temporary disturbances, while
retaining the characteristics of integral action during smaller but persistent distur-
bances.
The method of anti-reset windup described in Hanssen, et al. can be used to
meet these requirements [225]. The idea behind the method is to attenuate the rate
of change of the integral term, I(k), based on the size of the error term, e(k). When
the error is large, the rate of change of the integral term should approach zero. When
the error is small, the rate of change should be unmodified. To accomplish this goal,
the authors introduced a fuzzy logic scheme with two rules: when error is small, KI
remains at its nominal value (KI=KC ∆tτI ), and when error is large, KI is equal to zero.
By using the membership functions defined in Hanssen, et al. and applying the
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min-max inference rule, the equation for the integral term in (8) is adjusted to:
I(k)− I(k− 1) = KIKWe(k) (5.16)
KW = e−α|e(k)|. (5.17)
This method introduces a single tuning parameter, α, which sets the degree of atten-
uation for the integral term. Figure 5.4 shows a plot of KW versus |e(k)| for increasing
values of α.
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Figure 5.4: Degree of integral attenuation as a function of error. Plot of
KW versus |e(k)| (mg/dL) for increasing values of α. Error sizes are typical
to those encountered after a large meal.
This strategy is ideal for the AP because it is a flexible and dynamic method char-
acterized by a simple algebraic expression. Instead of placing fixed limitations on
the integral term that apply for all BG levels, it instead applies a weighting factor
appropriate for the current situation. This method is equivalent to using an increas-
ing value for τI as the error becomes larger. The flexibility provided by this method
allows for the minimization of undershoot after large meals, while still offering set-
point tracking to react to changes in insulin sensitivity. In addition, no information
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about meal timing needs to be supplied for the algorithm to function well. The bot-
tom panel of Figure 5.3 shows an advisory mode calculation of insulin action that
includes anti-reset windup protection. The buildup of the integral term that was
observed when using PID control was prevented, leading to a lower recommended
insulin dose during the meal.
5.2.4 Insulin Feedback
When designing the AP, it is prudent to draw inspiration from nature by exam-
ining how the pancreas is able to achieve glycemic control in people without T1DM.
A key feature of physiological glycemic control that is missing from a single-input
single-output PID design is that insulin in the blood suppresses further insulin pro-
duction [226]. This feature is necessary to prevent insulin stacking. Most studies
using PID control with subcutaneous insulin have incorporated this feature by using
an insulin feedback (IFB) algorithm [77, 101]. Since it is currently not possible to
measure plasma insulin concentration in real time, this method relies on a model of
insulin pharmacokinetics to estimate the plasma insulin concentration based on past
insulin delivery. In the original description of IFB, insulin pharmacokinetics were
represented by a second-order continuous-time transfer function between insulin de-
livered and plasma insulin concentration, with time constants determined from ex-
perimental data [101]. This continuous-time model can be discretized to match the
sampling period of the controller, resulting in the following equation:
CˆP(k) = a1CˆP(k− 1) + a2CˆP(k− 2) + b1UD(k− 1) + b2UD(k− 2). (5.18)
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Here, UD (U/h) is the closed-loop insulin delivery profile and CˆP(k) is the estimated
plasma insulin concentration. The final insulin dose is then calculated as:
UD(k) = (1+
γ
KPI
)u(k)− γCˆP(k− 1) (5.19)
where u(k) is the insulin dose that was calculated in Equation (5.10). Typically, the
insulin plasma concentration units are normalized so that the gain KPI is equal to
one [77, 101]. The parameter γ determines the degree to which the presence of
plasma insulin suppresses insulin delivery. The factor (1+ γKPI ) is needed so that the
insulin delivery UD(k) is equal to the basal rate when the system is at steady-state.
In subcutaneous insulin applications, the parameter γ is selected to be 0.5 to achieve
good performance [77, 101].
More complex models have also been developed for subcutaneous pharmacoki-
netic behavior. In Ruiz, et al. [227], the insulin concentration is divided into
three compartments: subcutaneous insulin (ISC), plasma insulin (IP), and intersti-
tial/effective insulin (IEFF). These three concentrations are estimated by:
ISC(k) = α11 ISC(k− 1) + β1UD(k− 1) (5.20)
IP(k) = α21 ISC(k− 1) + α22 IP(k− 1) + β2UD(k− 1) (5.21)
IEFF(k) = α31 ISC(k− 1) + α32 IP(k− 1) + α33 IEFF(k− 1) + β3UD(k− 1) (5.22)
IIFB(k) = γ1 ISC(k) + γ2 IP(k) + γ3 IEFF(k) (5.23)
where the parameters αij and βi are constants and IIFB is the combination of the three
compartments, with weighting factors γi. The numerical values of the parameters αij,
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βi, and γi are given in [227]. The final insulin dose is then calculated as:
UD(k) = (1+ γ1 + γ2 + γ3)u(k)− IIFB(k). (5.24)
This method is further described in a patent held by Medtronic Minimed, Inc. [228].
There is limited information available in the literature to supply a pharmacoki-
netic model of IP insulin. For SC insulin, the second-order continuous-time model
was identified to have time constants of 70 min and 55 min [101]. One study that was
completed to identify corresponding parameters for IP insulin delivery found time
constants of 60±8.7 min and 27.2±9.3 min [229], while an earlier study by the same
authors found parameters to be 34.6±5.9 min and 17.4±4.7 min [230]. In the absence
of further modeling data, we chose the more recently identified model parameters to
use in the implementation of IFB for our system. Once further experimental data is
obtained for the pharmacokinetics of the specific insulin to be used, the model can
be updated to provide a more accurate estimation.
5.3 Controller Optimization and Evaluation
The controller design procedure outlined above leaves several design parameters
to be determined: τC, α, and γ. First, candidate values for τC were selected using
robust stability and performance analysis. The other two parameters were selected
using simulation studies with Scenarios 1-3. The best value for α was determined
without IFB by examining the trade-off between the amount of postprandial under-
shoot and offset after a change in insulin sensitivity. Next, the best value for γ was
chosen without anti-reset windup protection (AWP) by examining the minimum and
maximum postprandial BG values. Lastly, the controller was tested with both IFB
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and AWP implemented.
5.3.1 Robust Stability and Performance
As discussed in Chapter 4, the AP must be robust to model uncertainty in order
to be safe for clinical use. The manner in which the body responds to insulin can
change as a function of the time of day, hormonal changes, exercise, and other factors
that are part of daily life. Experimental evidence shows that the insulin sensitivity
may vary by up to 50% [205]. The changes in the body’s insulin response can be
represented as perturbations to the gain and delay of the nominal model. In order
to determine whether the system will be stable for a specified model uncertainty,
the robust stability condition can be evaluated. A robust controller will be able to
perform according to its design specifications, even in the worst-case scenario of
model uncertainty [206].
In order to use this method, we must first represent a suitable family of possible
plants ΠI , in this case using multiplicative uncertainty. Revisiting the equations from
Chapter 4, we define ΠI as:
ΠI : GP(s) = G(s)(1+ wI(s)∆I(s)); |∆I(jω)| ≤ 1, ∀ω (4.15)
where GP is a possible process model, G is the nominal process model, and the
uncertainty weight satisfies the inequality |wI(jω)| ≤ lI(ω), ∀ω where
lI(ω) = max
GP∈ΠI
|GP(jω)− G(jω)
G(jω)
|. (4.16)
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The stability criterion is then given as:
RS ⇐⇒ ||wIT||∞ < 1 ∀ω (4.17)
where T is the complementary sensitivity function and wI is the multiplicative un-
certainty weight. To represent the parametric uncertainty in the gain and delay of the
nominal model, we use
wI =
(1+ rk2 )θmaxs + rk
θmax
2 s + 1
(4.18)
where rk =
Kmax−Kmin
Kmax+Kmin
and θmax is the maximum delay considered [206]. Robust perfor-
mance analysis allows us to determine whether certain specified performance mea-
sures will be met even in the presence of model uncertainty. The necessary relation
to show robust performance is given by:
RP ⇐⇒ max
ω
(|wPS|+ |wIT|) < 1 (4.19)
where S is the sensitivity function and wP is the performance weight
wP(s) =
s
M +ω
∗
B
s +ω∗B A
(4.20)
where M is the maximum peak of the sensitivity function, A is the steady state
tracking error, and ω∗B is the bandwidth frequency where the sensitivity function
crosses the magnitude of 0.707 [206]. In this study, A ≈ 0, ω∗B = 5× 10−5 hz, and
M = 2, as recommended in Skogestad, et al. [206].
We can use the robust stability and performance analyses to inform our choice of
τC. Figure 5.5 shows whether the RP and RS conditions were met under a specified
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model uncertainty for varying values of τC. In order to be able to retain RP and
RS for a delay uncertainty of 10 minutes and a gain uncertainty of 0.5, we should
choose a τC between 40 and 150 minutes. The lower value will result in faster, more
aggressive control, while the higher value will result in slower, more conservative
control. Setting τC to 40 min to obtain the fastest response, the controller designs in
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Figure 5.5: Robust stability and performance as a function of controller
tuning. Robust stability (left) and robust performance (right) for varying
values of τC. The analysis was done for three values of delay uncertainty:
5 minutes (solid line), 10 minutes (dashed line), and 15 minutes (dotted
line). The gain uncertainty was kept constant at 0.5.
Table 5.3 were evaluated.
To evaluate the controller with no integral action, the position form was used:
u(k) = u¯ + P(k) + D(k) (5.25)
where
P(k) = KCe(k) (5.26)
D(k) =
KCτD
∆t
[e(k)− e(k− 1)] (5.27)
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and u¯ is the basal rate needed to maintain a fasting glucose concentration of
110 mg/dL.
5.3.2 Evaluation of the Anti-Reset Windup Protection
To determine the best parameter α to use for the anti-reset windup algorithm, we
examined the trade-off between undershoot mitigation and setpoint tracking using
Scenarios 1 and 2. The undershoot was characterized by the minimum blood glu-
cose concentration during the postprandial period after a large meal. The setpoint
tracking was evaluated by examining the offset remaining at two time points follow-
ing a change in insulin sensitivity for the different AWP tunings as compared to the
PID controller with no AWP. The PID controller with no AWP represents the ideal
tracking case at each time point since it has full integral action. The first time point,
11 h, was chosen because after this amount of time the PID controller had made par-
tial progress toward the setpoint. The 20 h time point was chosen because after this
amount of time, the PID controller had nearly returned the BG to the setpoint. By
examining the offset at these two time points, we compared the asymptotic setpoint
tracking of the PID+AWP controllers to the ideal PID tracking on both a short- and
long-term time scale. We then plotted the offset versus the minimum BG for various
values of α, as shown in the left panel of Figure 5.6.
From this analysis, we determined that a good choice for α is 0.04. This option
keeps the undershoot above 100 mg/dL but also reduces the offset after a change in
insulin sensitivity. Note that the offset will be eliminated over time for all values of
α. The larger α is, the longer it takes to reach the setpoint again after a change in
insulin sensitivity. Figure 5.7 shows the simulation results for Scenarios 1-3 for the
optimal value of α, PID control with no anti-reset windup, and PD control.
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Figure 5.6: Evaluation of the trade-off between setpoint undershoot and
offset. Offset 11 h (black triangles) and 20 h (white squares) after a de-
crease in insulin sensitivity plotted versus minimum BG after a 100 g CHO
meal for varying values of anti-reset windup parameter α. The top panel
shows the offset versus minimum BG for PID+AWP, while the bottom
shows the results for PID+AWP+IFB (γ=0.5). The data points represent
the 10-subject mean and the error bars show standard deviation.
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Figure 5.7: Evaluation of the anti-reset windup in simulation. Demon-
stration of the best anti-reset windup tuning (solid black line) compared
to PID (dashed black line) and PD (dashed gray line) control. The top
panel of each plot shows the blood glucose concentration over time, while
the bottom panels show insulin delivered over time. The figures show the
results from Scenario 1 (100 g CHO meal, top), Scenario 2 (30% decrease
in insulin sensitivity, bottom left) and Scenario 3 (30% increase in insulin
sensitivity, bottom right). The lines show the mean of the 10 subjects, and
the error bars show standard deviation.
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Table 5.3: Variations on the PID controller design tested in this work.
Controller Integral Action Anti-Reset
Windup (AWP)
Insulin
Feedback (IFB)
PD 7 7 7
PID 3 7 7
PID+AWP 3 3 7
PID+IFB 3 7 3
PID+AWP+IFB 3 3 3
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Figure 5.8: Evaluation of IFB in simulation. Demonstration of best IFB
tuning (dashed gray line) compared to unmodified PID control (solid black
line) for a 100 g CHO meal. The top panel shows the blood glucose concen-
tration over time and the bottom panel shows the insulin delivered. The
lines show the mean of the 10 subjects, and the error bars show standard
deviation.
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5.3.3 Tuning the Insulin Feedback Algorithm
The IFB strategy was tested using Scenario 1 for several values of γ with no anti-
reset windup protection. Values of γ were tested from 0 to 0.5. The value of 0.5,
which has been used previously for SC insulin, gave the best performance. When
IFB was added to PID control, the minimum BG was raised by an average of 13.3 ±
2.4 mg/dL and the maximum BG was lowered by an average of 9.8 ± 3.8 mg/dL.
When using a paired-sample t-test to compare the minimum BG for each subject with
and without IFB, the difference is significant with a p-value of 3× 10−8. The same
statistical test for the maximum BG for each subject with and without IFB showed
significant difference with a p-value of 1.8× 10−5. The results of the simulation are
shown in Figure 5.8.
To determine whether adding IFB to the controller affects the choice of anti-reset
windup parameter α, we repeated the anti-reset windup evaluation with IFB added
(γ = 0.5). The results are presented in the right panel of Figure 5.6. As seen in the
figure, the shape of the data curve and optimal value of α = 0.04 remain the same
when IFB is added. For all values of α, the performance is better with IFB than
without it.
5.3.4 Evaluation of Finalized Design
Figure 5.9 shows a plot of the maximum versus minimum BG achieved by the 5
controller designs tested in this work following a 100 g CHO meal. The IFB algorithm
is able to raise the minimum BG, but not to the same degree that anti-reset windup
does. IFB has the added benefit of lowering the maximum BG peak. Overall, PID plus
IFB and anti-reset windup provides better control than either strategy alone, and both
provide great improvements over PID alone. The PD, PID+AWP, and PID+AWP+IFB
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controllers have some overlap on the plot in Figure 5.9; however, the PID iterations
have a clear advantage over the PD approach since they include setpoint tracking
while PD does not. The most important comparison to make is to determine whether
adding IFB to the PID+AWP controller results in significant improvement. These two
cases were compared using a paired-sample t-test to compare the maximum BG and
the minimum BG following the 100 g CHO meal. The maximum BG was decreased
by an average of 10±3.8 mg/dL when IFB was added to the PID+AWP controller.
This difference is significant with a p-value of 1.5 × 10−5. The minimum BG was
raised by an average of 2.9±1.5 mg/dL when IFB was added. While the difference
in the minimum BG is relatively small and not likely of clinical significance, it is
still statistically significant with a p-value of 2× 10−4. The benefit of adding IFB in
addition to AWP is the more aggressive initial action that is taken when there is little
insulin already in the body. Additionally, including the IFB mechanism is superior
clinically because it adds a safety layer to prevent insulin over-delivery. This type
of mechanism is a must for clinical application since preventing hypoglycemia is the
first priority.
The results achieved with IP insulin using IFB+AWP in this work are compared
to those achieved for Scenarios 1-3 with SC insulin in Laxminarayan, et al. [82] in
Table 5.4. The IP approach resulted in a much lower peak BG than the SC approach.
In addition, the IP system did not drive the BG as low as the SC system following
the meal, resulting in an overall safer scenario. The time to return to setpoint after a
change in insulin sensitivity was also much faster using IP insulin with the anti-reset
windup strategy presented in this work.
The final controller design was evaluated for Scenario 4 with sensor measurement
noise to create a realistic test. The measurement noise included in the metabolic
simulator was designed to emulate an SC sensor. There is currently no IP sensor
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Figure 5.9: Plot of the maximum BG versus the minimum BG following
a 100 g CHO meal. The large icon shows the mean, and the small icons
show the individual 10 subjects for each case. The PID with IFB and anti-
windup strategy was able to raise the minimum BG while also lowering
the maximum BG, leading to better and safer control than using either
strategy alone.
Table 5.4: Comparison of results with the intraperitoneal system to those
achieved with the subcutaneous system in a previous study (shown as
mean (standard deviation)).
IP System SC System [82]
Scenario 1 Max BG (mg/dL) 229 (15) 279 (14)
Scenario 1 Min BG (mg/dL) 105 (1.6) 92 (3)
Scenario 2 Return to setpoint (h) 20-30 ≈80
Scenario 3 Return to setpoint (h) 20-30 ≈80
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Figure 5.10: Simulation evaluation of the final controller design. Blood
glucose and insulin trace for the final controller design evaluated on 10 in
silico subjects using the 27 hour protocol from Scenario 4. The acceptable
glycemic zone of 70-180 mg/dL is shown by the black horizontal lines on
the top panel. The thick line shows the mean of the 10 subjects, and the
thin lines show plus and minus one standard deviation.
model available due to the paucity of data. The SC sensor noise model included in
the simulator is described in Breton, et al. [183]. The results are shown in Figure 5.10.
The controller was able to maintain the BG within the tight glycemic range of
80-140 mg/dL for 79% of the time, even in the presence of measurement noise. The
added noise did cause a lower minimum BG to occur during the simulation, but
hypoglycemia was still avoided. These results are comparable to those achieved in
Lee, et al. using a zone MPC control strategy with IP insulin and SC sensing [200].
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Table 5.5: Summary of the numerical results from the final controller eval-
uation.
Max BG
(mg/dL)
Min BG
(mg/dL)
% Time BG
80-140
mg/dL
% Time
BG<70
mg/dL
% Time
BG>180
mg/dL
196 ± 14 93 ± 7.3 78 ± 6 0 ± 0 5 ± 4
5.4 Discussion
An AP that uses IP insulin combined with IP sensing has the potential to greatly
improve closed-loop glycemic control. Since IP insulin has faster pharmacokinetic
and pharmacodynamic characteristics than SC insulin, the AP will be able to bring
the BG back to the desired setpoint faster after glycemic disturbances occur. Also,
since the insulin is cleared more quickly, there is less risk of hypoglycemia due to
delayed insulin action [195, 231].
In this study, the tuning of the PID controller was informed using robust stability
and performance analysis. The robustness of the controller is of great importance,
due to inter- and intra-patient variability in the response to insulin. The controller
was designed to maintain robust performance and stability even in the presence of
50% gain uncertainty and 10 minute delay uncertainty. These estimations of uncer-
tainty were based on Lee, et al. [188], and are intended to capture changes in insulin
sensitivity that can occur throughout the day, as well as unexpected delays due to
measurement dropouts, temporary pump failures, or other problems.
The addition of the anti-reset windup strategy used in this work decreases the
risk of hypoglycemia after meals, without increasing time spent in hyperglycemia.
In addition, setpoint tracking is maintained following changes in insulin sensitivity.
The anti-reset windup strategy used in this chapter can also be applied when SC
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insulin is used, although the tuning factor may need to be adjusted. This method
is recommended because it dynamically adjusts the amount of integration based on
the situation, leading to better control for both large, temporary disturbances and
smaller but persistent disturbances.
IFB is an important addition to an AP controller because it imitates the physiol-
ogy of the human body. Increased plasma insulin concentration inhibits the delivery
of more insulin, meaning there is less chance for insulin stacking and hypoglycemia.
IFB was initially introduced after the first clinical study of PID control with SC insulin
resulted in postprandial undershoot leading to hypoglycemia [79]. A following clini-
cal study applying IFB showed that the postprandial hypoglycemia was reduced, but
there were still episodes requiring rescue CHO to be delivered [77, 232]. Our study
shows that IFB alone is not enough to attenuate postprandial undershoot, and that
an anti-reset windup strategy in combination with IFB provides the best results. A
more accurate model of insulin pharmacokinetics may lead to improved performance
of the IFB algorithm. We recommend that such a model be identified before in vivo
studies using IFB with IP insulin are conducted.
There are other benefits to using intraperitoneal insulin delivery beyond faster
insulin action. This route better mimics the natural insulin production process by the
pancreas. When the insulin is delivered into the intraperitoneal space, it introduces
a positive portal-systemic insulin gradient throughout the body. This gradient is
expected to lead to better overall health. Other hormones involved in the metabolism
are also affected by the use of IP insulin, and there is some evidence to suggest
that the benefits of IP insulin use extend beyond improved glycemia. A thorough
explanation of these benefits is presented in Van Dijk, et al. [19].
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5.5 Conclusions and Future Work
A fully implanted AP operating in the IP space allows many of the challenges as-
sociated with subcutaneous insulin delivery to be overcome. Faster insulin transport
and action, along with more rapid glucose sensing, allow the controller to maintain
excellent glycemic control. In addition, IP insulin delivery may also have beneficial
endocrine effects, as discussed in van Dijk, et al. [19]. In this chapter, a model-based
tuning strategy was introduced to develop a PID controller for a fully implantable
AP. Furthermore, a dynamic anti-reset windup strategy was applied to minimize un-
dershoot of the setpoint after meals while still maintaining setpoint tracking. IFB was
also added to improve the controller response. This design may be further refined
with the development of more accurate models based on experimental data. Once
this data has been collected and analyzed, the updated controller will be evaluated
in an animal model to quantify the improved performance offered by this controller
in vivo.
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Conclusions and Future Work
This dissertation explored the impact of sensing and actuation characteristics
on the closed-loop artificial pancreas (AP) for people with type 1 diabetes mellitus
(T1DM). Conclusions from this work are presented below. Additionally, recommen-
dations for future work building from this dissertation are discussed.
6.1 Conclusions
Under current standards of treatment, people with T1DM must manually monitor
their BG and deliver insulin as needed. This process is difficult to accomplish, and
often results in hyperglycemia or hypoglycemia, both of which lead to long- and
short-term health complications. New developments in medical device technology,
such as the invention of insulin pumps and continuous glucose monitors (CGMs),
have provided additional tools to aid people in managing this disease, but even
these advanced tools still require manual monitoring, decision-making, and ongoing
education on the part of the user.
In this dissertation, the application of process control to T1DM treatment was
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explored. The development of an AP system to automatically deliver insulin using
feedback control based on CGM measurements will lead to better health outcomes for
people with diabetes, while also reducing the amount of effort required for successful
treatment. The necessary components of an AP are a CGM, a control algorithm, and
an insulin pump, plus a means of communication between the three. State-of-the-art
implementations of the AP being evaluated in clinical trials use both subcutaneous
(SC) glucose sensors and SC insulin pumps. These trials have shown promising
results, but there is still room for improvement, especially during the postprandial
period and other times when the BG is changing rapidly. Most SC-SC designs are
hybrid systems that require the user to announce a meal to the controller to trigger
a preemptive preprandial insulin bolus in order to achieve satisfactory results. The
use of the intraperitoneal (IP) space as an alternative site for insulin delivery and
glucose sensing is expected to reduce the lags in the control loop and improve AP
performance, allowing for a fully implantable, fully automated glucose regulation
system.
6.1.1 Clinical Evaluation of the AP in Adolescents
As discussed in Chapter 2, an AP system using zone model predictive control
(ZMPC) and the Health Monitoring System (HMS) hosted on the Diabetes Assistant
(DiAs) mobile platform was evaluated for feasibility in the adolescent population.
Adolescents frequently struggle to meet the recommended glycemic control criteria,
making them excellent candidates for AP use. The study took place in the outpatient
hotel environment with highly ambulatory conditions, thus serving as a transition
between the inpatient setting and the fully unsupervised outpatient setting. The
protocol included mild to moderate intensity exercise sessions at least twice per day
that were not announced to the controller. There were also free-choice announced
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meals to emulate free-living conditions.
Ten adolescents with T1DM completed 72 h of closed-loop control (CLC) during
this trial. The study showed that the ZMPC+HMS/DiAs system was feasible for use
in the adolescent population in a highly ambulatory hotel environment with frequent
unannounced exercise and announced meals. During CLC, the subjects spent 71%
of time in the desired range of 70-180 mg/dL. Additionally, the controller was able
to react to changes in the CGM during exercise sessions to suspend insulin delivery
as needed. The ZMPC+HMS algorithms were determined to be feasible for use in
adolescents. The results from this preliminary study indicate that an AP using the
ZMPC+HMS algorithms is likely to improve glycemic control in this population as
compared to the standard therapy.
6.1.2 Modeling of Glucose Sensor Dynamics
CGMs placed in the SC space are known to experience a measurement lag caused
by the diffusion of glucose from the blood vessels to the interstitial fluid. It was
hypothesized that a CGM placed in the IP space would have a smaller lag than one
placed in the SC space due to the increased proximity to major vasculature. The study
presented in Chapter 3 was conducted to compare the response of enzymatic CGMs
placed in the SC and IP space of non-diabetic swine, which provides a model for the
human endocrine system. Multiple sensors were place in the IP, SC, intravenous (IV)
and intra-arterial (IA) spaces of eight animals. BG measurements were also taken
using a glucometer. The IP and SC sensor signals were modeled as a function of
the BG to determine the time constant of the sensor response. The results showed
that the sensors placed in the IP space were characterized by a time constant that
was approximately half that of sensors placed in the SC space of the same animal.
This study demonstrated that IP sensor placement is a promising alternative to SC
153
Chapter 6. Conclusions and Future Work
placement, especially for use in AP applications.
A follow-up study was done to investigate the effects of long-term implantation
of fluorescent CGMs in the IP versus SC space of a non-diabetic sheep. Fluores-
cent sensors may be better suited for long-term implantation than enzymatic sensors
due to their demonstrated longevity. The purpose of this study was to provide the
proof-of-concept of a novel flushing mechanism developed by TheraNova, LLC to
prevent sensor encapsulation, which is known deteriorate the sensor response. The
mechanism was used to flush the IP sensor with saline, thus cleaning the surface and
allowing the sensor to maintain the same level of responsiveness over three months.
Further investigation with an increased sample size will determine whether the flush-
ing mechanism creates a significant improvement in sensor response as compared to
non-flushed sensors in the IP space.
6.1.3 Impact of Sensor Dynamics on AP Performance
Several studies have demonstrated that the use of an insulin delivery route with
faster pharmacokinetic and pharmacodynamic properties can lead to improved AP
performance. In Chapter 4, a parallel study was conducted to determine the impact
of glucose sensor dynamics on the control achieved by an AP. An initial analysis was
done to evaluate the error caused by a dynamic lag in the glucose measurement. The
study showed that a dynamic lag as large as 30 min resulted in a point-wise sensor
accuracy that would be considered clinically acceptable; however, the dynamic nature
of the error could be detrimental to AP performance.
A proportional-integral-derivative (PID) controller was designed using a model-
based method to evaluate the impact of sensor dynamics on an AP using IP or SC
insulin. Due to intra- and interpatient variabilities in the response to insulin, model
uncertainty is an important consideration in the development of an AP system. An
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analysis using robust performance and robust stability criteria determined that de-
creasing the sensor lag resulted in a system that was more robust to model uncer-
tainty.
In order to analyze the effect of sensor lag on the glycemic control achieved by
an AP, the glucose sensor model developed in Chapter 3 was integrated into the
University of Virgina (UVA) and University of Padova metabolic simulator. This
metabolic simulator allows AP controllers to be evaluated on 10 in silico patients
with T1DM using either IP or SC insulin. The addition of the glucose sensor model
allowed the sensor lag to be specified for the simulation. A series of simulations
were conducted to evaluate the performance of the PID controller using either IP
or SC insulin with a sensor time constant varying from 0 to 30 min. Decreasing
the sensor lag was found to significantly decrease the time spent in hyperglycemia
following a meal challenge. While designing the AP to use IP insulin rather than SC
insulin results in a large improvement in the quality of glycemic control achieved,
the results can be improved even further by decreasing the lag in the glucose sensor.
6.1.4 Implantable Artificial Pancreas Design
As discussed in Chapters 3-5 of this dissertation, the performance of the AP can
be improved by altering its design in order to reduce lags in the control loop. A
fully implantable AP using devices placed in the IP space is a promising solution.
The IP placement will reduce the delays in both insulin action and glucose sensing
that are currently experienced with SC devices. Additionally, the use of IP insulin
better mimics physiological insulin delivery by the pancreas, and therefore may lead
to better metabolic health. A fully implanted system will also eliminate the inconve-
nience of having external devices attached to the skin, along with the need to perform
frequent infusion set and CGM changes.
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In Chapter 5, a procedure for robust PID controller design for a fully implantable
AP was presented. The tuning parameters were selected using internal model con-
trol, leaving a single tuning parameter to determine the robustness of the controller.
This parameter was selected to be as small as possible while still maintaining robust
performance and stability for the anticipated model uncertainty.
The controller was evaluated in a series of simulation studies in the UVA/Padova
metabolic simulator. The initial design was found to result in an undesirable under-
shoot of the setpoint following a meal. An anti-reset windup strategy was imple-
mented to eliminate this undershoot by attenuating the buildup of the integral term
when the measured variable is far from the setpoint. Incorporating this strategy into
the controller eliminated the undershoot, while still maintaining setpoint tracking in
the case of a change in insulin sensitivity.
Insulin feedback (IFB) was also incorporated into the controller design. The IFB
algorithm uses a model to estimate the concentration of insulin in the blood and
modulate the insulin delivery computed by the controller accordingly. This physio-
logically inspired method prevents insulin over-delivery when there is already active
insulin in the body. Incorporation of the IFB algorithm using a model for IP insulin
pharmacokinetics from the literature resulted in safer control by delivering less in-
sulin once there was already a high concentration of insulin in the blood following a
large meal. The final controller design incorporated the IFB algorithm in combination
with the anti-reset windup strategy, as this configuration lead to the best results in
the simulation studies.
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6.2 Recommendations for Future Work
The work presented in this dissertation can be expanded upon to generate further
progress in the development of the AP. Potential future directions for work are de-
scribed below. Two main topics are discussed: future work in the outpatient clinical
evaluation of the ZMPC+HMS/DiAs system (a continuation of the work presented
in Chapter 2) and future work towards the development of a fully implantable AP (a
continuation of the work presented in Chapters 3-5).
6.2.1 Outpatient Use of the ZMPC+HMS/DiAs System
In Chapter 2, the evaluation of the ZMPC+HMS/DiAs system in adolescents in
the transitional hotel environment was presented. This study protocol emphasized
frequent physical activity and free-choice meals to emulate the conditions typically
experienced by active adolescents with T1DM. The results from this trial established
feasibility of the system in this population and setting, but there is still more work to
do to establish efficacy as compared to subjects’ usual therapy, especially over longer
periods of time and in the unsupervised fully outpatient environment.
A follow-up study to the one presented in Chapter 2 is currently underway at
Stanford University and the Barbara Davis Center for Diabetes. This study is follow-
ing a supplemental protocol that was submitted to the Food and Drug Administra-
tion (FDA) to expand upon the work from the initial study. A total of 20 adults will
use the ZMPC+HMS/DiAs system for two weeks of CLC in the unsupervised fully
outpatient setting. The Automated Notification System (ANS), part of the DiAs Web
Monitoring system, is in place to alert clinical staff on-call to any potential safety risks
during CLC. Additionally, fault detection algorithms developed at the University of
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California San Diego and Rensselaer Polytechnic Institute will be run in real-time to
evaluate their ability to detect failures in the insulin infusion set or CGM. These types
of fault detection algorithms are important to include in an AP to improve the safety
of the design, as an undetected failure of the insulin infusion set or glucose sensor
could lead to a health risk such as diabetic ketoacidosis.
One advantage of this study is its randomized crossover design. Half of the sub-
jects will use their usual sensor augmented pump therapy (SAP) during the first
two weeks, while the other half will use CLC. Then each subject will switch to the
other therapy for the second two weeks. This crossover design, combined with the ex-
tended CLC period of 2 weeks rather than 3 days, will allow the efficacy of the system
to be evaluated. However, unlike the first study, the subjects in this trial are all adults.
This transition was made because the AP system requires too much interaction to be
practical for use by adolescents attending school. Additionally, it may be necessary
to first demonstrate the safety and efficacy of fully unsupervised outpatient use of
the ZMPC+HMS/DiAs system in the adult population before performing studies in
the higher-risk adolescent population. It is anticipated that this criteria will be met
soon, as the ZMPC+HMS/DiAs system is already being evaluated in a separate 12
week fully unsupervised outpatient study in adults.
One weakness in the ZMPC+HMS/DiAs system revealed by the clinical study is
the frequent disruption of communication that can occur between the CGM or insulin
pump and the DiAs system. While clinical staff were on-site to assist the subjects with
reestablishing communication between the devices, this type of disruption may cause
more time to be spent out of closed-loop in the unsupervised outpatient environment
if users become frustrated with the device or cannot respond to disconnections in a
timely manner. Device usability is an increasingly important factor to include in the
design as the system moves further from being an experimental device and closer to a
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commercial product. An AP system that requires frequent adjustment or interaction
to remain in CLC may not be acceptable to patients. It will be important to include
user satisfaction surveys as part of the longer outpatient clinical trials in order to
receive feedback on user needs for the device. The user feedback can be used to
prioritize which features should be enhanced or changed by research engineers.
An important area for further engineering research is the optimization of the
method used to incorporate the announced meal bolus within the ZMPC+HMS sys-
tem. The results from the study in Chapter 2 revealed a pattern of hypoglycemia in
the period 2-4 hours following a meal. It is possible that this hypoglycemia occurred
due to the over-estimation of the meal size used to calculate the bolus, or due to a sub-
optimal insulin to carbohydrate ratio. The current iteration of the ZMPC+HMS/DiAs
system delivers only 80% of the calculated meal bolus if the BG value entered with
the meal announcement is less than 120 mg/dL. This reduction is intended to re-
duce potential hypoglycemia following the meal. The full bolus is given for meals
announced with a BG greater than 120 mg/dL, with an additional correction dose to
150 mg/dL if the BG is higher than that value.
While the meal bolus scheme has provided acceptable results in clinical stud-
ies, its performance could potentially be improved by altering its parameters. As
more clinical data is gathered from the outpatient studies described above, each meal
announcement (size, SMBG, and resulting bolus amount) should be examined to
determine whether any of the meal announcement factors were correlated with hy-
poglycemia in the postprandial period. Additional factors could be examined for
inclusion in the meal bolus calculation, such as the current rate of change of the
CGM. Inclusion of an additional correction bolus when the controller has already
acted and the CGM is high but decreasing could lead to an over-delivery of insulin.
Using the CGM rate of change in the bolus calculation could potentially prevent this
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over-delivery.
The clinical study showed that the controller responded as desired to exercise,
but there were still some hypoglycemic episodes with CGM<70 mg/dL that occurred
during or after the exercise periods. Since the exercise was not announced to the con-
troller, it was not able to take action in the form of a pump suspension until the feed-
back from the CGM indicated a rapid decrease or movement toward hypoglycemia
A promising area of research is the inclusion of an algorithm to detect exercise based
heart rate and accelerometer data. In a clinical study, a detection algorithm using
principal component analysis based on these two signals was able to detect the start
and end of exercise in approximately 5 min, before the CGM had changed noticeably
[233]. This algorithm could be added to the AP system to detect the exercise and
adjust the insulin delivery accordingly. The action taken when exercise is detected
could be to raise the target zone, to reduce the controller gain, or to use a lower basal
rate of insulin. Each of these options should be investigated to determine which
would best decrease the risk of hypoglycemia during exercise.
6.2.2 Towards a Fully Implantable Artificial Pancreas
In Chapter 5, a procedure for designing and evaluating a robust PID controller
for a fully implantable AP was presented. The control algorithm was designed and
tuned using models that were available in the literature [229] and identified from the
UVA/Padova metabolic simulator [200], and its performance was validated in silico.
The next step in this project will be to evaluate the implantable AP in vivo in an animal
model, as the system must first be shown to be safe in the animal model before it
can be tested in human studies. Before testing the controller in the animal model, a
crucial step will be to perform a system identification in the particular animal species
with the specific devices and insulin formation that will be used in the closed-loop
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testing. The models can then be updated to be accurate for this system, which will
lead to optimal results.
Collaborators have been identified who will conduct the system identification and
closed-loop experiments in canines, which are frequently used as a model in T1DM
research. A diabetic state can be induced in the animals either through surgery or
medication. The animal will be equipped with the implanted insulin pump and
glucose sensor, as well as a line for sampling intravenous blood. The system identifi-
cation experiments will begin with the animal in hyperglycemia. An IP insulin bolus
will then be administered to reduce the BG to the upper end of the euglycemic range.
After the BG has stabilized, another bolus will be delivered to bring the BG to the
lower end of the euglycemic range. Once again, after the BG has stabilized, a third
bolus will be delivered to bring the BG to a mild hypoglycemic state. At this point a
glucose bolus will be delivered to quickly raise the BG to the euglycemic range. The
following data will be recorded throughout the testing period: plasma insulin con-
centration over time, plasma glucose concentration over time, signal from implanted
glucose sensor over time, quantity of glucose delivered, and quantity of insulin de-
livered. The experiment should be repeated in at least two additional animals, and
may also be repeated in the same animal.
The wealth of data gathered from the animal studies will be used to improve the
models of both IP insulin pharmacokinetics and pharmacodynamic properties that
are used to tune the controller and implement the IFB algorithm. The methods de-
scribed in [234] and [70] can be used to assist in the modeling process. An important
consideration will be to divide the data so that the model and parameters identified
from one dataset can be validated on the second dataset.
The plasma insulin concentration time series will be used to identify a model
describing the plasma insulin concentration as a function of insulin delivered. The
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initial model structure can be the second-order transfer function described in Chapter
5, but additional model structures may be explored as appropriate based on the
data. The model and parameters identified will be used in the IFB algorithm. The
plasma glucose time series will be used to identify a model describing the plasma
glucose concentration as a function of insulin delivered. This process model will be
used to update the PID controller tuning using internal model control tuning rules.
This model may also be used in the future to develop an MPC controller for this
system. Lastly, the implanted glucose sensor time series will be used to identify
the lag between the plasma glucose concentration and the sensor measurement. The
same procedure described in Chapter 3 can be used to perform the modeling.
In addition to the in vivo studies, another important avenue of research will be
to continue work to improve the controller design. While the PID controller was
able to provide excellent results in simulation studies, an MPC design should also be
evaluated as a comparison. The candidate controllers should be evaluated based on
the quality of control achieved in simulation, as well as the computational complexity
that will affect their ability to be embedded in a fully implanted system, where space
and battery power will be at a premium.
Once the system identification has been performed and the controller design has
been finalized, the fully implantable AP will be evaluated in the animal model. An-
imal studies are required because the implantable insulin pump and glucose sensor
being used for this system are also under development and not yet approved for use
in humans. These studies should include challenges to the AP system such as large
meals and exercise in order to fully characterize the design performance. The studies
may also be used to evaluate and select between a subset of controller designs. The
results of these studies will provide the support to pursue human clinical testing.
The long term goal of this project is to evaluate the developed technology in
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human clinical trials so it can move toward being approved for outpatient use by
T1DM patients. Clinical evaluation of the fully implantable system will be much
more complex than the current clinical studies using SC devices because surgery will
be required to implant the IP insulin pump and glucose sensor. Additionally, before
the system can be used in humans, an additional system identification step will need
to be carried out to convert the model parameters from the animal system to the
human system.
A protocol will be developed for a proof-of-concept study to show that a fully
implantable IP-IP system can provide control successfully in human subjects. After
analyzing the outcomes of this pilot study, a more extensive clinical trial design will
be developed to compare the fully implantable system to a system using SC devices.
The hypothesis will be that the fully implantable controller will be able to maintain
more steady control of the BG, with better meal compensation than the SC-SC system.
6.3 Summary
The dream of an AP that uses feedback control to provide automated treatment
for people with T1DM is rapidly becoming a reality. Different versions of this device
are currently being evaluated in the unsupervised, fully outpatient setting under
daily-life conditions. It is only a matter of time before this technology becomes avail-
able as a standard treatment option for people with T1DM. The AP is designed to
relieve T1DM patients from the burden of constant self-monitoring. In addition, it
will improve glycemic control relative to what is possible with manual treatment.
Improved glycemic control will lead to fewer long-term health complications, while
also avoiding dangerous hypoglycemia.
A crucial part of the AP control scheme, no matter which algorithm is used, is
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the choice of sensor and actuator. For this reason, it is important to understand the
performance and capabilities of these devices. By characterizing different routes of
glucose sensing and insulin delivery and their impact on the AP performance, safer
and more effective controllers can be created to meet the treatment needs of people
with T1DM.
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Appendix A
Artificial Pancreas Clinical
Bibliography
There have been many clinical evaluations of the artificial pancreas (AP) published
since 2004. These studies have been compiled into a database to be used by the
research community to analyze trends and inform future decisions about protocol
design. At the time this dissertation is published, the searchable database of clinical
studies is publicly available at www.thedoylegroup.org/apdatabase. The following
pages contain a bibliography of all of these studies as of May 2016. The studies are
sorted in descending order by date.
190
List of Published AP Clinical Studies
[1] V. Gingras, A. Haidar, V. Messier, L. Legault, M. Ladouceur, and R. Rabasa-
Lhoret, “A simplified semi-quantitative meal bolus strategy combined with
single- and dual-hormone closed-loop delivery in patients with type 1 diabetes:
a pilot study,” Diabetes Technology & Therapeutics, 2016.
[2] T. T. Ly, D. B. Keenan, A. Roy, J. Han, B. Grosman, M. Cantwell, N. Kurtz,
R. von Eyben, P. Clinton, D. M. Wilson, and B. A. Buckingham, “Automated
overnight closed-loop control using a proportional-integral-derivative algorithm
with insulin feedback in children and adolescents with type 1 diabetes at dia-
betes camp,” Diabetes Technology & Therapeutics, vol. 18, no. 6, pp. 377–384, 2016.
[3] J. T. Ilkowitz, R. Katikaneni, M. Cantwell, N. Ramchandani, and R. A. Heptulla,
“Adjuvant liraglutide and insulin versus insulin monotherapy in the closed-loop
system in type 1 diabetes a randomized open-labeled crossover design trial,”
Journal of Diabetes Science and Technology, 2016.
[4] S. del Favero, F. Boscari, M. Messori, I. Rabbone, R. Bonfanti, A. Sabbion,
D. Iafusco, R. Schiaffini, R. Visentin, R. Calore, Y. L. Moncada, S. Galasso,
A. Galderisi, V. Vallone, F. D. Palma, E. Losiouk, G. Lanzola, D. Tinti, A. Rig-
amonti, M. Marigliano, A. Zanfardino, N. Rapini, A. Avogaro, D. Cher-
navvsky, L. Magni, C. Cobelli, and D. Bruttomesso, “Randomized summer camp
crossover trial in 5- to 9-year-old children: outpatient wearable artificial pancreas
is feasible and safe,” Diabetes Care, 2016.
[5] J. L. Sherr, N. S. Patel, C. I. Michaud, M. M. Palau-Collazo, M. A. Van Name,
W. V. Tamborlane, E. Cengiz, L. R. Carria, E. M. Tichy, and S. A. Weinzimer,
“Mitigating meal-related glycemic excursions in an insulin-sparing manner dur-
ing closed-loop insulin delivery: the beneficial effects of adjunctive pramlintide
and liraglutide,” Diabetes Care, 2016.
[6] E. Renard, A. Farret, J. Kropff, D. Bruttomesso, M. Messori, J. Place, R. Visentin,
R. Calore, C. Toffanin, F. D. Palma, G. Lanzola, P. Magni, F. Boscari, S. Galasso,
A. Avogaro, P. Keith-Hynes, B. Kovatchev, S. D. Favero, C. Cobelli, L. Magni,
J. H. DeVries, and A. Consortium, “Day and night closed-loop glucose control
191
Appendix A. Artificial Pancreas Clinical Bibliography
in patients with type 1 diabetes under free-living conditions: results of a single-
arm 1-month experience compared with a previously reported feasibility study
of evening and night at home,” Diabetes Care, 2016.
[7] T. T. Ly, S. A. Weinzimer, D. M. Maahs, J. L. Sherr, A. Roy, B. Grosman,
M. Cantwell, N. Kurtz, L. Carria, L. Messer, R. von Eyben, and B. A. Buck-
ingham, “Automated hybrid closed-loop control with a proportional-integral-
derivative based system in adolescents and adults with type 1 diabetes: individ-
ualizing settings for optimal performance,” Pediatric Diabetes, 2016.
[8] B. Grosman, J. Ilany, A. Roy, N. Kurtz, D. Wu, N. Parikh, G. Voskanyan, N. Kon-
valina, C. Mylonas, R. Gottlieb, F. Kaufman, and O. Cohen, “Hybrid closed-loop
insulin delivery in type 1 diabetes during supervised outpatient conditions,”
Journal of Diabetes Science and Technology, vol. 10, no. 3, pp. 708–713, 2016.
[9] S. M. Anderson, D. Raghinaru, J. E. Pinsker, F. Boscari, E. Renard, B. A. Bucking-
ham, R. Nimri, F. J. Doyle III, S. A. Brown, P. Keith-Hynes, M. D. Breton, D. Cher-
navvsky, W. C. Bevier, P. K. Bradley, D. Bruttomesso, S. D. Favero, R. Calore,
C. Cobelli, A. Avogaro, A. Farret, J. Place, T. T. Ly, S. Shanmugham, M. Phillip,
E. Dassau, I. S. Dasanayake, C. Kollman, J. W. Lum, R. W. Beck, B. Kovatchev,
and f. t. C. t. R. S. Group, “Multinational home use of closed-loop control is safe
and effective,” Diabetes Care, 2016.
[10] M. Reddy, P. Herrero, M. E. Sharkawy, P. Pesl, N. Jugnee, D. Pavitt, I. F. God-
sland, G. Alberti, C. Toumazou, D. G. Johnston, P. Georgiou, and N. S. Oliver,
“Metabolic control with the Bio-Inspired Artificial Pancreas in adults with type
1 diabetes a 24-hour randomized controlled crossover study,” Journal of Diabetes
Science and Technology, vol. 10, no. 2, pp. 405–413, 2016.
[11] H. Blauw, A. C. van Bon, R. Koops, J. H. DeVries, and on behalf of the PC-
DIAB consortium, “Performance and safety of an integrated bihormonal artifi-
cial pancreas for fully automated glucose control at home,” Diabetes, Obesity and
Metabolism, 2016.
[12] S. J. Russell, M. A. Hillard, C. Balliro, K. L. Magyar, R. Selagamsetty, M. Sinha,
K. Grennan, D. Mondesir, L. Ehklaspour, H. Zheng, E. R. Damiano, and F. H.
El-Khatib, “Day and night glycaemic control with a bionic pancreas versus con-
ventional insulin pump therapy in preadolescent children with type 1 diabetes:
a randomised crossover trial,” The Lancet Diabetes & Endocrinology, vol. 4, no. 3,
pp. 233–243, 2016.
[13] D. R. Cherñavvsky, M. D. DeBoer, P. Keith-Hynes, B. Mize, M. McElwee, S. De-
martini, S. F. Dunsmore, C. Wakeman, B. P. Kovatchev, and M. D. Breton, “Use
of an artificial pancreas among adolescents for a missed snack bolus and an
underestimated meal bolus,” Pediatric Diabetes, vol. 17, no. 1, pp. 28–35, 2016.
192
Appendix A. Artificial Pancreas Clinical Bibliography
[14] V. Gingras, R. Rabasa-Lhoret, V. Messier, M. Ladouceur, L. Legault, and
A. Haidar, “Efficacy of dual-hormone artificial pancreas to alleviate the
carbohydrate-counting burden of type 1 diabetes: a randomized crossover trial,”
Diabetes & Metabolism, vol. 42, no. 1, pp. 47–54, 2016.
[15] M. Tauschmann, J. M. Allen, M. E. Wilinska, H. Thabit, Z. Stewart, P. Cheng,
C. Kollman, C. L. Acerini, D. B. Dunger, and R. Hovorka, “Day-and-night hybrid
closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living,
randomized clinical trial,” Diabetes Care, 2016.
[16] J. Kropff, S. Del Favero, J. Place, C. Toffanin, R. Visentin, M. Monaro, M. Messori,
F. Di Palma, G. Lanzola, A. Farret, F. Boscari, S. Galasso, P. Magni, A. Avog-
aro, P. Keith-Hynes, B. P. Kovatchev, D. Bruttomesso, C. Cobelli, J. H. DeVries,
E. Renard, L. Magni, and AP@home consortium, “2 month evening and night
closed-loop glucose control in patients with type 1 diabetes under free-living
conditions: a randomised crossover trial,” The Lancet Diabetes & Endocrinology,
vol. 3, no. 12, pp. 939–947, 2015.
[17] D. Elleri, M. Biagioni, J. M. Allen, K. Kumareswaran, L. Leelarathna, K. Caldwell,
M. Nodale, M. E. Wilinska, A. Haidar, P. Calhoun, C. Kollman, N. C. Jackson,
A. M. Umpleby, C. L. Acerini, D. B. Dunger, and R. Hovorka, “Safety, efficacy
and glucose turnover of reduced prandial boluses during closed-loop therapy in
adolescents with type 1 diabetes: a randomized clinical trial,” Diabetes, Obesity
and Metabolism, vol. 17, no. 12, pp. 1173–1179, 2015.
[18] H. Thabit, M. Tauschmann, J. M. Allen, L. Leelarathna, S. Hartnell, M. E. Wilin-
ska, C. L. Acerini, S. Dellweg, C. Benesch, L. Heinemann, J. K. Mader, M. Holzer,
H. Kojzar, J. Exall, J. Yong, J. Pichierri, K. D. Barnard, C. Kollman, P. Cheng, P. C.
Hindmarsh, F. M. Campbell, S. Arnolds, T. R. Pieber, M. L. Evans, D. B. Dunger,
and R. Hovorka, “Home use of an artificial beta cell in type 1 diabetes,” New
England Journal of Medicine, vol. 373, no. 22, pp. 2129–2140, 2015.
[19] A. Haidar, R. Rabasa-Lhoret, L. Legault, L. E. Lovblom, R. Rakheja, V. Messier,
m. D’Aoust, C. M. Falappa, T. Justice, A. Orszag, H. Tschirhart, M. Dallaire,
M. Ladouceur, and B. A. Perkins, “Single- and dual-hormone artificial pan-
creas for overnight glucose control in type 1 diabetes,” The Journal of Clinical
Endocrinology & Metabolism, vol. 101, no. 1, pp. 214–223, 2015.
[20] M. I. de Bock, A. Roy, M. N. Cooper, J. A. Dart, C. L. Berthold, A. J. Retterath,
K. E. Freeman, B. Grosman, N. Kurtz, F. Kaufman, T. W. Jones, and E. A. Davis,
“Feasibility of outpatient 24-hour closed-loop insulin delivery,” Diabetes Care,
vol. 38, no. 11, pp. e186–e187, 2015.
[21] A. Haidar, L. Legault, L. Matteau-Pelletier, V. Messier, M. Dallaire,
M. Ladouceur, and R. Rabasa-Lhoret, “Outpatient overnight glucose control
193
Appendix A. Artificial Pancreas Clinical Bibliography
with dual-hormone artificial pancreas, single-hormone artificial pancreas, or
conventional insulin pump therapy in children and adolescents with type 1 di-
abetes: an open-label, randomised controlled trial,” The Lancet Diabetes & En-
docrinology, vol. 3, no. 8, pp. 595–604, 2015.
[22] E. Dassau, S. A. Brown, A. Basu, J. E. Pinsker, Y. C. Kudva, R. Gondhalekar,
S. Patek, D. Lv, M. Schiavon, J. B. Lee, C. Dalla Man, L. Hinshaw, K. Castorino,
A. Mallad, V. Dadlani, S. K. McCrady-Spitzer, M. McElwee-Malloy, C. A. Wake-
man, W. C. Bevier, P. K. Bradley, B. Kovatchev, C. Cobelli, H. C. Zisser, and
F. J. Doyle III, “Adjustment of open-loop settings to improve closed-loop results
in type 1 diabetes: a multicenter randomized trial,” The Journal of Clinical En-
docrinology & Metabolism, vol. 100, no. 10, pp. 3878–3886, 2015.
[23] T. T. Ly, A. Roy, B. Grosman, J. Shin, A. Campbell, S. Monirabbasi, B. Liang,
R. v. Eyben, S. Shanmugham, P. Clinton, and B. A. Buckingham, “Day and night
closed-loop control using the integrated Medtronic hybrid closed-loop system
in type 1 diabetes at diabetes camp,” Diabetes Care, vol. 38, no. 7, pp. 1205–1211,
2015.
[24] S. Del Favero, J. Place, J. Kropff, M. Messori, P. Keith-Hynes, R. Visentin,
M. Monaro, S. Galasso, F. Boscari, C. Toffanin, F. Di Palma, G. Lanzola,
S. Scarpellini, A. Farret, B. Kovatchev, A. Avogaro, D. Bruttomesso, L. Magni,
J. H. DeVries, C. Cobelli, E. Renard, and on behalf of the AP@home Consor-
tium, “Multicenter outpatient dinner/overnight reduction of hypoglycemia and
increased time of glucose in target with a wearable artificial pancreas using mod-
ular model predictive control in adults with type 1 diabetes,” Diabetes, Obesity
and Metabolism, vol. 17, no. 5, pp. 468–476, 2015.
[25] H. Zisser, E. Dassau, J. J. Lee, R. A. Harvey, W. Bevier, and F. J. Doyle III, “Clinical
results of an automated artificial pancreas using technosphere inhaled insulin to
mimic first-phase insulin secretion,” Journal of Diabetes Science and Technology,
vol. 9, no. 3, pp. 564–572, 2015.
[26] S. A. Brown, B. P. Kovatchev, M. D. Breton, S. M. Anderson, P. Keith-Hynes, S. D.
Patek, B. Jiang, N. Ben Brahim, P. Vereshchetin, D. Bruttomesso, A. Avogaro,
S. Del Favero, F. Boscari, S. Galasso, R. Visentin, M. Monaro, and C. Cobelli,
“Multinight "bedside" closed-loop control for patients with type 1 diabetes,”
Diabetes Technology & Therapeutics, vol. 17, no. 3, pp. 203–209, 2015.
[27] A. Haidar, L. Legault, V. Messier, T. M. Mitre, C. Leroux, and R. Rabasa-Lhoret,
“Comparison of dual-hormone artificial pancreas, single-hormone artificial pan-
creas, and conventional insulin pump therapy for glycaemic control in patients
with type 1 diabetes: an open-label randomised controlled crossover trial,” The
Lancet Diabetes & Endocrinology, vol. 3, no. 1, pp. 17–26, 2015.
194
Appendix A. Artificial Pancreas Clinical Bibliography
[28] R. Mauseth, S. M. Lord, I. B. Hirsch, R. C. Kircher, D. P. Matheson, and C. J.
Greenbaum, “Stress testing of an artificial pancreas system with pizza and ex-
ercise leads to improvements in the system’s fuzzy logic controller,” Journal of
Diabetes Science and Technology, vol. 9, no. 6, pp. 1253–1259, 2015.
[29] D. A. Finan, E. Dassau, M. D. Breton, S. D. Patek, T. W. McCann, B. P. Kovatchev,
F. J. Doyle III, B. L. Levy, and R. Venugopalan, “Sensitivity of the predictive
hypoglycemia minimizer system to the algorithm aggressiveness factor,” Journal
of Diabetes Science and Technology, vol. 10, no. 1, pp. 104–110, 2015.
[30] D. Elleri, J. M. Allen, M. Tauschmann, R. El-Khairi, P. Benitez-Aguirre, C. L.
Acerini, D. B. Dunger, and R. Hovorka, “Feasibility of overnight closed-loop
therapy in young children with type 1 diabetes aged 3–6 years: comparison
between diluted and standard insulin strength,” BMJ Open Diabetes Research &
Care, vol. 2, no. 1, 2014.
[31] M. A. Quemerais, M. Doron, F. Dutrech, V. Melki, S. Franc, M. Antonakios,
G. Charpentier, H. Hanaire, P. Y. Benhamou, on behalf of the Diabeloop Consor-
tium, G. Charpentier, S. Franc, A. Penfornis, Y. Reznik, P. Y. Benhamou, D. Rac-
cah, E. Renard, B. Guerci, N. Jeandidier, H. Hanaire, C. Simon, M. Doron, M. An-
tonakios, and R. Guillemaud, “Preliminary evaluation of a new semi-closed-loop
insulin therapy system over the prandial period in adult patients with type 1 di-
abetes: the WP6.0 Diabeloop study,” Journal of Diabetes Science and Technology,
vol. 8, no. 6, pp. 1177–1184, 2014.
[32] R. Nimri, I. Muller, E. Atlas, S. Miller, A. Fogel, N. Bratina, O. Kordonouri,
T. Battelino, T. Danne, and M. Phillip, “MD-Logic overnight control for 6 weeks
of home use in patients with type 1 diabetes: randomized crossover trial,” Dia-
betes Care, vol. 37, no. 11, pp. 3025–3032, 2014.
[33] G. Freckmann, N. Jendrike, S. Pleus, H. Buck, S. Bousamra, P. Galley, A. Thukral,
R. Wagner, S. Weinert, and C. Haug, “Use of microdialysis-based continuous
glucose monitoring to drive real-time semi-closed-loop insulin infusion,” Journal
of Diabetes Science and Technology, vol. 8, no. 6, pp. 1074–1080, 2014.
[34] D. Elleri, G. Maltoni, J. M. Allen, M. Nodale, K. Kumareswaran, L. Leelarathna,
H. Thabit, K. Caldwell, M. E. Wilinska, P. Calhoun, C. Kollman, D. B. Dunger,
and R. Hovorka, “Safety of closed-loop therapy during reduction or omission of
meal boluses in adolescents with type 1 diabetes: a randomized clinical trial,”
Diabetes, Obesity and Metabolism, vol. 16, no. 11, pp. 1174–1178, 2014.
[35] F. Cameron, G. Niemeyer, D. M. Wilson, B. W. Bequette, K. S. Benassi, P. Clinton,
and B. A. Buckingham, “Inpatient trial of an artificial pancreas based on multiple
model probabilistic predictive control with repeated large unannounced meals,”
Diabetes Technology & Therapeutics, vol. 16, no. 11, pp. 728–734, 2014.
195
Appendix A. Artificial Pancreas Clinical Bibliography
[36] P. G. Jacobs, J. El Youssef, J. Castle, P. Bakhtiani, D. Branigan, M. Breen, D. Bauer,
N. Preiser, G. Leonard, T. Stonex, and W. K. Ward, “Automated control of
an adaptive bihormonal, dual-sensor artificial pancreas and evaluation during
inpatient studies,” IEEE Transactions on Biomedical Engineering, vol. 61, no. 10,
pp. 2569–2581, 2014.
[37] H. P. Chase, F. J. Doyle III, H. Zisser, E. Renard, R. Nimri, C. Cobelli, B. A. Buck-
ingham, D. M. Maahs, S. Anderson, L. Magni, J. Lum, P. Calhoun, C. Kollman,
R. W. Beck, and for the Control to Range Study Group, “Multicenter closed-
loop/hybrid meal bolus insulin delivery with type 1 diabetes,” Diabetes Technol-
ogy & Therapeutics, vol. 16, no. 10, pp. 623–632, 2014.
[38] V. S. Renukuntla, N. Ramchandani, J. Trast, M. Cantwell, and R. A. Heptulla,
“Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant ther-
apy in type 1 diabetes in a closed loop setting with ePID algorithm,” Journal of
Diabetes Science and Technology, vol. 8, no. 5, pp. 1011–1017, 2014.
[39] H. Thabit, A. Lubina-Solomon, M. Stadler, L. Leelarathna, E. Walkinshaw,
A. Pernet, J. M. Allen, A. Iqbal, P. Choudhary, K. Kumareswaran, M. Nodale,
C. Nisbet, M. E. Wilinska, K. D. Barnard, D. B. Dunger, S. R. Heller, S. A. Amiel,
M. L. Evans, and R. Hovorka, “Home use of closed-loop insulin delivery for
overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre,
randomised crossover study,” The Lancet Diabetes & Endocrinology, vol. 2, no. 9,
pp. 701–709, 2014.
[40] M. Reddy, P. Herrero, M. El Sharkawy, P. Pesl, N. Jugnee, H. Thomson, D. Pavitt,
C. Toumazou, D. Johnston, P. Georgiou, and N. Oliver, “Feasibility study of a
Bio-Inspired Artificial Pancreas in adults with type 1 diabetes,” Diabetes Technol-
ogy & Therapeutics, vol. 16, no. 9, pp. 550–557, 2014.
[41] T. T. Ly, M. D. Breton, P. Keith-Hynes, D. De Salvo, P. Clinton, K. Benassi,
B. Mize, D. Chernavvsky, J. Place, D. M. Wilson, B. P. Kovatchev, and B. A.
Buckingham, “Overnight glucose control with an automated, unified safety sys-
tem in children and adolescents with type 1 diabetes at diabetes camp,” Diabetes
Care, vol. 37, no. 8, pp. 2310–2316, 2014.
[42] M. D. Breton, S. A. Brown, C. H. Karvetski, L. Kollar, K. A. Topchyan, S. M.
Anderson, and B. P. Kovatchev, “Adding heart rate signal to a control-to-range
artificial pancreas system improves the protection against hypoglycemia during
exercise in type 1 diabetes,” Diabetes Technology & Therapeutics, vol. 16, no. 8,
pp. 506–511, 2014.
[43] S. J. Russell, F. H. El-Khatib, M. Sinha, K. L. Magyar, K. McKeon, L. G. Goer-
gen, C. Balliro, M. A. Hillard, D. M. Nathan, and E. R. Damiano, “Outpatient
196
Appendix A. Artificial Pancreas Clinical Bibliography
glycemic control with a bionic pancreas in type 1 diabetes,” New England Journal
of Medicine, vol. 371, no. 4, pp. 313–325, 2014.
[44] L. Leelarathna, S. Dellweg, J. K. Mader, J. M. Allen, C. Benesch, W. Doll,
M. Ellmerer, S. Hartnell, L. Heinemann, H. Kojzar, L. Michalewski, M. Nodale,
H. Thabit, M. E. Wilinska, T. R. Pieber, S. Arnolds, M. L. Evans, R. Hovorka, and
on behalf of the AP@home Consortium, “Day and night home closed-loop in-
sulin delivery in adults with type 1 diabetes: three-center randomized crossover
study,” Diabetes Care, vol. 37, no. 7, pp. 1931–1937, 2014.
[45] B. P. Kovatchev, E. Renard, C. Cobelli, H. C. Zisser, P. Keith-Hynes, S. M. Ander-
son, S. A. Brown, D. R. Chernavvsky, M. D. Breton, L. B. Mize, A. Farret, J. Place,
D. Bruttomesso, S. Del Favero, F. Boscari, S. Galasso, A. Avogaro, L. Magni,
F. Di Palma, C. Toffanin, M. Messori, E. Dassau, and F. J. Doyle III, “Safety of
outpatient closed-loop control: first randomized crossover trials of a wearable
artificial pancreas,” Diabetes Care, vol. 37, no. 7, pp. 1789–1796, 2014.
[46] R. A. Harvey, E. Dassau, W. C. Bevier, D. E. Seborg, L. Jovanovicˇ, F. J. Doyle III,
and H. C. Zisser, “Clinical evaluation of an automated artificial pancreas using
zone-model predictive control and health monitoring system,” Diabetes Technol-
ogy & Therapeutics, vol. 16, no. 6, pp. 348–357, 2014.
[47] A. Haidar, D. Farid, A. St-Yves, V. Messier, V. Chen, D. Xing, A.-S. Brazeau,
C. Duval, B. Boulet, L. Legault, and R. Rabasa-Lhoret, “Post-breakfast closed-
loop glucose control is improved when accompanied with carbohydrate-
matching bolus compared to weight-dependent bolus,” Diabetes & Metabolism,
vol. 40, no. 3, pp. 211–214, 2014.
[48] K. Turksoy, L. T. Quinn, E. Littlejohn, and A. Cinar, “An integrated multivari-
able artificial pancreas control system,” Journal of Diabetes Science and Technology,
vol. 8, no. 3, pp. 498–507, 2014.
[49] R. Hovorka, D. Elleri, H. Thabit, J. M. Allen, L. Leelarathna, R. El-Khairi, K. Ku-
mareswaran, K. Caldwell, P. Calhoun, C. Kollman, H. R. Murphy, C. L. Acerini,
M. E. Wilinska, M. Nodale, and D. B. Dunger, “Overnight closed-loop insulin de-
livery in young people with type 1 diabetes: a free-living, randomized clinical
trial,” Diabetes Care, vol. 37, no. 5, pp. 1204–1211, 2014.
[50] S. Del Favero, D. Bruttomesso, F. Di Palma, G. Lanzola, R. Visentin, A. Fil-
ippi, R. Scotton, C. Toffanin, M. Messori, S. Scarpellini, P. Keith-Hynes, B. P.
Kovatchev, J. H. DeVries, E. Renard, L. Magni, A. Avogaro, C. Cobelli, and on
behalf of the AP@home Consortium, “First use of model predictive control in
outpatient wearable artificial pancreas,” Diabetes Care, vol. 37, no. 5, pp. 1212–
1215, 2014.
197
Appendix A. Artificial Pancreas Clinical Bibliography
[51] F. H. El-Khatib, S. J. Russell, K. L. Magyar, M. Sinha, K. McKeon, D. M. Nathan,
and E. R. Damiano, “Autonomous and continuous adaptation of a bihormonal
bionic pancreas in adults and adolescents with type 1 diabetes,” The Journal of
Clinical Endocrinology & Metabolism, vol. 99, no. 5, pp. 1701–1711, 2014.
[52] L. Leelarathna, H. Thabit, J. M. Allen, M. Nodale, M. E. Wilinska, K. Powell,
S. Lane, M. L. Evans, R. Hovorka, and on behalf of the AP@home consortium,
“Evaluating the Performance of a Novel Embedded Closed-loop System,” Jour-
nal of Diabetes Science and Technology, vol. 8, no. 2, pp. 267–272, 2014.
[53] A. C. van Bon, Y. M. Luijf, R. Koebrugge, R. Koops, J. B. L. Hoekstra, and
J. H. DeVries, “Feasibility of a portable bihormonal closed-loop system to control
glucose excursions at home under free-living conditions for 48 hours,” Diabetes
Technology & Therapeutics, vol. 16, no. 3, pp. 131–136, 2014.
[54] K. Turksoy, L. Quinn, E. Littlejohn, and A. Cinar, “Multivariable adaptive identi-
fication and control for artificial pancreas systems,” IEEE Transactions on Biomed-
ical Engineering, vol. 61, no. 3, pp. 883–891, 2014.
[55] R. Nimri, I. Muller, E. Atlas, S. Miller, O. Kordonouri, N. Bratina, C. Tsioli,
M. A. Stefanija, T. Danne, T. Battelino, and M. Phillip, “Night glucose control
with MD-Logic artificial pancreas in home setting: a single blind, randomized
crossover trial-interim analysis: MD-Logic night control in home-setting,” Pedi-
atric Diabetes, vol. 15, no. 2, pp. 91–99, 2014.
[56] I. Capel, M. Rigla, G. García-Sáez, A. Rodríguez-Herrero, B. Pons, D. Sub-
ías, F. García-García, M. Gallach, M. Aguilar, C. Pérez-Gandía, E. J. Gómez,
A. Caixàs, and M. E. Hernando, “Artificial pancreas using a personalized rule-
based controller achieves overnight normoglycemia in patients with type 1 dia-
betes,” Diabetes Technology & Therapeutics, vol. 16, no. 3, pp. 172–179, 2014.
[57] D. A. Finan, T. W. McCann, L. Mackowiak, E. Dassau, S. D. Patek, B. P. Ko-
vatchev, F. J. Doyle III, H. Zisser, H. Anhalt, and R. Venugopalan, “Closed-loop
control performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM)
system in a feasibility study,” Journal of Diabetes Science and Technology, vol. 8,
no. 1, pp. 35–42, 2014.
[58] Y. M. Luijf, J. H. DeVries, K. Zwinderman, L. Leelarathna, M. Nodale, K. Cald-
well, K. Kumareswaran, D. Elleri, J. M. Allen, M. E. Wilinska, M. L. Evans,
R. Hovorka, W. Doll, M. Ellmerer, J. K. Mader, E. Renard, J. Place, A. Farret,
C. Cobelli, S. D. Favero, C. D. Man, A. Avogaro, D. Bruttomesso, A. Filippi,
R. Scotton, L. Magni, G. Lanzola, F. D. Palma, P. Soru, C. Toffanin, G. D. Nicolao,
S. Arnolds, C. Benesch, and L. Heinemann, “Day and night closed-loop control
198
Appendix A. Artificial Pancreas Clinical Bibliography
in adults with type 1 diabetes: a comparison of two closed-loop algorithms driv-
ing continuous subcutaneous insulin infusion versus patient self-management,”
Diabetes Care, vol. 36, no. 12, pp. 3882–3887, 2013.
[59] J. L. Sherr, E. Cengiz, C. C. Palerm, B. Clark, N. Kurtz, A. Roy, L. Carria,
M. Cantwell, W. V. Tamborlane, and S. A. Weinzimer, “Reduced hypoglycemia
and increased time in target using closed-loop insulin delivery during nights
with or without antecedent afternoon exercise in type 1 diabetes,” Diabetes Care,
vol. 36, no. 10, pp. 2909–2914, 2013.
[60] R. Mauseth, I. B. Hirsch, J. Bollyky, R. Kircher, D. Matheson, S. Sanda, and
C. Greenbaum, “Use of a “fuzzy logic” controller in a closed-loop artificial pan-
creas,” Diabetes Technology & Therapeutics, vol. 15, no. 8, pp. 628–633, 2013.
[61] B. P. Kovatchev, E. Renard, C. Cobelli, H. C. Zisser, P. Keith-Hynes, S. M. An-
derson, S. A. Brown, D. R. Chernavvsky, M. D. Breton, A. Farret, M.-J. Pel-
letier, J. Place, D. Bruttomesso, S. Del Favero, R. Visentin, A. Filippi, R. Scotton,
A. Avogaro, and F. J. Doyle III, “Feasibility of outpatient fully integrated closed-
loop control: first studies of wearable artificial pancreas,” Diabetes Care, vol. 36,
no. 7, pp. 1851–1858, 2013.
[62] K. Turksoy, E. S. Bayrak, L. Quinn, E. Littlejohn, and A. Cinar, “Multivariable
adaptive closed-loop control of an artificial pancreas without meal and activity
announcement,” Diabetes Technology & Therapeutics, vol. 15, no. 5, pp. 386–400,
2013.
[63] R. Nimri, T. Danne, O. Kordonouri, E. Atlas, N. Bratina, T. Biester, M. Avbelj,
S. Miller, I. Muller, M. Phillip, and T. Battelino, “The "Glucositter" overnight
automated closed loop system for type 1 diabetes: a randomized crossover trial,”
Pediatric Diabetes, vol. 14, no. 3, pp. 159–167, 2013.
[64] D. Elleri, J. M. Allen, K. Kumareswaran, L. Leelarathna, M. Nodale, K. Caldwell,
P. Cheng, C. Kollman, A. Haidar, H. R. Murphy, M. E. Wilinska, C. L. Acerini,
D. B. Dunger, and R. Hovorka, “Closed-loop basal insulin delivery over 36 hours
in adolescents with type 1 diabetes: randomized clinical trial,” Diabetes Care,
vol. 36, no. 4, pp. 838–844, 2013.
[65] E. Dassau, H. Zisser, R. A. Harvey, M. W. Percival, B. Grosman, W. Bevier, E. At-
las, S. Miller, R. Nimri, L. Jovanovicˇ, and F. J. Doyle III, “Clinical evaluation of a
personalized artificial pancreas,” Diabetes Care, vol. 36, no. 4, pp. 801–809, 2013.
[66] A. Haidar, L. Legault, M. Dallaire, A. Alkhateeb, A. Coriati, V. Messier, P. Cheng,
M. Millette, B. Boulet, and R. Rabasa-Lhoret, “Glucose-responsive insulin and
glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 di-
abetes: a randomized crossover controlled trial,” Canadian Medical Association
Journal, vol. 185, no. 4, pp. 297–305, 2013.
199
Appendix A. Artificial Pancreas Clinical Bibliography
[67] M. Phillip, T. Battelino, E. Atlas, O. Kordonouri, N. Bratina, S. Miller, T. Bi-
ester, M. Avbelj Stefanija, I. Muller, R. Nimri, and T. Danne, “Nocturnal glucose
control with an artificial pancreas at a diabetes camp,” New England Journal of
Medicine, vol. 368, no. 9, pp. 824–833, 2013.
[68] A. Dauber, L. Corcia, J. Safer, M. S. D. Agus, S. Einis, and G. M. Steil, “Closed-
loop insulin therapy improves glycemic control in children aged <7 years: a
randomized controlled trial,” Diabetes Care, vol. 36, no. 2, pp. 222–227, 2013.
[69] S. Schmidt, D. Boiroux, A. K. Duun-Henriksen, L. Frøssing, O. Skyggebjerg, J. B.
Jørgensen, N. K. Poulsen, H. Madsen, S. Madsbad, and K. Nørgaard, “Model-
based closed-loop glucose control in type 1 diabetes: the DiaCon experience,”
Journal of Diabetes Science and Technology, vol. 7, no. 5, pp. 1255–1264, 2013.
[70] S. J. Russell, F. H. El-Khatib, D. M. Nathan, K. L. Magyar, J. Jiang, and E. R.
Damiano, “Blood glucose control in type 1 diabetes with a bihormonal bionic
endocrine pancreas,” Diabetes Care, vol. 35, no. 11, pp. 2148–2155, 2012.
[71] M. J. O’Grady, A. J. Retterath, D. B. Keenan, N. Kurtz, M. Cantwell, G. Spital,
M. N. Kremliovsky, A. Roy, E. A. Davis, T. W. Jones, and T. T. Ly, “The use of
an automated, portable glucose control system for overnight glucose control in
adolescents and young adults with type 1 diabetes,” Diabetes Care, vol. 35, no. 11,
pp. 2182–2187, 2012.
[72] S. A. Weinzimer, J. L. Sherr, E. Cengiz, G. Kim, J. L. Ruiz, L. Carria,
G. Voskanyan, A. Roy, and W. V. Tamborlane, “Effect of pramlintide on pran-
dial glycemic excursions during closed-loop control in adolescents and young
adults with type 1 diabetes,” Diabetes Care, vol. 35, no. 10, pp. 1994–1999, 2012.
[73] C. Cobelli, E. Renard, B. P. Kovatchev, P. Keith-Hynes, N. Ben Brahim, J. Place,
S. Del Favero, M. Breton, A. Farret, D. Bruttomesso, E. Dassau, H. Zisser, F. J.
Doyle III, S. D. Patek, and A. Avogaro, “Pilot studies of wearable outpatient
artificial pancreas in type 1 diabetes,” Diabetes Care, vol. 35, no. 9, pp. e65–e67,
2012.
[74] M. Breton, A. Farret, D. Bruttomesso, S. Anderson, L. Magni, S. Patek,
C. Dalla Man, J. Place, S. Demartini, S. Del Favero, C. Toffanin, C. Hughes-
Karvetski, E. Dassau, H. Zisser, F. J. Doyle III, G. De Nicolao, A. Avogaro, C. Co-
belli, E. Renard, B. Kovatchev, and on behalf of The International Artificial Pan-
creas (iAP) Study Group, “Fully integrated artificial pancreas in type 1 diabetes:
modular closed-loop glucose control maintains near normoglycemia,” Diabetes,
vol. 61, no. 9, pp. 2230–2237, 2012.
[75] D. Elleri, J. M. Allen, M. Biagioni, K. Kumareswaran, L. Leelarathna, K. Cald-
well, M. Nodale, M. E. Wilinska, C. L. Acerini, D. B. Dunger, and R. Hovorka,
200
Appendix A. Artificial Pancreas Clinical Bibliography
“Evaluation of a portable ambulatory prototype for automated overnight closed-
loop insulin delivery in young people with type 1 diabetes: home prototype for
overnight closed-loop therapy,” Pediatric Diabetes, vol. 13, no. 6, pp. 449–453,
2012.
[76] R. Nimri, E. Atlas, M. Ajzensztejn, S. Miller, T. Oron, and M. Phillip, “Feasibil-
ity study of automated overnight closed-loop glucose control under md-logic
artificial pancreas in patients with type 1 diabetes: the dream project,” Diabetes
Technology & Therapeutics, vol. 14, no. 8, pp. 728–735, 2012.
[77] A. C. van Bon, L. D. Jonker, R. Koebrugge, R. Koops, J. B. Hoekstra, and J. H.
DeVries, “Feasibility of a bihormonal closed-loop system to control postexercise
and postprandial glucose excursions,” Journal of Diabetes Science and Technology,
vol. 6, no. 5, pp. 1114–1122, 2012.
[78] J. L. Ruiz, J. L. Sherr, E. Cengiz, L. Carria, A. Roy, G. Voskanyan, W. V. Tam-
borlane, and S. A. Weinzimer, “Effect of insulin feedback on closed-loop glucose
control: a crossover study,” Journal of Diabetes Science and Technology, vol. 6, no. 5,
pp. 1123–1130, 2012.
[79] C. Patte, S. Pleus, P. Galley, S. Weinert, C. Haug, and G. Freckmann, “Feasibility
of overnight closed-loop control based on hourly blood glucose measurements,”
Journal of Diabetes Science and Technology, vol. 6, no. 4, pp. 902–909, 2012.
[80] H. R. Murphy, K. Kumareswaran, D. Elleri, J. M. Allen, K. Caldwell, M. Bia-
gioni, D. Simmons, D. B. Dunger, M. Nodale, M. E. Wilinska, S. A. Amiel, and
R. Hovorka, “Safety and efficacy of 24-h closed-loop insulin delivery in well-
controlled pregnant women with type 1 diabetes: a randomized crossover case
series,” Diabetes Care, vol. 34, no. 12, pp. 2527–2529, 2011.
[81] G. M. Steil, C. C. Palerm, N. Kurtz, G. Voskanyan, A. Roy, S. Paz, and F. R.
Kandeel, “The effect of insulin feedback on closed loop glucose control,” The
Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 5, pp. 1402–1408, 2011.
[82] R. Hovorka, K. Kumareswaran, J. Harris, J. M. Allen, D. Elleri, D. Xing, C. Koll-
man, M. Nodale, H. R. Murphy, D. B. Dunger, S. A. Amiel, S. R. Heller, M. E.
Wilinska, and M. L. Evans, “Overnight closed loop insulin delivery (artificial
pancreas) in adults with type 1 diabetes: crossover randomised controlled stud-
ies,” British Medical Journal, vol. 342, p. d1855, 2011.
[83] D. Elleri, J. M. Allen, M. Nodale, M. E. Wilinska, J. S. Mangat, A. M. F. Larsen,
C. L. Acerini, D. B. Dunger, and R. Hovorka, “Automated overnight closed-loop
glucose control in young children with type 1 diabetes,” Diabetes Technology &
Therapeutics, vol. 13, no. 4, pp. 419–424, 2011.
201
Appendix A. Artificial Pancreas Clinical Bibliography
[84] H. R. Murphy, D. Elleri, J. M. Allen, J. Harris, D. Simmons, G. Rayman, R. Tem-
ple, D. B. Dunger, A. Haidar, M. Nodale, M. E. Wilinska, and R. Hovorka,
“Closed-loop insulin delivery during pregnancy complicated by type 1 dia-
betes,” Diabetes Care, vol. 34, no. 2, pp. 406–411, 2011.
[85] J. El Youssef, J. R. Castle, D. L. Branigan, R. G. Massoud, M. E. Breen, P. G. Ja-
cobs, B. W. Bequette, and W. K. Ward, “A controlled study of the effectiveness of
an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hy-
perglycemia in type 1 diabetes,” Journal of Diabetes Science and Technology, vol. 5,
no. 6, pp. 1312–1326, 2011.
[86] B. Kovatchev, C. Cobelli, E. Renard, S. Anderson, M. Breton, S. Patek, W. Clarke,
D. Bruttomesso, A. Maran, S. Costa, A. Avogaro, C. D. Man, A. Facchinetti,
L. Magni, G. D. Nicolao, J. Place, and A. Farret, “Multinational study of subcu-
taneous model-predictive closed-loop control in type 1 diabetes mellitus: sum-
mary of the results,” Journal of Diabetes Science and Technology, vol. 4, no. 6,
pp. 1374–1381, 2010.
[87] J. R. Castle, J. M. Engle, J. E. Youssef, R. G. Massoud, K. C. J. Yuen, R. Kagan,
and W. K. Ward, “Novel use of glucagon in a closed-loop system for prevention
of hypoglycemia in type 1 diabetes,” Diabetes Care, vol. 33, no. 6, pp. 1282–1287,
2010.
[88] E. Atlas, R. Nimri, S. Miller, E. A. Grunberg, and M. Phillip, “MD-Logic Artificial
Pancreas System: A pilot study in adults with type 1 diabetes,” Diabetes Care,
vol. 33, no. 5, pp. 1072–1076, 2010.
[89] F. H. El-Khatib, S. J. Russell, D. M. Nathan, R. G. Sutherlin, and E. R. Dami-
ano, “A bihormonal closed-loop artificial pancreas for type 1 diabetes,” Science
Translational Medicine, vol. 2, no. 27, p. 27ra27, 2010.
[90] E. Renard, J. Place, M. Cantwell, H. Chevassus, and C. C. Palerm, “Closed-loop
insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin
delivery: feasibility study testing a new model for the artificial pancreas,” Dia-
betes Care, vol. 33, no. 1, pp. 121–127, 2010.
[91] A. C. van Bon, J. Hermanides, R. Koops, J. B. Hoekstra, and J. H. DeVries, “Post-
prandial glycemic excursions with the use of a closed-loop platform in subjects
with type 1 diabetes: a pilot study,” Journal of Diabetes Science and Technology,
vol. 4, no. 4, pp. 923–928, 2010.
[92] R. Hovorka, J. M. Allen, D. Elleri, L. J. Chassin, J. Harris, D. Xing, C. Kollman,
T. Hovorka, A. M. F. Larsen, M. Nodale, and others, “Manual closed-loop insulin
delivery in children and adolescents with type 1 diabetes: a phase 2 randomised
crossover trial,” The Lancet, vol. 375, no. 9716, pp. 743–751, 2010.
202
Appendix A. Artificial Pancreas Clinical Bibliography
[93] W. L. Clarke, S. Anderson, M. Breton, S. Patek, L. Kashmer, and B. Kovatchev,
“Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin
delivery and a model predictive control algorithm: the Virginia experience,”
Journal of Diabetes Science and Technology, vol. 3, no. 5, pp. 1031–1038, 2009.
[94] D. Bruttomesso, A. Farret, S. Costa, M. C. Marescotti, M. Vettore, A. Avogaro,
A. Tiengo, C. Dalla Man, J. Place, A. Facchinetti, and others, “Closed-loop arti-
ficial pancreas using subcutaneous glucose sensing and insulin delivery and a
model predictive control algorithm: preliminary studies in Padova and Mont-
pellier,” Journal of Diabetes Science and Technology, vol. 3, no. 5, pp. 1014–1021,
2009.
[95] S. A. Weinzimer, G. M. Steil, K. L. Swan, J. Dziura, N. Kurtz, and W. V. Tam-
borlane, “Fully automated closed-loop insulin delivery versus semiautomated
hybrid control in pediatric patients with type 1 diabetes using an artificial pan-
creas,” Diabetes Care, vol. 31, no. 5, pp. 934–939, 2008.
[96] G. M. Steil, K. Rebrin, C. Darwin, F. Hariri, and M. F. Saad, “Feasibility of au-
tomating insulin delivery for the treatment of type 1 diabetes,” Diabetes, vol. 55,
no. 12, pp. 3344–3350, 2006.
[97] E. Renard, G. Costalat, H. Chevassus, and J. Bringer, “Closed loop insulin de-
livery using implanted insulin pumps and sensors in type 1 diabetic patients,”
Diabetes Research and Clinical Practice, vol. 74, no. Suppl 2, pp. S173–S177, 2006.
[98] H. C. Schaller, L. Schaupp, M. Bodenlenz, M. E. Wilinska, L. J. Chassin, P. Wach,
T. Vering, R. Hovorka, and T. R. Pieber, “On-line adaptive algorithm with glu-
cose prediction capacity for subcutaneous closed loop control of glucose: evalua-
tion under fasting conditions in patients with type 1 diabetes,” Diabetic Medicine,
vol. 23, no. 1, pp. 90–93, 2006.
[99] R. Hovorka, L. J. Chassin, M. E. Wilinska, V. Canonico, J. A. Akwi, M. O. Federici,
M. Massi-Benedetti, I. Hutzli, C. Zaugg, H. Kaufmann, and others, “Closing the
loop: the adicol experience,” Diabetes Technology & Therapeutics, vol. 6, no. 3,
pp. 307–318, 2004.
203
Appendix B
Individual Glucose Traces
The following pages contain the individual glucose and insulin traces for each of
the 10 subjects from the clinical study presented in Chapter 2. This study is regis-
tered on clinicaltrials.gov with clinical trial registration number NCT02506764. The
legend for each graph is as follows: (Top) The CGM is plotted over time as black
circles. The red solid and dashed lines show hypoglycemia thresholds of 70mg/dL
and 50mg/dL. The green shaded areas show times of exercise, the blue shaded areas
show times of pump suspension and the red shaded areas show times where the
CGM was less than 70mg/dL. The magenta circles show the meter glucose values.
The red stars indicate the time of HMS alerts, the black asterisks indicate the time of
carbohydrate treatments, and the yellow triangles indicate the time of meals. (Bot-
tom) The insulin is plotted over time. The left axis shows insulin doses that were less
than 0.6U and the right axis shows insulin doses that were greater than 0.6U.
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09
/1
7 
17
:0
0
09
/1
8 
05
:0
0
09
/1
8 
17
:0
0
09
/1
9 
05
:0
0
09
/1
9 
17
:0
0
09
/2
0 
05
:0
0
09
/2
0 
17
:0
0
M
ea
l
Tr
ea
t
H
M
S
 
50
 
7010
0
15
0
20
0
25
0
30
0
35
0
40
0
CGM (mg/dL)
IT
T 
Ex
er
ci
se
Pu
m
p 
Su
sp
en
d
H
yp
o
In
 C
LC
M
et
er
09
/1
7 
17
:0
0
09
/1
8 
05
:0
0
09
/1
8 
17
:0
0
09
/1
9 
05
:0
0
09
/1
9 
17
:0
0
09
/2
0 
05
:0
0
09
/2
0 
17
:0
0
Ti
m
e 
of
 D
ay
0
0.
2
0.
4
0.
6
Insulin < 0.6 U
071421
Insulin > 0.6 U
Su
bje
ct 
10
214
